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SUMMARY
The discovery of peptide domains, which can facilitate translocation of polypeptides or 
nucleic acids across biological membranes, has important implications for the therapeutic 
use of recombinant proteins, oligonucleotides and plasmid DNA.
The initial aim involved the synthesis of a cell penetrating peptide sequence based on the 
homeodomain o f the Drosophila protein Antennapedia (pAntp) which has been found to 
translocate through the membrane of neurons in vitro and accumulates in their nuclei. 
The challenge of the project was to work out how these peptides function and the kinetics 
involved in their translocation. A selection of fluorescent probes was incorporated in the 
peptide sequence to allow analysis of the cellular uptake of the peptide(s) using 
techniques such as electron, confocal and low light microscopy. Both electron and 
confocal microscopy gave evidence to suggest that the uptake and intracellular movement 
of the peptides in B16 cells was due to endocytosis. The other translocating system was 
VP22 from the herpes simplex virus, which is found to exhibit the unusual property of 
intercellular transport. This function was investigated in vitro and in animal tissues, 
namely muscle and tumour. Although spread of VP22 was observed in mouse tumour 
tissue, this effect was not seen in muscle. The methods of gene delivery that have been 
studied include viral and non-viral methods. While viral vectors are efficient transfection 
agents in vivo, they exhibit a number of significant disadvantages including 
immunogenicity and the production of replication competent viruses. Although the 
efficiency o f non-viral methods in vivo is relatively low compared with viral vectors, 
such methods display low toxicity and are unlikely to provoke inflammation. The ability 
of the peptides to transfer DNA into cells was tested using in vitro transfection 
techniques. Conditions were optimised in B16 cells and the transfection efficiency varied 
between a series of mammalian cell lines. The level of gene expression was enhanced by 
the addition o f 25 lysine residues to penetratin particularly in the presence o f chloroquine. 
This implies that uptake is mostly by endocytosis. However, the overall transfection 
efficiency was not better than endosomolytic agents. The assembly of virus-like particles 
to facilitate gene delivery was achieved by using synthetic components. These particles 
accomplished cellular uptake and efficient endosomal escape, fulfilling some of the 
useful attributes of viral vectors.
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1.1 THE PROMISE OF GENE THERAPY
Over the past several decades the development o f methods for delivering genes to 
mammalian cells has stimulated great interest in the possibility o f treating human disease 
by gene-based therapies. The gene therapy concept is based on the assumption that 
definitive treatment for genetic diseases should be possible by directing treatment to the 
site o f the defect itself, the mutant gene, rather than to secondary effects o f mutant gene 
products. Somatic gene therapy involves the process of inserting specific genetic 
information into a cell in order to replace, augment or eliminate an absent or defective 
gene and holds promise as a major innovation in medical science. The new gene serves 
as the code enabling the patient’s cells to produce a specific protein that prevents or 
fights a disease. There are several reasons for this expanding interest in the discovery 
and development o f gene delivery systems. Firstly, aimed at treating diseases at the most 
basic level, gene therapy could represent an important advance in the treatment o f genetic 
disorders, such as haemophilia, cystic fibrosis, Duchenne muscular dystrophy and 
acquired multifactorial diseases, such as metabolic disorders, different forms o f cancer 
and HIV infection (Anderson, 1992; Crystal, 1995; Friedmann et al., 1997; Ledley, 1994; 
Hodgson et al., 1995). Secondly, the clinical use o f conventional protein drugs presents 
various limitations including formulation difficulties leading to low bioavailability and 
poor pharmacokinetics as well as a high cost o f scale-up and manufacture. Hence gene 
therapy methods show high promise in aiming to overcome these limitations. Gene 
therapy can be used potentially to, (i) restrict expression o f a therapeutic protein to 
specific cells within the body, (ii) control the level o f expression in response to clinical 
needs, and (iii) achieve expression for a sustained time after a single administration. The 
intracellular distribution of therapeutic proteins can also be controlled by gene therapy. 
Successful development o f gene therapy technologies will require a multidisciplinary 
approach for the design and optimization o f delivery systems. There would also be a 
need to adjust gene-dosing regimens according to the needs o f the patient. Different
1
biological targets and diseases will require different therapeutic technologies. Although 
gene therapy offers several new and promising approaches to disease treatment, there 
remains the issue o f relatively low efficacy experienced in various clinical trials 
(Williams, 1995). Thus, it is critical to identify ways to improve the efficiency o f gene 
delivery and expression in order to broaden the clinical opportunities o f gene therapy. 
There are a number o f obstacles (extracellular and intracellular), which can potentially 
reduce the amount o f DNA getting through to its target site. To optimize and combine 
the different functions for extracellular and intracellular requirements is a major 
challenge. The significance o f each o f these barriers will depend on the intended route o f  
administration and the location o f target cells. Any advance in gene delivery will require 
a better understanding o f these barriers at a fundamental level in an attempt to improve 
efficiency.
1.2 APPROACHES TO SOMATIC GENE THERAPY
Finding the right method or vector for introducing new genetic material into the cell 
remains a substantial challenge in the development o f gene therapy. Scientists are 
working on ways to deliver therapeutic genes to enough o f the right types o f cells to 
achieve the desired treatment outcome. Multiple methods have been developed to 
transfer genes into cells o f patients and various research groups have explored these 
options (Miller, 1992; Kay et al., 1993; Ledley, 1995; Knowles et al., 1995; Mendell et 
al., 1995). The efficiency o f transfer, whether or not persistence o f expression is desired, 
and the levels o f  expressed gene product that can be achieved, are some o f the 
characteristics that will determine the type of vector employed. The principle strategies 
for gene delivery can be classified according to the nature o f the product to be 
administered to a patient. There are two basic ways by which genes can be provided to 
patients. Both methods involve the introduction o f genes into vectors that are capable o f  
transporting genes into cells. More commonly, cells are removed from a selected tissue 
in a patient, exposed to gene delivery vectors in vitro (ex vivo) and the genetically 
corrected cells are returned to the patient. Other methods involve introduction o f vectors 
directly into the tissue to be treated (in vivo).
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1.2.1 Ex vivo gene therapy (cell-based)
Early clinical trials involved transfer of ex vivo adenosine deaminase (ADA) gene into 
lymphocytes o f a patient having an otherwise lethal defect in this enzyme, which 
produces immune deficiency (Miller, 1992). The results o f this trial were relatively 
limited due to relatively small amounts o f cells containing the therapeutic gene and 
subsequent low levels o f expression o f ADA. Other approaches to gene therapy used 
either implanted cells or modified viruses for gene transfer. The first approved trial of 
gene transfer involved an ex vivo approach (Culver and Blaese, 1994). There have been 
safety and efficacy issues concerning the applications o f both cell- and viral-mediated 
strategies for the treatment o f other diseases, including cystic fibrosis (Marshall, 1995). 
There are other ex vivo gene therapy strategies based on the introduction o f genes into 
bone marrow cells and these are being used in clinical trials for the treatment of 
Gaucher’s disease (Ohashi et al., 1992), AIDS (Yu et al., 1995; Riddell et al., 1992) and 
to protect bone marrow from chemotherapy toxicity (Deisseroth et al., 1994). More 
recently, exciting results have been obtained by successful human gene therapy clinical 
trials for the treatment o f inherited severe combined immunodeficiency (SCID), which 
can occur when mutations in several different genes o f immune cells exist (Cavazzana- 
Calvo et al., 2000), treatment of haemophilia (Kay et al., 2000) and growth o f new blood 
vessels to treat cardiovascular disease (Isner and Asahara, 1999).
1.2.2 Viral-based In vivo gene therapy
Viral vectors are based on natural viruses where at least one viral gene has been replaced 
by the therapeutic gene. Viral vectors are widely used since the molecular biology of 
viruses is well understood and they give high levels o f RNA uptake and expression. 
Introduction o f DNA into the target cell is performed via optimized and highly evolved 
pathways o f infection without further viral spread post transduction. Such pathways 
provide these vectors with access to a number o f target cells, uptake via receptor- 
mediated endocytosis and efficient intracellular trafficking from the endosomes to the
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nucleus. Hence, a number of viruses have been explored for gene delivery in vivo 
(Rosenfeld et al., 1992).
1.2.2.1 Retroviral vectors
Retroviruses were the first viral vectors used in gene therapy. They splice copies o f their 
genes permanently into the chromosomes o f the cells they invade (Miller, 1990). This 
permanent integration o f therapeutic genes reduces the ability o f physicians to terminate 
therapy as a result o f adverse effects. Retroviral genes stably integrate and this process is 
not transient. Other factors may shut down expression. Although retroviruses have been 
used for direct administration to patients, this has been limited by the rapid inactivation 
by human complement. Recently, some groups have attempted to modify retroviruses by 
inhibiting complement activation and complement-mediated elimination (Rother et a l., 
1995; Rother et al., 1995). Other challenges include the random splicing o f DNA into 
host chromosomes that may lead to activation o f cellular oncogenes. Also, there is an 
inherent inability to characterize completely the retroviral vector preparations used for 
gene transduction generating replication-competent retroviruses (Temin, 1990).
1.2.2.2 Adenoviral vectors
These vectors are o f interest because o f their potential for in vivo gene delivery. 
Adenoviruses are capable o f infecting non-dividing and dividing cells efficiently, 
expressing large amounts o f gene products (Trapnell, 1993; Addison et al., 1995; Chen et 
al., 1994). Integration o f adenoviral DNA sequences does not appear to be an integral 
part o f  their life cycle. This feature avoids the possibility o f disturbing vital cellular 
genes. Because the DNA eventually disappears, there would have to be repeated 
administration o f treatments for chronic diseases such as cystic fibrosis. The more 
serious obstacle to the use of adenoviral vectors in patients is the activation o f host 
immune responses and inflammation in target tissues (Dai et al., 1995). Various reports 
have described cellular immune responses against transduced cells (Yang et al., 1995; 
Yei et al., 1994; Brody et al., 1994). Such responses have perhaps contributed to a lack
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o f gene expression using adenoviral vectors in patients (Knowles et a l ,  1995; Eissa et al., 
1994; Fang et al., 1995).
1.2.2.3 Adeno-associaied viral vectors
Adeno-associated viruses (AAV) are DNA viruses capable o f permanently inserting their 
genome into the chromosomes o f the host cell (Kotin, 1994). AAV vectors can infect 
both dividing and non-dividing cells (Podsakoff et al., 1994). AAV vectors are appealing 
because they cause no known diseases in people and have been shown to produce 
efficient long-term gene transfer (Xiao et al., 1996; Kessler et al., 1996). However, due 
to their smaller size, they may not be able to accommodate large genes compared to 
retroviruses. The requirement for a helper virus to produce sufficient titers o f the virus 
for clinical use has negatively impacted the success o f AAV vector production (Flotte et 
a l,  1995).
1.2.2.4 Other viral vectors
There are several other viruses being explored as vectors as well including herpesviruses, 
alphaviruses and poxviruses. None is perfected yet, but each is likely to have its own 
therapeutic niche. For example, herpesviruses have potential as vectors for therapy 
aimed at neurological disorders. They are attracted to neurons, some o f which retain the 
virus in a harmless state for the lifetime o f the affected person. Alphaviruses have 
several features, which make them suited for use as expression vectors. The RNA 
genome is infectious due to its positive polarity, that is, naked genomic RNA is able to 
initiate an infection when introduced into the cytoplasm o f a cell (Liljestrom, 1995). The 
alphaviruses upon which today’s vectors are based (Semliki Forest and Sindbis virus) are 
not widespread, vector proteins are not produced and therefore there will be no pre­
existing immunity against the vector (Liljestrom, 1995).
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1.2.3 Bacterial-mediated gene delivery
One requirement for bacteria to transfer genetic material into mammalian cells is the 
ability to invade the host cell. Certain intracellular pathogens have developed specific 
mechanisms for cell entry and growth within cells. Several groups have reported direct 
introduction o f DNA from bacteria to mammalian cells. Work by Grillot-Courvalin et 
al., 1998 showed that an invasive strain of E. coli could express EGFP in both dividing 
and quiescent cells. This strain o f E coli is unable to synthesize cell wall and lyse 
without the presence o f diaminopimelic acid (DAP). These DAP-ve E. coli were 
modified by the incorporation of two separate genes. The first was the invasin gene from 
Yersinia pseudotuberculosis, which is necessary for entry o f E. coli into nonphagocytic 
cells that express a subset o f pl-integrins. The second gene, hly, encodes for the 
listeriolysin O gene from Listeria monocytogenes and allows E. coli (and DNA) to escape 
from the entry vesicle.
Bacterial transfer o f DNA for stimulation o f the mucosal immune response holds some 
potential and has been reported by Dietrich et al., 1998. An attenuated self-destructive 
strain o f Listeria monocytogenes was shown to express a listeria-specific phage lysin 
from the ActA promoter. The suicide lysin is expressed once the promoter is activated, 
causing the bacteria to lyse and release plasmid DNA into the cytosol. This system has 
potential for oral administration since the bacteria invades its host through the intestinal 
mucosal surface. Also, antigen presentation occurs shortly after infection, presenting an 
opportunity for DNA vaccine development.
Lemmon et al., 1997 described introduction o f a gene for E. coli nitroreductase, using the 
obligate anaerobe Clostridium beijerinckii. This enzyme activates a nontoxic drug CB 
1954 to a bifunctional anticancer agent. Significant nitroreductase activity was detected 
only in tumours. This selectivity is thought to be due to the hypoxic environment 
required for growth o f these bacteria since the oxygen tension in normal tissues is 
sufficiently high to prevent germination of clostridia. These hypoxic regions typically 
occur in many solid tumours in humans.
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1.2.4 Non-viral gene delivery
A non-viral gene medicine is composed o f a gene encoding a therapeutic protein, a 
synthetic gene delivery system that controls the location o f the gene within the body and 
a plasmid-based gene expression system that controls both the function o f a gene within a 
target cell and secretion o f the produced therapeutic protein (Tomlinson and Rolland, 
1996). Gene medicines are designed to be administered to a patient by conventional 
routes using conventional methods such as direct injection into target tissues (e.g., muscle 
and tumours), inhalation or intravenous injection. They are intended to have low toxicity 
due to the use o f synthetic material for gene delivery and non-integrating plasmids. The 
plasmids degrade within the body, leading to a finite duration o f gene expression. At the 
doses applied, there is no report so far o f plasmid integration into host chromosomes in 
vivo. Thus they should not lead to insertional mutagenesis or oncogenesis as compared to 
the risks associated with the use o f several viral vectors. Several groups have described 
non-viral approaches for gene transfer (Ledley, 1995; Perales et a l., 1994; Baker et al., 
1997; Cotten and Wagner, 1997; Wolff et al., 1990). These systems are attractive for 
various reasons: (I) they can be generated by assembly o f few, defined components, (II) 
they can be very flexible regarding the size o f DNA to be transported, (III) the whole 
diversity o f chemical reactions and physical interactions may be utilized for the synthesis 
and assembly o f transfection material, (IV) plasmid DNA and transfection reagents can 
be produced at a large scale with rather low costs, and (V) safety testing o f synthetic 
material is less laborious than testing o f recombinant material.
1.2.4.1 Naked DNA gene transfer
Plasmids are colloidal systems o f  specific hydrodynamic size, very hydrophilic 
macromolecules and have a highly negative surface charge. These properties determine 
their biological distribution, cellular uptake, intracellular trafficking and nuclear 
translocation (Lew et al., 1995; Liu et al., 1995; Ledley et al., 1994; Thierry et al., 1995). 
Wolff et al., 1990 reported efficient gene transfer in rodent muscle cells, mainly in the 
myofibres, after intramuscular application o f naked DNA in saline without any cationic
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lipids or retroviruses. This was a surprising finding that led to subsequent studies on the 
use o f naked DNA to express therapeutic proteins. The slow turnover rate o f myofibre 
nuclei is thought to allow plasmid DNA to persist for up to several months. Wolff et al., 
1992 showed that expression o f luciferase DNA under regulation by the rous sarcoma 
viral (RSV) promoter lasts for at least 19 months postinjection. Hence, plasmid DNA 
appears to exhibit significant stability when injected into muscle tissue (Utvik et al., 
1999). Elicitation o f a greater degree o f efficiency o f plasmid uptake may be achieved by 
combining DNA transfer with myotoxic agents that selectively destroy myofibres (Davies 
et a l., 1993).
Conditions have been worked out for the local gene transfer o f naked DNA in a number 
o f animal tissues including skin (Hengge et al., 1996). Budker et al., 1996 reported high 
levels o f luciferase expression by injecting naked plasmid DNA into the portal veins of 
mice. However, the levels were achieved with hyperosmotic injection solutions and 
occlusion o f the blood outflow from the liver. These conditions widen the sinusoid 
fenestrae and enhance extravasation o f plasmid DNA. Again Budker et al., 1998 
demonstrated efficient expression o f plasmid DNA within muscle when all blood vessels 
leading into and out o f the hindlimb were occluded. Vile and Hart, 1993 described 
injection o f DNA, encoding the (3-gal gene expressed from two promoters, into B16 
melanomas resulted in extensive transduction of tumour cells in B16s whereas no 
expression was seen in other cell types, due to the inclusion o f cell type-specific 
expression cassette into the vector. The transfection efficiency appears to be species- 
dependent with less expression observed in animals bigger than mice. Also, very large 
amounts o f DNA have to be injected. Nevertheless, Mumper et al., 1996 developed 
polymeric gene delivery systems as an example of optimization o f formulation for gene 
delivery to muscle. They showed that plasmid DNA formulated in 5% polyvinyl 
pyrrolidone was better dispersed in the tissue as compared to plasmid DNA formulated in 
saline. These systems are designed to disperse and retain the DNA throughout the 
muscle as well as protect it from nuclease degradation.
Alternatives to injection by needle include administration involving propelling the 
solution by needle-free jet injection, (Furth et al., 1992). Also, Yang et al., 1990 
demonstrated in vitro and in vivo gene transfer by particle bombardment using the gene
gun where gold microparticles are loaded with DNA and fired into the target tissue. 
Also, improved local expression was obtained by delivering electrical pulses to the DNA- 
loaded area (Aihara and Miyazaki, 1998; Heller et al., 1996).
Following characterization o f the expression and pharmacokinetics o f plasmid DNA  
delivered alone or complexed with cationic liposomes, reports by Meyer et a l., 1995 
attempted to elucidate the mechanism o f DNA uptake by cells. They showed that 
reduced gene expression in the presence o f dextran sulfate and saturation o f the dose- 
expression relationship supported receptor-mediated DNA uptake.
The high relative efficiency o f plasmid DNA in all situations encourages more 
applications of this method to problems o f therapeutic strategies for various diseases and 
DNA-based vaccination protocols (Ulmer et al., 1993). Isner, 1998 reported early 
clinical trial results o f treatment o f an ischaemic limb after intraarterial gene transfer o f 
naked DNA encoding for vascular endothelial growth factor (VEGF). Improvements in 
levels o f serum VEGF, proliferation o f new blood vessels and increase in capillary 
density were observed. Long et al., 1999 reported higher plasma insulin concentrations 
and significantly reduced hyperglycaemia in diabetic mice after naked plasmid was 
injected into skeletal muscle.
1.2.4.2 Expression plasmids
Expression plasmids for non-viral gene therapy should direct the synthesis o f therapeutic 
proteins in a manner that is accurate, achieves a level sufficient for therapeutic effect, and 
is controlled in duration. In plasmids, the size o f the inserted DNA fragment that 
contains the therapeutic gene(s) is unlimited. Plasmids o f high quality (>90% 
supercoiled DNA, 99% purity) can be purified from bacterial fermentations in high yield 
and in a cost-effective manner. Conditions for maintaining the chemical stability o f  
plasmids at or near ambient temperatures are known, and plasmids may be stored for long 
time periods as aqueous suspensions or lyophilized material (Nordstrom, 1999). 
Improvements in the persistence o f gene expression will further help to overcome the 
limitations in gene delivery and create new therapeutic opportunities. The single most 
important influence o f plasmid expression levels in transfected cells is the
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enhancer/promoter. Hartikka et al., 1996 reported significant superiority of the 
cytomegalovirus (CMV) promoter to RSV when plasmids were injected into mouse 
muscle. A comparison o f both promoters showed that expression by CMV was two-fold 
greater than with the RSV promoter and four-fold greater than simian virus (SV40) 
promoter (Qin et al., 1997). The most active constructs contain a CMV promoter, a 
cleavable intron (int), and an improved bovine growth hormone-derived terminator and 
polyadenylation signal (BGH) (Feigner, 1996). Wheeler et al., 1996 found that similar 
constructs gave at least 50 times higher expression in mouse lung compared to previous 
CMV based vectors.
Different groups have considered factors that affect the persistence o f plasmid 
expression. Although integration o f■ expression plasmids into genomic DNA would be 
the most effective way to ensure plasmid persistence in transfected cells, it is not 
desirable since random integration into genomic sites may result in activation of 
oncogenes. W olff et al., 1990 reported no integration into host chromosomes in vivo. In 
addition, lack o f persistent expression in vivo could result from destruction o f transfected 
cells by the immune system (Davies et al., 1997). Loss or degradation of transfected 
DNA may be overcome by the introduction o f replication elements. Although the best- 
characterized origins are from viral sources, research is moving towards characterizing 
mammalian origins o f replication (Wohlgemuth et al., 1996) to avoid the risks o f  
immunogenicity associated with viral origins. Another mechanism that may be 
responsible for short-lived expression in vivo is promoter shutdown and this is thought to 
be due to short-lived transcription factors. Generally, immunological issues are 
significantly reduced in comparison with viral vector approaches.
1.2.4.3 Lipid-based gene delivery systems
Liposome-mediated gene delivery has been used successfully by various groups to 
transfer both reporter and physiologically relevant genes in vitro and in vivo (Caplen et 
al., 1995; Alton et al., 1993; Conary et al., 1994; Hyde et al., 1993; Leventis and Silvius, 
1990; Logan et al., 1995). The prototype cationic lipid for gene transfer is DOTMA 
(Feigner et al., 1994). Formulations o f DNA with cationic lipids such as DOTMA and a
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neutral phospholipid, commonly DOPE, produce lipid/plasmid DNA complexes that are 
capable o f introducing DNA into cells at high efficiency (Feigner et a l., 1989). 
Commercially available cationic lipid mixtures (Lipofectin and Lipofectamine) are used 
routinely for basic research. Cationic lipids that have been investigated more recently for 
gene transfer in vitro (Jiao et al., 1992; McLachlan et al., 1994; Cheng, 1996; Walker et 
al., 1996) include variations of quaternary amine-based cationic lipids including DMRIE 
(Wheeler et al., 1996) and covalent linkage o f polylysine (Zhou and Huang, 1994) or 
polycations such as spermine and spermidine (Behr et al., 1989; Loeffler et al., 1990) 
onto the diacylated backbone or sterol.
Neutral lipids such as DOPE and cholesterol are generally included in plasmid/lipid 
complexes and are thought to effect the release o f plasmids from the endosomes after 
endocytic uptake o f the plasmid/lipid complex by the cells (Farhood et al., 1995). 
Different structures have been described for the resulting complex formed when plasmids 
interact with cationic lipids, which can be micellar or liposomal in structure. Gustafsson 
et al., 1995 used cryoelectron microscopy to show that plasmid/lipid systems resembled 
multilamellar vesicles suggesting that lipid bilayers were able to maintain their structure 
and form stacks o f bilayers with DNA intercalated between the bilayers. Gao and Huang, 
1995 reported that plasmid/DC-Chol:DOPE complexes appeared as ‘spaghetti and 
meatball’ structures. Another proposed model involves the reorganization o f the initial 
lipid structure by fusion o f adjacent lipid structures induced by the polyanionic plasmid. 
This results in the coating o f the DNA with a lipid bilayer along the entire length o f the 
plasmid and possible hexagonal packed structures (Sternberg et al., 1994; Gershon et al., 
1993).
The processes by which plasmids are able to access the nucleus for expression to be 
initiated after transfection o f the cells are still unclear. Only a few mechanistic studies 
have been initiated with the aim o f elucidating the processes that enable plasmids to 
dissociate from a plasmid/lipid complex and translocate to the nucleus o f the transfected 
cells. Many factors influence the pathway of entry including the colloidal and surface 
properties of the system and the type o f transfected cell. Most experimental results now 
support that the uptake o f complexes occurs by an endocytic pathway (Wrobel and 
Collins, 1995; Zhou and Huang, 1994). Zabner et al., 1995, presented direct evidence of
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endocytic uptake by following the entry o f unlabeled and gold particle-labeled plasmids 
condensed with cationic lipids into different cell types in vitro. Indirect evidence has 
been obtained by showing that chloroquine, a lysosomotrophic agent which raises the pH 
o f the endosomal compartment and prevents fusion o f endosomes with lysosomes, was 
able to increase in vitro transfection efficiency of plasmid/lipid complexes (Feigner et al., 
1994; Zhou and Huang, 1994; Legendre and Szoka, 1992). In vitro uptake o f  
plasmid/lipid complexes has been reported to require 4-6 hours o f incubation to achieve 
maximal gene transfer into cells (Van der Woude et al., 1995).
Cationic lipids have been used extensively over the recent years in preclinical studies to 
deliver genes to the lung epithelium o f various species, including rats, by aerosol delivery 
(Stribling et al., 1992). They used a 1: 1 molar ratio o f cationic: neutral lipid to generate 
DNA-lipid complexes suitable for delivery to the mouse airway in aerosol form. The 
first clinical trial using cationic lipid-based systems was initiated by Nabel et al., 1993. 
DC-chol/DOPE-based systems were used to complex a gene expression system 
containing the HLA B7 gene. The plasmid/lipid complex was injected into melanomas to 
induce an immune response against the antigen and potentially enhanced presentation o f  
tumour-specific antigens. Studies in five patients demonstrated uptake and expression o f  
plasmid in the tumours and a partial local response against the tumour. The consistently 
growing number of clinical trials indicates the promise o f such approaches.
1.2.4.4 Polymer-based gene delivery system
1.2.4.4.1 Condensing cationic polymers
Dendrimers are a class o f polymers in which an amine starting material is repeatedly 
substituted at its amino termini to provide a branched structure. At each round o f  
synthesis, another layer o f branched chains is added and termed a ‘generation’. For 
example, a dendrimer with three layers is a 3rd generation dendrimer. Application of 
cationic polymers, such as polybrene has been solely restricted to in vitro gene transfer 
due to their relative low efficiency, cytotoxicity or non-biodegradability. As a result, 
novel polycationic polymers have recently been investigated for in vitro gene transfection
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by several groups (Kabanov and Kabanov, 1995; Haensler and Szoka, 1993; Kukowska- 
Latallo et al., 1996; Boussif et al., 1995). Non-linear cationic polymers, such as 
polyamidoamine cascade dendrimers (e.g., Starbust™ dendrimers) can be produced by 
controlled synthesis with either ammonia or an etnylenediamine core by successive 
addition o f methyl acrylate and ethylenediamine. Because each layer should be fully 
substituted, the resulting spheroidal dendrimer has a precise diameter, molecular weight 
and number of terminal amines. Dendrimers can condense plasmids through electrostatic 
interactions o f their terminal primary amines with the DNA phosphate groups. 
Tomlinson and Rolland, 1996 examined the effect o f the colloidal and surface 
characteristics o f plasmid/dendrimer complexes on gene delivery efficiency. 
Plasmid/dendrimer complexes have been shown to have different zeta potential values
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depending on the concentration o f the dendrimers in the complex. Kukowska-Latallo et 
al., 1996 reported the efficient in vitro transfer of plasmids into various mammalian cells 
using higher generation dendrimers (5th to 10th), which was enhanced by addition of  
chloroquine. Tang et al., 1996 showed data to suggest that transfection activity is 
dramatically enhanced using degraded dendrimers that are capable o f causing endosomal 
escape due to the presence o f titratable amines on these polymers.
There has been enormous interest in the use of the cationic polymer, polyethyleneimine 
(PEI) for gene delivery. PEI is not only among the best vectors currently available fo r in 
vitro work but is proving to be a versatile and effective carrier for different in vivo 
situations. PEI has the highest cationic charge density o f any known organic 
macromolecule (Kichler et al., 1999) since one in every three nitrogens is in an amine 
group and the overall protonation level increases from 20% to 45% between pH values of 
7 and 5 (Suh et al., 1994). PEI has been shown to mediate gene transfer into a variety of 
cells and primary cultures with an efficiency at least as high as that o f cationic liposomes 
(Boussif et al., 1995), without the addition of any cell-binding ligand or endosomolytic 
moiety. In contrast to polylysine, PEI combines DNA binding and condensing activity 
with a high pH-buffering capacity almost over the entire pH range (Tang and Szoka, 
1997). Marshall et al., 1999 showed that PEI was better than polylysine at condensing 
and transfecting yeast artificial chromosomes (YACs). PEI has also been found to 
enhance the delivery o f adenovirus-bacterial artificial chromosome (BAC) DNA
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complexes to cultured cells (Baker and Cotten, 1997). Chemical modification o f PEI 
does not interfere with its high buffering capacity and ability to cause endosomal lysis 
and several cell-binding ligands have been successfully coupled with PEI to mediate 
selective gene transfer. Zanta et a l., 1997 reported efficient transfection in hepatocyte- 
derived cell lines using galactosylated PEI. Transferrin and antiCD3 antibody were both 
incorporated by covalent linkage to PEI. The resulting conjugates achieved up to 1000- 
fold increase in transfection efficiency (Kircheis et al., 1997). More recently, the 
integrin-binding peptide CYGGRGDTP was coupled via a disulphide bridge to 
dithiopyridine-derivatized PEI 25 kDa (Erbacher et al., 1999b). Grafting an RGD- 
containing peptide to PEI condensed plasmid DNA into a homogeneous population o f 30- 
100 nm toroidal particles and improved transfection in fibroblast and epithelial cells by 
two orders o f magnitude. Exchange o f aspartic acid (D) by glutamic acid (E) in the 
peptide sequence reduced the transfection levels to those o f non-targeting complexes 
indicating the involvement o f integrins in gene delivery with RGD complexes. 
Observations by Pollard et al., 1998 demonstrated that DNA complexed with PEI was 
transferred to the nucleus after microinjection into the cytoplasm, a property that is not 
seen with cationic lipids. In additional contrast to cationic lipid complexes, trafficking 
through the nuclear envelope appeared to be the rate-limiting step as opposed to the 
disassembly o f PEI/DNA complexes in the nucleus.
One o f the most promising aspects o f PEI-based gene transfer comes from results in vivo 
that show PEI to have the edge on the other vectors. Intraventricular injection o f 
PEI/DNA complexes formulated in 5% glucose showed the complexes to be highly 
diffusible in the cerebrospinal fluid o f newborn and adult mice, diffusing from a single 
site o f injection throughout the entire brain ventricular spaces (Goula et al., 1998). 
Abdallah et al., 1996 showed extremely high levels o f transgene expression in the mature 
mouse brain. Intravenous delivery o f cationic polymer/DNA complexes was found to 
induce clearance by the reticuloendothelial system (Plank et al., 1996). A delivery 
system produced by Ogris et al., 1999 involving polyethylene glycol (PEG) conjugation 
after transferrin-PEI/DNA formation, prevented interactions with plasma proteins, 
complement factors and erythrocytes. Also, modification with PEG did not interfere with 
in vitro transfection activity and interaction with the transferrin receptor was still
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possible. Similar work done by Erbacher et al., 1999a showed that conjugation of PEG 
to PEI/DNA complexes protected the complexes from parasitic interactions but interfered 
with condensation o f DNA. In this case, conjugation o f PEG occurred before DNA was 
condensed with the ligand-PEI conjugate.
1.2.4.4.2 Non-condensing cationic polymers
Gene delivery systems have been designed to control the distribution o f gene expression 
systems in muscle tissue after direct intramuscular administration and consequently 
enhance their cellular bioavailability (Mumper et al., 1995; Mumper et al., 1996). Such 
systems increase the steady-state levels o f both reporter and therapeutic genes expressed 
in muscle as compared to gene expression systems injected in isotonic saline.
One o f the most effective muscle delivery system is based on protective, interactive, non­
condensing polymers. These colloidal polymers include polyvinyl derivatives that 
interact with a plasmid via hydrogen bonding and hydrophobic interactions, facilitating 
uptake and reducing net negative surface charge o f the plasmid. Immunohistochemical 
staining o f rat muscle sections after intramuscular injection o f either naked DNA or a 
polyvinyl pyrrolidone-based (PVP) formulation o f plasmid showed that the polymeric 
gene delivery system increased the number and distribution o f cells expressing a P- 
galactosidase gene (Mumper et al., 1996). Kinetic studies also demonstrated that 
formulation o f plasmids with PVP extends the range o f  dose responsiveness. Levy et al., 
1996 showed that the injection of 50-100 pg o f plasmid in saline into rodent muscles 
provided maximal levels o f gene expression, whereas Mumper et al., 1996 reported that 
using PVP in the same models increased levels with doses higher than 100 pg o f plasmid.
1.3 FACTORS LIMITING POLYCATION-BASED DNA DELIVERY.
In some applications, the delivery o f RNA or oligonucleotides into the cytoplasm is 
sufficient for obtaining the desired biological effect. The majority o f gene transfer 
approaches, however, aims at the delivery of DNA into the nucleus o f  the cell, where 
gene expression results from transcription into RNA, processing and delivery o f RNA
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into the cytoplasm, followed by translation into the corresponding protein. In any case 
the nucleic acid has to be delivered across cellular membranes: the cell surface 
membrane, the endosomal or lysosomal membranes, or the nuclear envelope. Basically, 
gene delivery can be envisaged as a series o f hurdles (both extracellular and intracellular) 
that successively deplete the mass o f DNA that progresses towards the target site. 
Improvement in the efficiency o f any individual step would be expected to improve the 
overall efficiency.
1.3.1 Extracellular
The presence o f serum nucleases rapidly degrades plasmid DNA. Kawabata et al., 1995 
reported a half-life of less than 10 minutes to degradation. DNA is found in blood at very 
low levels that varies among species due to the range o f deoxyribonuclease activity found 
in these species. Various groups have shown that some cationic polymer-DNA 
complexes prevent such degradation and so could potentially solve this problem (Dash et 
al., 1997; Kayatose and Kataoka, 1998; Leong et al., 1998). It has also been found that 
serum inhibits association o f complexes with the cell membrane. However, this can be 
improved by increasing the charge ratio, which allows the polyplexes to overcome the 
serum proteins (Mastrangeli et al., 1996). The inhibition may also be overcome by 
allowing complexes to incubate in polyanion-containing media before addition to serum- 
transfecting media.
Hashida et al., 1996 have reviewed the biodistribution o f macromolecules and particles 
from the systemic circulation. The main uptake route o f DNA was through scavenger 
receptors found on nonparenchymal cells in the liver. These data indicate the need to 
neutralize the polyanionic nature o f DNA to avoid uptake by these liver cells. Several 
groups have published studies involving intravenous administration using polypeptide 
DNA-condensing agents, often targeted to the liver (Wu and Wu, 1993; Perales et a l., 
1994b). However, these systems have been found to show variable transfection activity. 
The particle size o f complexes is likely to be a major determinant o f activity, since access 
to the liver probably requires particles smaller than 100 nm in diameter (Perales et al., 
1994a). Often, DNA-polylysine particles are reported to be greater than 100 nm in
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diameter. The circulatory system is bounded by endothelium, which is mostly 
characterized as continuous endothelium. This implies that cells are held tightly together, 
and are located upon a basement membrane that structurally prevents molecules with 
diameters greater than 15 nm from passing through. Hence, in most tissues, exit of 
materials from the circulation becomes progressively difficult as molecular weight 
increases. Exception to this is tissues that contain leaky endothelium such as some 
tumours, inflamed tissues, spleen and liver. For 100 nm particles extravasation is likely 
to be highly dependent on blood pressure within the liver (Pouton, 1998). Systemically, 
such particles are almost invariably opsonized by serum proteins such as albumin, and are 
taken up by macrophage populations, mainly in the liver and spleen, unless they have a 
hydrophilic coating to reduce the level o f opsonization and recognition (Stolnik et a l.,
1995). In addition, the binding o f albumin to cationic particles is known to reduce the 
zeta potential and promote aggregation o f particles. Studies by Nishida et al., 1991 
suggest that cationic macromolecules are more readily taken up by the liver and spleen 
than are neutral polymers. Other studies on particles (Tabata and Ikada, 1988) postulate 
that particles with the lowest surface potential have lowest uptake by phagocytosis.
A few studies utilizing non-viral gene delivery systems have described considerable lung 
expression, which was also accompanied by severe systemic toxicity with up to 50% of  
the animals dying from lung embolism (Kircheis et al., 1999; Ogris et al., 1999). 
Obstruction o f the lung capillaries is not surprising considering that the lung provides the 
first capillary bed encountered by the transfection complexes after intravenous injection. 
Particle sizes o f 300-400 nm or less should not cause obstruction o f the lung capillaries 
but the positive charge o f the particles can be responsible for broad non-specific 
interaction with plasma components, extracellular matrix and cell membranes (Kircheis 
et al., 1999). These interactions with serum or salt are likely to lead to growth o f the 
particles, which finally are retained in the capillaries. Avid binding o f positively charged 
complexes to cell membranes, e.g. binding to the lung capillary endothelium can enhance 
this process. Plank et al., 1996 have investigated opsonization o f different DNA- 
polycationic delivery systems through the ability o f these complexes to cause 
complement activation. It was found that complement activation relates to the positive 
charge on the complexes with potency o f activation being chain-length specific for
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polylysine. Condensation with DNA reduced the activation o f complement in all cases, 
with higher charge ratios resulting in greater complement activation. Similar activation 
was reported for all polycations tested including, polylysine, PEI, and dendrimers. 
Cationic lipids gave lower complement activation than polycations, but short chain 
oligolysines had similar properties to the lipids. Modifying complexes with PEG resulted 
in reduction in complement activation activity.
1.3.2 Intracellular
1.3.2.1 Membrane binding and internalization
The binding force o f polycation-mediated delivery is thought to be the electrostatic 
interaction between the positive charges of the complex and the negative charges o f the 
cellular membrane. The uptake o f most macromolecules or particles into cells by passive 
diffusion across the plasma membrane is limited by their low solubility in lipid bilayers. 
Some polypeptides such as herpes simplex virus tegument protein VP22 (Elliott and 
O’Hare, 1997) and the Drosophila homeoprotein, Antennapedia (pAntp) (Derossi et a l.,
1996) have the ability to translocate directly across the plasma membrane by mechanisms 
which are not fully understood. These polypeptides may have a role in the delivery o f  
macromolecules (Prochiantz, 1996; Fahraeus et al., 1996) but have not yet been 
harnessed for delivery o f DNA plasmids. Uptake o f most macromolecules or particles 
occurs into membrane-bound compartments by pinocytosis, adsorptive endocytosis, 
receptor-mediated endocytosis or phagocytosis (Gruenberg and Maxfield, 1995; 
Robinson et al., 1996). The default pathway in the absence o f an escape or trafficking 
mechanism will be fusion with lysosomes and ultimately degradation. Consequently, 
DNA taken up into a vesicle must have a means o f escape or much o f the internalized 
DNA will be lost through degradation. The plasma membranes extracellular surface has 
a net negative charge, which allows cationic particles to bind by electrostatic interaction. 
Adsorptive endocytosis is then likely to occur regardless o f what complex provides the 
excess cationic charge. Moreover, there is no guarantee than endocytosis will lead to
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transfection. Polylysine-DNA complexes are internalized, provided the net charge is 
positive, and even then only in the presence of chloroquine (Pouton, 1998).
A  specific interaction with the extracellular surface may result in tighter binding and 
offers the possibility o f cell-specific targeting o f DNA delivery systems. Targeting 
ligands have been incorporated into DNA complexes to aid (1) targeting specific cell 
types and (2) enhancing intracellular delivery. One simple form o f receptor-mediated 
transfection makes use of the binding o f integrins to the tripeptide Arg-Gly-Asp (RGD). 
Hart et a l., 1996 reported increased transfection o f polylysine-DNA complexes 
incorporating an RGD sequence, probably by promoting internalization following 
integrin binding, in the same pathway as that followed by adenoviruses. Another useful 
ligand is transferrin, because its receptor is ubiquitously expressed and readily 
internalized upon binding to its ligand. Hence, a rapid rate o f uptake could be exploited. 
Also, transferrin is known to recycle through the endosomal compartment without 
necessarily being routed to the lysosome (Wagner et a l., 1994). In these cases, 
internalization is by the efficient cellular process o f receptor-mediated endocytosis. For 
this purpose conjugates with polylysine, protamines, histones, PEI, cationic lipids and 
other polycations have been generated and tested. Data from these experiments suggest 
that the nature o f the cationic carrier can strongly influence which o f the cellular barriers 
are most limiting for gene delivery.
1.3.2.2 Cytoplasmic trafficking
A general association between cytotoxicity and transfection suggests that a degree o f  
membrane-damage must be mediated for DNA to get access to the cytoplasm. Successful 
transfection relies on achieving the correct balance between gaining adequate access o f  
DNA into the cytoplasm and causing excessive and lethal damage to the cell (Pouton and 
Seymour, 1998). The ability o f chloroquine to promote transfection activity o f  
polycation-DNA complexes against a variety o f target cells suggests that a vesicular stage 
with acidification is probably involved. Although the mechanism by which chloroquine 
mediates escape from the endosome has not been established beyond doubt, it seems 
likely that a major disruption o f endosomal function is required due to osmotic swelling
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(Pouton, 1998). This is challenged by reports that other lysosomotrophic bases, such as 
ammonium sulphate, which are similarly capable o f buffering the endosomal pH, do not 
promote transfection. Observations by Erbacher et al., 1996 postulated an alternative 
explanation, which is that chloroquine mediates its action via complex dissociation. 
Viruses have acquired special mechanisms to release their genome from endosomes into 
the cytoplasm. In the case of membrane-free viruses such as adenoviruses, the 
endosomal acidification process specifically activates viral coat protein domains that 
trigger disruption o f the endosomal membrane. In the case o f enveloped viruses such as 
influenza virus the viral membrane fuses with the endosomal membranes. Several 
authors have explored viral means o f endosomal escape (Wagner et al., 1991; Plank et 
al., 1992; Cotten et al., 1990). Cotten et al., 1990 reported that inactivated adenoviral 
particles used to mediate complex escape from the endosome increased transfection 
efficiency dramatically. The disadvantage o f a single administration using viral systems 
led to a synthetic approach for delivery. Wagner et al., 1992b utilized a peptide derived 
from the fiisogenic N-terminus o f the influenza virus haemagglutinin HA-2. 
Employment o f pH sensitive peptides as endosomal-releasing agents for DNA-peptide 
complexes, have since been reported by several groups (Gottschalk et al., 1996; Wilke et 
a l,  1996; Wyman et al., 1997). These peptides may have specificity for endosomal pH 
due to acidic residues (glutamic and aspartic acids) aligning on one side o f an 
amphipathic helix. At neutral pH the negatively charged carboxylic groups destabilize 
the alpha helical structure; acidification o f the carboxylic group shifts the equilibrium 
towards amphipathic helical structure, which promotes multimerization of peptides 
and/or membrane interaction. By introduction o f additional glutamic acids into the 
peptide sequence the pH specificity can be enhanced. The concept that peptide-mediated 
endosome disruption is essential for an efficient delivery o f nucleic acids may also be 
relevant for the delivery o f other biologically active compounds such as antisense 
oligonucleotides, drugs, peptides, or proteins.
Boussif et al., 1995; Abdallah et al., 1996; Kircheis et al., 1997 have all incorporated PEI 
to promote escape from the endosome. Another system currently available is dendrimers 
(Haensler and Szoka, 1993; Tang et al., 1996).
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Much research activity has focused on endosomal escape, the implication being that 
delivery to the cytoplasm would enable the particle to approach the nuclear envelope. 
However, the cytoplasm is a viscous fluid and diffusion o f macromolecular particulate 
systems within this medium may be extremely slow (Luby-Phelps et al., 1987; Meyer et 
al., 1997). Escape from the endosome may leave a condensed particle o f  DNA stranded 
at a site some distance from the nuclear envelope. Vesicles, organelles, and other 
colloidal structures are transported actively using molecular motors associated with the 
micro tubule network or actin micro filaments (Cole and Lippincott-Schwartz, 1995; 
Hamm-Alvarez, 1998). Movement along microtubules is mediated by two classes of  
motor proteins in an oriented manner. Kinesins (and associated proteins) direct 
movement in an outward direction, usually linked to the secretory pathway. Dyneins 
(dynactin) move vesicles in the inward direction, normally associated with the endocytic 
pathway, towards the perinuclear region (Pouton and Seymour, 1998). Coonrod et al., 
1997 noted inhibition o f transfection when vinblastine and cytochalasin B were used to 
depolymerise microtubules. This implies that nuclear transport o f DNA requires routing 
endo somes.
1.3.2.3 Decomplexation
For transcription factor to bind with the plasmid DNA, it is assumed that the cationic 
moieties have to be removed. In other words, the plasmid DNA may have to be ‘naked’ 
or partially uncondensed for transcription to take place. Erbacher et al., 1996 have 
postulated that part o f the mode o f action o f chloroquine may be to promote dissociation 
of DNA and polylysine within the endosome, resulting in improved translocation of DNA 
to the nucleus, or improved rates of transcription. This is contradicted by Wolfert and 
Seymour, 1998 who found that microinjection o f polylysine-DNA complexes into the 
cytoplasm o f Xenopus oocytes in the absence o f chloroquine achieved higher levels of 
gene expression than equivalent injections o f free DNA. However, intranuclear injection 
of polylysine-DNA complexes achieved expression levels comparable to those o f free 




The nuclear membrane is a barrier preventing uptake o f most macromolecules greater 
than 70 kDa into the nucleus, unless they are able to interact with the nuclear pore active 
transport system (Pante and Aebi, 1996; Jans and Hubner, 1996). Dowty et al., 1995 and 
Fritz et al., 1996 have observed that only <1% NIH 3T3 cells expressed p-galactosidase 
after cytoplasmic injection o f a lacZ reporter gene, whereas lacZ was efficiently 
expressed when injected into the cytoplasm of primary rat muscle cells. Both data 
suggest that transport o f naked DNA into the nucleus o f cells is inefficient in a large 
number o f some cell types. Intracellular macromolecular transport into and out o f the 
nucleus occurs through the nuclear pore complex (NPC), which has a functional diameter 
of 26 nm. The current model for nuclear import is a two-step process. The first step is 
energy-dependent binding o f proteins to the nuclear pore complex. The second step is 
energy-independent, temperature-sensitive translocation through the NPC. There are no 
strict consensus sequences but there are similarities between most nuclear localization 
signals (NLSs). They typically include clusters o f four or more cationic residues and are 
often flanked by the a  helix breakers, proline or glycine (Pouton, 1998). The motif - 
PKKKRKV-, has been shown to direct the nuclear import o f the SV40 large tumour 
antigen (Kalderon et al., 1984). Another recently found NLS is required for the efficient 
nuclear import o f the human immunodeficiency virus type-1 (HIV-1) core into quiescent 
cells (Bukrinsky et al., 1993). Substitution of one o f the lysine residues from the HIV-1 
matrix protein NLS -KKKYKLK- results in total abolition o f nuclear import of the HIV 
core (Bukrinsky et al., 1993).
Several groups speculated that polylysine may act as a nuclear targeting signal due to the 
fact that most o f these signals are composed of an array o f highly basic amino acids (K 
and R). Furthermore, the small diameter o f compact toroid forms o f DNA achieved by 
interaction o f DNA with polylysine may also permit the direct entry o f the complexes 
into the nucleus via nuclear pores which are smaller than 30 nm in diameter (Bukrinsky 
et al., 1993). One indication for a nuclear targeting capacity o f polylysine comes from 
results presented by Page et al., 1995 who reported that the injection o f polylysine-DNA 
mixtures into the cytoplasm of mouse embryonic stem cells led to transgenic animals
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with about 50% efficiency compared to intranuclear injection o f naked DNA. In contrast, 
injection o f naked DNA into the cytoplasm did not lead to transgenesis. However, it is 
unclear whether polylysine acts as a transport signal or as a protective agent in these 
experiments.
Nuclear trafficking may become a major barrier for successful gene transfer, considering 
that in vivo, many cells and cell types are resting. Rosenkranz et al., 1992 showed 
nuclear localization o f FITC-labeled insulin-polylysine conjugate after transfection with 
plasmid-insulin-polylysine particles, suggesting that polylysine may indeed be able to 
promote entry o f material into the nucleus. In growing cells, plasmid DNA may 
passively enter the nucleus during cell division after the nuclear membrane is broken 
down (Zauner et al., 1998). '
The effect o f membrane-active peptides and related agents may help to elucidate the 
mechanisms and to overcome membrane barriers o f different gene transfer systems.
1.4 MEMBRANE TRANSLOCATING SEQUENCES
The membrane o f eukaryotic cells represents a barrier normally impermeable to non- 
lipophilic substances. Introducing large hydrophilic molecules into the cytoplasmic or 
nuclear compartments o f live cells without disrupting the plasma membrane seems an 
unattainable goal. In consequence, internalization o f extracellular compounds requires 
the presence o f specific channels, or specialized endocytic mechanisms. Recently, 
several groups have reported that some transcription factors can be internalized by cells 
in culture and addressed to the cytoplasmic and nuclear compartments. Among these 
factors are homeodomain-containing polypeptides and Tat protein.
A 60-amino-acid long DNA-binding domain of Antennapedia, has been found to have 
unexpected properties which opens up new possibilities for cellular delivery. 
Antennapedia is a drosophila homeoprotein. Homeoproteins are transcription factors 
involved in several important biological processes occurring primarily, but not 
exclusively, during development. The DNA binding domain o f these transcription 
factors is highly conserved and is called the homeodomain. It consists o f 60 amino acids 
arranged in three a-helices. It was also demonstrated that a 16-amino acid long peptide
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that corresponds to the third helix is capable of translocating through biological 
membranes (Joliot et al., 1991a). Internalization occurred in various cell types at both 
37°C and 4°C, hence eliminating classical endocytosis (energy-independent mechanism) 
(Derossi et al., 1994). A proposed model for Antennapedia third helix internalization 
involves the interaction o f the peptide with charged phospholipids on the outer side o f the 
membrane. Destabilization o f the bilayer results in the formation o f inverted micelles 
that travel across the membrane and eventually open on its cytoplasmic side (Figure 1.1).
Extracellular medium
Cytoplasm
Figure 1.1. A model for Antennapedia third helix internalization (Derossi et al., 1998).
This 16 amino acid sequence has since been patented and is called Penetratin peptide. It 
has a number o f advantages; it represents a non-disruptive procedure for introducing 
molecules into various types o f cells, which is probably not targeted to the lysosome. 
Also, it has been found that for internalization to take place, only low concentrations o f  
Penetratin are required. The amount of internalized peptide was found to increase with 
an increase in the external concentration without any cytotoxic effect (Appligene product 
information, 1997).
Various experiments were carried out to determine the effect o f point mutations o f the 
antennapedia-homeodomain (Antp-HD) on its biological properties. Induction o f a 
biological effect (neurite elongation) requires internalization, transcription regulation and 
specific binding to a cognate homeoprotein target site. Also, tryptophan present within 
the third helix was found to be vital for internalization (Prochaintz, 1997) since studies o f  
protein-lipid interaction reported that tryptophans are known inducers o f inverted 
micelles (de Kruijff et a l ,  1985). Antp-HD has been used in vivo where it was injected
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into the developing nervous system o f chick embryos (Joliot et al., 1991a). In vitro, 
however, a high efficiency o f translocation has been observed, significant enough to 
require dilution o f the peptide before use. Antp-HD displays high stability as it can be 
recovered intact from the nucleus with fully conserved DNA-binding properties, four 
days after cell internalization. Several groups have now used penetratin to internalize 
peptides, phosphopeptides, full-length proteins, and antisense oligonucleotides inside live 
cells. Penetratin was coupled to a small synthetic peptide and added to tissue culture 
medium of human keratinocyte-derived HaCaT cells where entry into the G l/S phase was 
blocked (Fahraeus et al., 1996). The penetratin sequence was used as a vector for the 
intracellular addressing o f a protein kinase C inhibitor which provoked rapid 
modification o f growth cone morphology (Theodore et al., 1995). The coupling o f the 
penetratin sequence to superoxide dismutase 1 (SOD1) antisense oligonucleotide not only 
caused efficient cellular uptake even in the presence o f serum, but also caused inhibition 
of SOD1 activity and promotion of cell death at low concentrations o f the oligonucleotide 
(Troy et al., 1996). Pooga et al., 1998 described experiments to demonstrate that peptide 
nucleic acid (PNA) oligomer coupled to the cell-penetrating peptide, pAntp, can enter 
Bowes melanoma cells and suppress galanin receptor expression. PNAs though effective 
binders o f RNA are particularly difficult to ferry across the plasma membrane. By 
linking a 21-mer PNA that interacts with galanin receptor type mRNA to a naturally 
occurring penetratin, they have been able to down regulate the receptors in rats, leading 
to decreased galanin binding and a resultant increased tolerance to pain. This unique 
translocating system allows direct targeting to the cytoplasm and nucleus, is non-cell-type 
specific and highly efficient. It also presents a natural, poorly immunogenic system that 
would be a preferred choice to viruses or bacterial toxins, for injection into humans for 
therapeutic purposes.
Another example o f a transcription factor internalized by cells in culture and capable o f  
driving exogenous polypeptides into the cells is the Tat protein o f human 
immunodeficiency virus (HIV) (Fawell et al., 1994). This protein is internalized by an 
unknown mechanism. However, the basic residues present between positions 37 and 72 




Figure 1.2. Tat peptide amino acid sequence (37-72).
In addition, lysosomotrophic agents, such as chloroquine, enhance the amount o f  
polypeptide found in the cells implying that Tat-driven internalization involves the 
endocytic pathway and allows for targeting of high molecular weight proteins. Currently, 
delivery o f therapeutic compounds in vivo can only be achieved when the molecules are 
small (typically <600 Da). For instance, delivery o f bioactive peptides across the blood 
brain barrier is generally restricted to small, lipophilic peptides. Schwarze et al., 1999 
showed that intraperitoneal injection o f the 120-kDa p-gal protein, fused to the protein 
transduction domain from the HIV-Tat protein, results in delivery o f the biologically 
active fusion protein to all tissues in mice, including the brain. These results open new 
possibilities for direct delivery o f proteins into patients in the context o f  protein therapy. 
HIV-Tat peptides have only recently been shown to ferry magnetic particles efficiently 
into haematopoietic and neural progenitor cells (Lewin et al., 2000). The peptide vectors 
derived from these proteins also contain a relatively high number o f positively charged 
amino acids (lysine and arginine), as do most proteins with nuclear localization signals. 
Rojas and colleagues, 1998 also presented a novel approach that allows the efficient 
delivery o f  proteins into living cells. They demonstrated that proteins o f up to 41 kDa 
become cell-membrane permeable simply after their attachment to a short membrane- 
translocating peptide sequence (MTS). The MTS is a 12-residue hydrophobic peptide 
sequence modified from an h region o f the signal sequence of Kaposi fibroblast growth 
factor. They genetically engineered Schistosoma japonicum  glutathione S-transferase 
(GST) to contain the 12-residue MTS at its C-terminus. The resulting fusion protein, 
GST-MTS, was efficiently imported into every cell in vitro by a process mediated by free 
membrane penetration facilitated by the strong interactions between the MTS and the 
lipids o f the cell membrane lipid bilayer. Previously, the largest molecule transported in 
this way was a 25-residue peptide.
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One o f the major obstacles to the development of any successful gene therapy lies in the 
delivery of a target protein to sufficient numbers o f cells to elicit a therapeutic response. 
Although viral delivery strategies have proven to be very efficient, high immunogenicity 
coupled with the inefficiency of in vivo transfection still limit the extent o f gene transfer. 
The potentially detrimental effects o f the increased host immune response may however, 
outweigh the therapeutic benefit achieved by virally targeting a greater proportion of 
cells. A novel approach reported by Dilber et al., 1999, which harnesses the unique 
ability o f the herpes simplex virus type 1 (HSV-1) VP22 protein to spread from cell to 
cell, may provide a means to overcome this.
The HSV-1 VP22 protein forms part o f the viral tegument, a poorly understood region of 
the virion located between the capsid and the envelope. The recent discovery that VP22•i,
possesses novel trafficking properties has aroused significant interest in its potential as a 
protein delivery vehicle (Elliott and O’Hare, 1997) since transport was observed after 
introduction o f the VP22 gene by several routes, including transfection or microinjection 
of the isolated gene in plasmid constructs or by infection with a non-replicating 
herpesvirus encoding the VP22 gene. In infected cells, cytoplasmically located VP22 is 
rapidly excreted via a golgi-independent pathway and is subsequently imported into 
neighbouring uninfected cells by a process requiring an intact actin cytoskeleton. 
Imported VP22 accumulates in the nucleus, where it may affect the regulation o f cellular 
factors, increasing susceptibility to HSV infection (Elliott and O’Hare, 1997). The 
intercellular spread o f VP22 appears to be a highly efficient process, with VP22 
synthesized in one microinjected cell capable of reaching up to 200 surrounding cells 
(Elliott and O’Hare, 1997). In addition, this transport activity was retained in a fusion 
protein consisting o f VP22 linked to green fluorescent protein (GFP) which behaved 
essentially like the native protein with respect to expression, localization and spread 
(Elliott and O’Hare, 1997). A short C-terminal deletion mutant o f VP22 lacking 34 
residues was expressed normally and exhibited unaltered cytoplasmic localization in the 
primary cells expressing VP22 but failed to spread to the surrounding cells implying its 
importance in the transport o f VP22. The widespread delivery o f functional p53 protein 
using VP22 (VP22-p53 fusion protein) to a human tumour cell line induced apoptosis in 
targeted cells (Phelan et al., 1998). Dilber et al., 1999 showed that the spread o f VP22
27
was consistent with the enhanced biological activity of VP22-thymidine kinase (TK) 
fusion proteins in one of the most commonly used suicide gene therapy strategies. 
Recent work has shown that gap junctions are important mediators o f the bystander effect 
both in vitro and in vivo (Vrionis et a l., 1997). Dilber et a l., 1999 demonstrated that in 
VP22-TK expressing cells devoid o f gap junction activity, the addition o f ganciclovir 
resulted in a cytotoxic bystander effect in vitro, and cytotoxicity leading to tumour 
regression in vivo. This makes the VP22 system an attractive delivery vehicle for 
numerous gene therapy strategies, including those with restricted delivery.
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1.5 AIMS AND OBJECTIVES
Internalization o f exogenous macromolecules by live cells provides a powerful approach 
for studying cellular functions. More significantly, understanding the mechanism of  
transfer from the extracellular milieu to the cytoplasm and nucleus could also contribute 
to the development o f new therapeutic approaches. The first part o f this study was to 
investigate the properties o f two membrane-translocating sequences, penetratins and 
VP22.
Penetratins are a class of peptides with translocating properties capable o f carrying 
hydrophilic compounds across the plasma membrane by an ‘energy-independent’ 
phenomenon that is poorly understood. As part o f this project to understand the 
translocation mechanism o f fluorescent derivatives o f penetratin, further studies 
attempted to investigate the kinetic efficiency of cellular uptake as well as the nature of 
the interaction o f the peptide with membranes. One potential way to improve the 
efficacy o f gene therapy is to construct plasmids, which express fusions o f therapeutic 
proteins with membrane translocating peptide sequences (MTPs). Such fusion proteins 
may be able to translocate from transfected cells to other cells in the locality, producing a 
bystander effect, or generally improving the biodistribution o f the gene product within 
the target tissue. The intercellular transport of EGFP fusion constructs incorporating the 
cell-permeable peptide, penetratin and its mutant derivative, were examined in order to 
further elucidate their translocation.
The introduction o f nucleic acids, peptides/proteins, and small molecules into the 
appropriate target cells and tissues is being developed as a therapeutic approach to a 
range o f diseases. Elliott and O’Hare, 1997 demonstrated the remarkable ability of 
herpes simplex virus-1 protein VP22 to ferry proteins between cells. VP22 is efficiently 
transported from the cytoplasm of the original expressing cell and subsequently imported 
to many neighbouring cells, where it accumulates in the nucleus. Following direct 
injection into muscle and tumour tissue, the transport o f VP22 was investigated, in an 
attempt to exhibit delivery in vivo since in vitro models are often markedly different to 
those in vivo , thus making correlation difficult.
29
Several proteins and polypeptides have been proposed as vectors for the delivery of  
macromolecules into living cells. In contrast, toxins and proteins from pathogenic 
agents, capable o f translocating across the membrane and reaching the cytoplasm, have 
been relatively efficient in protein delivery (Fawell et al., 1994), but o f limited 
applicability in gene delivery. Since the discovery o f the ability o f penetratin to 
internalize cells in culture, reaching the cytoplasm and nucleus, part II o f this project 
examined the possibility o f using penetratin as a vector for the intracellular transport o f  
plasmid DNA. In an attempt to elucidate the interaction o f penetratin with DNA in 
complexed systems, comparisons are made with other cationic/plasmid DNA systems and 
endosomolytic agents currently used as effective non-viral gene delivery systems. A 
limited panel o f cell lines including epithelial, fibroblast and tumour cell lines are 
included to study the influence o f different membrane structures on peptide uptake.
The future of gene therapy o f various diseases is dependent on delivery o f DNA to cells 
in vivo, driven by the rapid advancement of both viral and non-viral modes of gene 
transfer. Although the use o f viral vectors constitutes the most efficient process for gene 
transfer, their use is limited due to safety issues. Hence, the assembly o f synthetic virus­
like particles is a credible strategy, since these particles may possess some o f the useful 
attributes o f viral vectors but are completely devoid o f infective capacity in mammalian 
cells. Cell-surface integrins are interesting potential targets for gene delivery by 
polycation-DNA complexes since they are exploited for cell entry by a number o f  
viruses. This section o f the project investigates construction o f synthetic virus-like 
particles that can accomplish selective receptor-binding function, and efficient endosomal 
escape. Although a cationic particle is required for DNA condensation, a 
polylysine/ligand-binding moiety is utilized in this study to create targeting particles that 
are electrically neutral or slightly negative in order to avoid tissue interactions in vivo, 
which often immobilize cationic particles. Further investigations are done to attempt to 
correlate the in vitro biological activity o f complexes with their physical attributes such 
as particle size since ideal transfection particles for in vivo gene transfer should not only 
be small but also electroneutral.
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C H A P T E R  2
G E N E R A L  M A T E R IA L S  A N D  M E T H O D S
2.1 PEPTIDE SYNTHESIS
The peptides were assembled using Fmoc (Atherton and Sheppard, 1989) chemistry on a 
Perseptive Biosystems 9050+ automatic peptide synthesiser with customised protocols. 
Amino acids, with side chain protection where necessary, were protected at the primary 
amino acid end with N-(-9-fluorenyl)methoxycarbonyl (Fmoc) and activated as O- 
pentafluorophenyl (Opfp) esters, (Perseptive Biosystems). The amino acids were coupled 
in the specified order to a polyethylene glycol-polystyrene resin (PEG-PS)™, with 
polyethylene glycol units attached as spacers building from C to N terminus. The resin 
was obtained with the C-terminal amino acid already attached via a cleavable ester bond 
with a typical substitution of 0.2 mMol/gram. Side chain protections used were t-butyl 
for ser, thr, glu, asp; trityl for cys, asn; 2,2,5,7,8-pentamethylchroman-6-sulfonyl (pmc) 
for arg, t-butoxycarbonyl for lys and trp. A 4-fold excess o f amino acid to resin 
substitution was used.
Coupling was performed using HBTU (benzotriazol-N,N,N,N-tetramethyluronium 
hexafluorophosphate) chemistry-1 equivalent o f HBTU, 1-hydroxybenzotriazole (HOBt) 
and 2 equivalents o f  N-methylmorpholine are dissolved with the protected amino acid in 
dimethylformamide (DMF) and added to the DMF solvated resin where the previous 
amino acid has been N-a-deprotected (Fmoc removed with 20% piperidine solution in 
DMF) exposing a free amino terminus. Figure 2.1 shows a general schematic 
representation o f reactions. The final Fmoc group was removed and the resin washed in 
succession with methanol and dichloromethane and dried under high vacuum.
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2.2 PEPTIDE PURIFICATION
The peptide was released from the resin (500 mg) during 2 h with a cocktail (50 ml) o f  
trifluoroacetic acid (TFA) 92.5%, phenol 2%, water 2%, ethanedithiol 2%, anisole 1% 
and triisobutylsilane 1%. Concentration and ether precipitation yielded the white peptide, 
which was collected by centrifugation, washing three times with ether and vacuum drying 
for 30 minutes.
Characterization was performed using reverse-phase HPLC on a C l8 silica wide-pore 
column (15 cm x 2.1 mm) with an elution gradient o f 10%-50% acetonitrile containing 
0.1% TFA over 40 minutes at 217 nm and 277 nm simultaneously. The peptides were 
purified to a single peak on analytical HPLC. Further purification where necessary was 
performed on a 25 cm x 22 mm column using the same conditions. Purity was estimated 
at greater than 90%. Samples o f by-products were o f similar peptides and present in trace 
amounts. The molecular weight was confirmed by mass spectrometry performed on a 
VG Quattro triple quadruple instrument with electrospray ionisation. The purified 
peptides were then lyophilized for use in biological assays. Although the peptides are 
chemically synthesized from the C -  N terminus, they have been written in the opposite 
direction to how they are synthesized.




• Mutant penetratin (mutant pAntp)
H2N-RQIKIWFQNRRMKFKK-COOH
• Bifunctional penetratin (K2spenetratin)
H2N-K25-RQIKIWFQNRRMKWKK-COOH
• RGD-containing peptide couple to oligolysine (K2 5 -RGD) 
H 2N-K 2 5 -GACDCRGDCFCA-COOH
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Figure 2.1. Schematic representation of the coupling reaction o f peptide synthesis
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2.3 CELL CULTURE TECHNIQUES
2.3.1 Solutions
2.3.1.1 Water
Milli-Q water used for the preparation o f all culture solutions was obtained from a Milli- 
Q PF Plus system with ultrafiltration cartridge (Millipore, UK, Ltd).
2.3.1.2 Phosphate buffered saline
Phosphate buffered saline (PBS) tablets without magnesium or calcium ions were 
obtained from Oxoid Ltd, UK. This solution was made by dissolving one tablet per 100 
ml milli-Q water at a pH of 7.3. PBS solutions were sterilized by autoclaving at 121°C 
for 15 minutes.
2.3.1.3 Sodium Bicarbonate and sodium hydroxide
Solutions o f 7.5% (w/v) sodium bicarbonate and 1 M sodium hydroxide were prepared 
individually using milliQ water and sterilised by autoclaving.
2.3.1.4 Ethylene Diamine Tetraacetic Acid (EDTA)
A 0.02% (w/v) solution of ethylenediamine tetraacid (EDTA) was prepared in PBS. 
EDTA in PBS solutions was also sterilised by autoclaving.
2.3.1.5 Trypan Blue
This dye, made as a 0.1% (w/v) solution in PBS, was used to assess cell viability. It was 
obtained from BDH laboratory Reagents Ltd.
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2.3.1.6 Culture media and additives
All solutions used for the preparation o f culture medium for cells were obtained from 
GIBCO BRL, Paisley, unless prepared as above. Eagle’s Minimum Essential Medium 
(MEM) with Earle’s salts, without sodium bicarbonate and L-glutamine was obtained as 
lOx concentrates. MEM non-essential amino acids solution (MEM-NEAA), L-glutamine 
(200 mM), and penicillin (10000 iu/ml)-streptomycin (10000 jag/ml) were obtained as 
lOOx concentrates. Foetal calf serum (FCS) from various suppliers was batch tested to 
determine which provided optimum growth o f cells. As a result, FCS with batch 
numbers 06Q5262A, 30Q5262A and 06Q7554F from GIBCO were used. Growth media 
were prepared aseptically according to the formulae below, stored at 4°C and used within 
three weeks o f preparation.
Table 2.1 below shows formulae for making MEM
ADDITIVE VOLUME (ml)
Eagle’s MEM lOx 50




7.5% w /vN aH C 03 15
MilliQ water to 500
1 MNaOH Adjust to pH 7.4 ~ 2 ml
2.3.2 Equipment and disposable items
All aseptic techniques were carried out in a laminar flow cabinet (MDH Ltd) designed for 
vertical re-circulation o f air. Cells were cultured in an LEEC PF2 anhydric incubator 
(Laboratory and Engineering Company) with a set temperature o f 37°C.
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Growing cell cultures were viewed daily under an inverted light microscope (WILD M4, 
Wild Heerburg Ltd). For determination o f cell concentration in suspension, a double grid 
haemocytometer (Neubauer 0.1mm Dept, Weber, UK) was used to count appropriately 
diluted samples.
9 9Sterile 75 cm and 175 cm filter top tissue culture flasks were obtained from Falcon, 
Becton Dickinson and Co, UK. Six- and 96-well plates were obtained from Nunc, 
Denmark. Cryopreservation ampoules used for storing frozen cells in liquid nitrogen 
were obtained from Coming, UK.
2.3.3 Cell Culture methods
All cells were grown in Eagle’s MEM containing 10% FCS and maintained at 37°C in a 
LEEC anhydric incubator in a humidified atmosphere o f 95%/5% carbon dioxide. Daily 
check ups were made to check cell cultures for evidence o f bacterial and fungal 
contamination. All cell lines were grown as monolayer cultures and subcultured at 80- 
100% confluence. The medium was changed every 48 hours.
For subculture, used culture medium was discarded and the 175 cm3 flask was rinsed 
three times with 10 ml aliquots o f PBS and then incubated at 37°C with 2 ml o f 0.02% 
EDTA for approximately 5 minutes. Detached cells were diluted to 10 ml with complete 
culture medium, and an appropriate aliquot of suspension transferred to a sterile 175 cm3 
flask containing 50 ml o f fresh culture medium. Cells treated with EDTA solution were 
similarly diluted to 10 ml after detachment but were then centrifuged at 1000 rpm for 6 
minutes, the supernatant discarded and then resuspended in 10 ml o f culture medium 
before transfer into flasks for subsequent culture.
2.3.3.1 Determination o f  cell concentration
After cells are detached from flask, the cell suspension was briefly vortexed in a 
whirlimixer. To 100 pi o f suspension was added 200 pi o f PBS and 200 pi o f Trypan 
Blue solution all in a microcentrifuge tube. A sample was loaded on to a grid
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haemocytometer overlaid with a coverslip. Viable cells could be seen by a bright ‘halo’ 
light around their cellular membrane as opposed to dead cells which were permeabilised 
and stained blue by the dye. The viable cell numbers in the four squares surrounding the 
central square were counted and this was repeated for the other side o f the 
haemocytometer grid, using an inverted light microscope.
The viable cell concentration in the original suspension was calculated as follows:
Cells/ml = Av. cell count per chamber x 104x dilution factor (5) 
Equation 2.1.
2.3.3.2 Cell storage and recovery
Cells were prepared for storage by detachment o f a confluent monolayer according to the 
protocol mentioned in the previous section followed by centrifugation at 200 g  (1000 
rpm) for 8 minutes. The supernatant was then discarded and the cells resuspended in 
filter sterilised (0.2 pm acrodisc) solution o f culture medium supplemented with 10% v/v 
dimethylsulphoxide (spectrophotometric grade, Aldrich, UK) as a cryopreservative. Cell 
suspensions were then dispensed in 1.8 ml aliquots into coming tubes, transferred to a 
Union Carbide BF6 biological freezer unit plug which fitted into a Union Carbide LR-40 
liquid nitrogen freezer. This permitted the cells to be cooled down to -70°C at a rate of 
approximately 1°C per minute. The cells were then transferred to a Union Carbide LR- 
40 liquid nitrogen freezer where they were stored at approximately -148°C.
For cell recovery, the contents of an ampoule was thawed rapidly by brief incubation in a 
37°C water bath followed by dilution with 10 ml o f fresh medium added dropwise. Cells 
were centrifuged for 8 minutes at 200 g  and the supernatant was discarded. The cells
'y
were then resuspended in 10 ml o f fresh medium and the transferred into a 175 cm flask 
containing 50 ml o f medium and then incubated under standard culture conditions. Cells 
were cultured for at least two passages in order to establish them before they were used 
for experiments.
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2.4 TRANSFECTION OF CELLS
One hour prior to transfection, monolayers o f rapidly dividing cells were washed once 
with warm Opti-MEM™, which is a serum-free medium specifically designed for 
transfection experiments and then 1.5 ml of this medium was added to each well. Five 
hundred microlitres o f complex containing 2 pg o f DNA and variable quantities o f gene 
transfer agent were added to each well. Transfection was carried out for four hours at 
37°C after which time the transfection medium was replaced with fresh complete culture 
medium and cells were cultured for a further 24 hours before harvesting for analysis. For 
all transfection studies, each data point represents the mean ± standard deviation (SD) of 
triplicate samples and each experiment was repeated on at least two occasions (often 
three times).
2.5 MOLECULAR BIOLOGY METHODS
2.5.1 DNA preparation
The following three reporter plasmid constructs were used for transfection experiments 
(Appendix D). pCMV(3 (Clontech) is a 7.2 kb reporter plasmid, which contains the E.coli 
(3-galactosidase gene under the transcriptional control o f the human cytomegalovirus 
(CMV) immediate early promoter/enhancer element. pEGFP-Nl (Clontech, UK) 
contains the enhanced GFP under the control o f CMV promoter. EGFP expressing cells 
can readily be detected by visualization using a fluorescence microscope or by FACS 
analysis. The plasmid, pCMV/wc (a kind gift from J.-P Behr) contains the firefly 
luciferase reporter gene encoding luciferase under the transcriptional control o f the 
cytomegalovirus (CMV) promoter. The following steps were used to produce milligram 
quantities o f all plasmids used throughout this project.
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2.5.2 Preparation of competent E.coli DH5a cells
Escherichia coli strain DH5a was used for the propagation o f all plasmids.
Competent E.coli DH5a cells were prepared and transformed with the appropriate 
plasmid using the heat shock technique as described by Sambrook et al., 1989:
Tfbl buffer
30 mM KC1 3 ml o f a 1 M solution
lOOmMRbCl 1.209 g
10 mM CaCb 12.5 ml o f 80 mM solution
50 mM MnCb 5 ml (1 M solution)
Water to 100 ml
Adjust to pH 5.8 with 0.2 M acetic acid and filter sterilise.
Tfbll buffer
10 mM MOPS 0.209 g
75 mM CaC12 1.100 g
lOmMRbCl 0.1209 g
15% (v/v) glycerol 15 ml
Water to 100 ml
Adjust to pH 6.6 with 1 M KOH and filter sterilise.
A single colony o f E.coli DH5oc was picked from a fresh agar plate and inoculated into 5 
ml o f LB medium and incubated at 37°C overnight in a shaking incubator. The following 
morning, 1 ml o f culture was diluted to 100 ml with LB and grown under standard 
conditions until the optical density (OD550 nm) o f the solution reached 0.48 (2.5 -  3 hours). 
The cell suspension was then chilled on ice for 5 minutes and centrifuged in sterile falcon
tubes for 5 minutes, 600 rpm (Beckham J2-MC) at 4°C. The supernatant was discarded
and the cells re-suspended in 40 ml o f Tfbl buffer (2/5th volume o f culture) and chilled on
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ice for 5 minutes. Cells were centrifuged at 6000 rpm for 5 minutes at 4°C and the 
supernatant discarded. Cells were subsequently re-suspended in 4 ml (l/25 th volume of 
culture) of Tfbll buffer and chilled on ice for 15 minutes. Cells were stored in 200 pi 
aliquots, snap frozen in a dry-ice/methanol bath and stored at -70°C until required.
2.5.3 Transformation of competent E.coli DH5oc cells
200 pi o f competent cell suspension was thawed at room temperature and then placed on 
ice for 10 minutes. Plasmid DNA (<100 ng) was then added and gently mixed followed 
by incubation on ice for 30-45 minutes. The cells were shocked by incubating at 37°C 
for 2 minutes or 42°C for 90 seconds and then returned to ice for 20 minutes. The cell 
suspension was then diluted to 800 pi with LB followed by incubation at 37°C for 1 hour. 
After this time, 200 pi o f this suspension was plated out on an LB-agar plate (Appendix 
C) containing ampicillin and tetracycline (Appendix B) at concentrations o f 50 pg/ml and
12.5 pg/ml respectively. Plates were inverse incubated overnight at 37°C.
2.5.4 Plasmid propagation, isolation and purification
A single colony o f E.coli DH5a containing the desired plasmid was isolated from an LB- 
agar plate supplemented with ampicillin and tetracycline (50 pg/ml and 12.5 pg/ml 
respectively) and inoculated into 10 ml o f LB broth containing the same antibiotics 
(primary culture). This primary culture was grown for 8 hours at 37°C on a shaking 
incubator at 300 rpm (New Brunswick Scientific, UK) and then a 5 ml aliquot was 
expanded in 500 ml o f LB broth, also containing the appropriate antibiotics, and grown 
overnight.
The plasmids were isolated by the alkaline lysis method (Bimboim and Doly, 1979) and 
the cell lysate purified by anion exchange chromatography using the Plasmid Maxi kit 
(Qiagen Inc., Surrey, UK) according to the manufacturers’ protocol. The isolated DNA 
was dissolved in TE buffer (Tris 10 mM, EDTA 1 mM), pH 8 and stored at -20°C.
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2.5.5 Purification of DNA by phenol/chloroform extraction
One volume o f phenol: chloroform: isoamyl alcohol (25: 24: 1) was added to the DNA 
solution and the two solutions mixed by ‘flicking’ the microcentrifuge tube. The tube 
was then centrifuged at 14000 rpm for 1 minute (Jouan A14 microfuge, France) to 
separate the phases, and the upper aqueous phase removed without disturbing the 
interface. This process was repeated once, followed by the addition o f  1 volume o f 24: 1 
chloroform-isoamyl alcohol to precipitate the remaining protein and reduce the amount of  
dissolved phenol, which is in the aqueous phase. Once again the upper aqueous phase 
was removed and the DNA within this phase precipitated using one o f the following 
precipitation methods.
2.5.6 Ethanol precipitation of DNA
To a volume o f DNA solution in a centrifuge tube was added 0.1 volumes o f 3 M sodium 
acetate solution and 2 volumes of absolute ethanol. The sample was then chilled 
overnight at -70°C or for 15 minutes in an ethanol/dry-ice bath. After this time, the 
sample was centrifuged at 14000 rpm for 10 minutes at 4°C, the supernatant was 
discarded and the DNA pellet washed once with 70% ethanol. The sample was again 
centrifuged at 14000 rpm for 10 minutes, the supernatant discarded and the pellet air 
dried for 5 minutes, being careful not to over dry. The pellet o f  DNA was then re­
suspended in 10 mM Tris-Cl buffer, pH 8.5.
2.5.7 Isopropanol precipitation of DNA
The salt concentration o f the DNA solution was adjusted with sodium acetate 0.3 M and 
0.7 volumes o f isopropanol added at room temperature. The DNA solution was 
immediately centrifuged at 14000 rpm for 20 minutes at 4°C. After carefully decanting 
the supernatant the pellet was washed in 70% ethanol at room temperature and 
centrifuged for a further 10 minutes at 4°C. Once again the supernatant was removed and
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the pellet air-dried for 5 minutes. The DNA pellet was then re-suspended in 10 mM Tris- 
Cl buffer, pH 8.5.
2.5.8 Sample purity and quantification
For quantification o f plasmid DNA, a 10-20 pi aliquot o f sample was diluted to 1 ml with 
distilled water and the absorbance o f the solution measured at 260 nm (A260) and 280 nm 
(A28o)- The concentration o f DNA in the original solution was calculated as follows:
Concentration o f DNA (pg/ml) = Dilution factor x 501 x A260
^ased on the assumption that 50 pg/ml solution of double stranded DNA has an 
absorbance o f 1 at 260 nm (Sambrook et al., 1989; Laboratory manual).
The purity o f DNA was calculated as follows:
Ratio = A260 /A280
Ratios between 1.8 and 2.0 (indicates high purity) were consistently obtained.
2.5.9 Sample identification
A sample o f purified DNA was linearised with a restriction endonuclease (New England 
Biolabs, UK) for 2 hours at 37°C and then loaded on to a 1% w/v agarose gel in 0.5x 
TBE. The gel was then electrophoresed in the same buffer at 80 volts for one hour 
against marker DNA (EcoR I/Hind III cut X DNA) o f variable length to confirm the size 
of isolated DNA. At the end o f a run, gels were stained with ethidium bromide in 0.5x 
TBE at a concentration o f 0.5 pg/ml for 10 minutes. The DNA bands were visualised 
using an ultraviolet light box. The gel verified that the majority o f the DNA was 
supercoiled and free from contaminating nucleic acids (genomic DNA or RNA).
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2.5.10 Calculation of cationic polymer to DNA charge ratio
The calculation o f negative charge provided by the DNA was determined on the basis 
that each nucleotide in the DNA sequence is associated with a single negative charge. A 
mean value o f 330 was used as the molecular weight o f a monophosphorylated 
nucleotide, as established from data given by Sambrook et al., 1989; Feigner et al., 
1994).
No. o f  mols of positive charges = Mass o f peptide x No. o f positively charged groups
Molecular weight o f peptide
No. o f mols of negative charges = Mass of DNA
330
(+/-) charge ratio = No. o f molecules o f positive charges 
No. o f molecules o f negative charges
The complexation of plasmid DNA with PEI introduced a concept o f  N/P ratio. This is 
the ratio o f nitrogens from PEI to phosphates from DNA. According to the protonation 
profile o f PEI, every sixth nitrogen atom is protonated under physiological conditions 
(Boussif et a l ,  1995). Hence only a theoretical charge ratio can be calculated from a pH 
titration o f PEI. More recent literature (Erbacher et al., 1999a) has reported a shift in the 
protonation profile o f PEI complexation with DNA. Here a significantly higher 
percentage o f PEI (about 10% more than was previously found) becomes charged at 
physiological pH.
2.6 METHODS OF ANALYSIS
2.6.1 Preparation of cell extracts post transfection for analysis
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Solutions
Phosphate buffered saline (PBS)
0.1 M sodium phosphate buffer (pH 7.3)
Lysis buffer (see section 2.6.2).
2.6.1.1 Detergent Lysis M ethod
After the appropriate period o f incubation post transfection, the cell monolayer was 
washed twice with 2 ml o f PBS. Washed monolayers were treated with 250 pi o f lysis 
buffer per well and the plates were frozen at -70°C. After thawing at room temperature 
for 30 minutes, the cell extracts were collected and transferred into sterile micro- 




Luciferase levels within cells were quantified using the Promega luciferase assay system
20(Promega, UK) according to the manufacturer’s instructions. As little as 10’ moles 
(0.001 pg) o f firefly luciferase can be measured using this kit. A standard curve o f light 
units vs. relative enzyme concentration was produced using purified firefly luciferase 
(Appendix E). The Promega lysis buffer (lx: 25 mM Tris-phosphate, pH 7.8; 2 mM 
DTT; 1, 2-diaminocyclohexane-N, N, N ’, N ’-tetraacetic acid; 10% glycerol; 1% Triton® 
X-100 and BSA 1 mg/ml) was employed. Supplementation with 1 mg/ml BSA ensures 
that luciferase is not lost from solution by adsorption onto container walls. After 
centrifugation o f the cell lysate, 20 pi o f room temperature cell extract (supernatant) were 
mixed with 100 pi o f luciferase assay reagent (luciferase assay substrate + 10 ml of assay 
buffer) again at room temperature. The disposable test tube containing the reaction 
mixture was then immediately placed into the luminometer. Light output was measured
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using a Turner Designs TD-20/20 luminometer. The instrument settings were as follows: 
a delay o f 2 seconds, integrate for 10 seconds, sensitivity level 25.1%.
The time course for the expression o f luciferase in B 16 cells was studied. Appendix J 
shows the sensitivity o f the luminescent assay. Expression o f luciferase peaked at around 
24 hours, after which there was a decline in expression. Hence all transfection 
experiments were analysed after 24 hours o f incubation.
2.6.2.2 Protein assay
The luciferase figures were converted to relative values by dividing the assay level per 
well by the amount o f protein (mg) in the well at the end o f the transfection. The protein 
content in cell extracts was measured using the Bio-Rad Dc protein assay kit. Samples 
were prepared according to the manufacturer’s protocol (macro-assay) and calibration 
curves were constructed using bovine serum albumin as a standard. Spectrophotometric 
measurements were made at 750 nm. A typical standard curve is shown in appendix F.
2.7 CHARACTERIZATION METHODS
2.7.1 Particle size analysis
Photon Correlation Spectroscopy (PCS) was used to obtain the mean hydrodynamic 
diameter o f complexes using the ZetaPlus particle sizing software (Brookhaven 
Instruments Corporation). Measurements were made using an argon laser o f wavelength 
633 nm at a temperature o f 20°C and an angle o f 90°. To reduce particulate 
contamination all glassware for sample preparation and measurements were washed three 
times with prefiltered Millipore water and left to dry in a laminar flow cabinet. All 
complexes were prepared in 5% glucose. Briefly, 102 pg o f plasmid DNA were mixed 
with various quantities o f peptides to produce a range o f charge ratios. The complexes 
were incubated for 20 minutes at room temperature prior to measurements being made.
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PARTI




INVESTIGATION OF INTERNALIZATION AND CELLULAR 
TRAFFICKING OF FLUORESCENT PEPTIDE DERIVATIVES
3.1 INTRODUCTION
Classically, direct cytoplasmic access is usually attained by membrane disrupting 
techniques, such as microinjection, electroporation or toxin-based techniques. Hence, the 
reported ability o f the Drosophila protein, pAntp, to enter cells without rupturing the 
plasma membrane, where it appears to reach the cytoplasm and target the nucleus, is o f  
great interest. This discovery o f membrane translocation can provide a useful tool for 
investigating and influence various intracellular processes in cellular systems. Also, it 
presents potential applications in cell biology and may form the foundation of a delivery 
system, which can be used to internalize different molecules into cells. So far, the 
mechanism by which penetratin performs this cellular internalization has not been 
confirmed. One suggestion for its mechanism of translocation is the formation o f  
inverted micelles as a result o f destabilization o f the lipid bilayer. One aspect o f this 
chapter looks at the transport o f penetratin peptides across cells in culture in an attempt to 
elucidate its mechanism o f translocation. Fluorescent derivatives o f wildtype penetratin 
and a published mutant (reported to be inactive) were synthesized. A number o f  
fluorescent dyes were coupled separately to the peptides in order to follow the mobility o f  
these fluorescent derivatives within cells. To achieve this, laser scanning confocal 
microscopy and transmission electron microscopy techniques were both employed. This 
chapter also describes studies o f the interactions between various peptides o f interest and 
the lipid bilayer o f plasma membranes in an attempt to explain the mechanisms o f  
membrane translocation that these peptides utilize. This involved studies o f peptide- 
membrane interactions using a novel fluorescence technique. Fluorescence 
measurements were made using a spectrophotometer with software for collection o f data 
against time. Hence, it was possible to probe the affinity o f these peptides and their 
derivatives for the membranes.
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3.2 MATERIALS AND METHODS
Peptide syntheses and cell culture techniques have been described in Chapter 2.
3.2.1 Preparation of labelled peptides
3.2.1.1 Fluorescent dyes
A number o f fluorescent labels were used during the course o f this study.
The green fluorescent dye, BODIPY FL CASE, was supplied as 1 mg orange powder by 
Molecular Probes, Inc, USA. . ' '
Biotin was obtained from SigmaAldrich, UK. It appeared as a white powder and has a 
molecular weight o f 341.4.
Amersham Life Science, UK, supplied fluorescein-linked streptavidin (-FITC) and 
human transferrin biotin-labelled. Both were obtained in solution and were stored at 2 -  
8 °C. Colloidal gold-labelled streptavidin (10 nm) was obtained from SigmaAldrich, UK. 
It was supplied as a red liquid suspension. Aliquots o f 100 pi were prepared and stored 
at -20°C.
3.2.1.1.1 Synthesis o f ADMP.
The other dye employed was ADMP (Bennett et al., 1999), a coumarin-based amino acid. 
This dye was described by Dr Sukhi Bansal and was synthesized at King’s College, 
University o f London. The synthesis involved wet chemistry techniques and was under 
the supervision o f Dr Bansal. It was obtained as a light brown powder and with a 
molecular weight o f 264.
The synthetic strategy involved four steps:
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The first step involved the synthesis of chloromethoxycoumarin, a reaction between 
equimolar quantities o f the phenol (40 mM, 6.16 g) and the acetoacetate (40 mM, 5.40 
ml) using toluene (200 ml) as solvent in the presence of an ion exchange catalyst, 
Amberlyst 15 (4 g). The reaction was allowed to proceed over 24 hours after which TLC 
was used to confirm completion. The TLC solvent system was ethylacetate: hexane (2: 
1) (BDH, Ltd.). Recrystallization was carried out to ensure purity for step 2, using 
boiling ethanol. A 60% yield was achieved (Scheme 1).
STEP 1
Me














Dried sodium hydride (0.036 mol) was dissolved in 30 ml DMF, cooled to between -10 
and -30°C and stirred under nitrogen. To the suspension was added
MeO+
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diethylacetamidomalonate (0.039 mol) dissolved in 50 ml DMF. The mixture was stirred 
at room temperature for one hour. This mixture was then added to a solution o f  
chloromethoxycoumarin dissolved in one litre o f DMF, stirring overnight at room 
temperature. The DMF was removed using a rotatory evaporator, after which the mixture 
was washed to remove sodium chloride. Again, TLC was used to confirm identity and 
ensure completion. An extraction was carried out with ethylacetate and 0.1 M HC1 and 
the sample was dried using anhydrous sodium sulphate (Scheme 2). The product was 
recrystallized from ethanol, and analyzed by TLC, which showed the presence o f  
impurities. Column chromatography with silica gel was employed to remove impurity 
fractions. The solvent system was ethylacetate: hexane (2: 1).
,CC>2Et 










Step 2 Ethyhcetatedimethoxycournarin (Scheme 2)
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Step three was an acidification step. Hydrochloric acid (6 M) was added to the product 
from step two and refluxed overnight at 250°C. The sample was evaporated to dryness 
using a vacuum. The TLC solvent system was n-butanol: water: acetic acid (4: 1: 1). 
Recrystallization procedures involved boiling in ethanol (15 ml) and 1 M NaOH (6 ml). 
The product was then acidified with acetic acid (2.5 ml) leaving a brown precipitate.
STEP 3
MeO 6M H21 MeO
Step four involved the addition of frnoc N-hydroxysuccinimide (1.15 g) (NovaBiochem) 
to the amino acid (1.0 g) in a mixture of acetonitrile (Rathbum, Ltd): water (1: 1). 
DIPEA (1.25 ml) (Fluka) was added as a coupling agent. The mixture was stirred 
overnight, after which 1 M HC1 (40 ml) was added. The TLC solvent system was 














A ninhydrin test was carried out on ADMP. The detector system was a mixture o f 0.3 g 
ninhydrin, 100 ml 1-butanol and 3 ml glacial acetic acid. The absence o f a purple stain 
confirmed the coupling o f the fmoc to the coumarin compound. ADMP has the 
following properties:
Absorbance maximum at 345 nm, e = 11000 M^cm' 1 
Fluorescence emission at 429 nm
The purity o f the label was carried out with HPLC and its identity confirmed using 
Nuclear Magnetic Resonance (NMR) (appendix H).
3.2.1.2 Coupling o f  fluophores to peptides
The coupling reactions o f both ADMP and Biotin to the peptides were as follows:
Into an eppendorf, 1 ml of DMF was added, after which 40 mg o f the fluophores was 
added. A combination o f coupling agents was used: equal molarities o f 1, 3 
diisopropylcarbodiimide (DIPCIDI) (Fluka, UK) and N-hydroxybenzotriazole (HOBt) 
(PerSeptive Biosystems, UK) were added to the eppendorf. Then the peptide coupled to 
dry resin was added. The reaction mixture was left for one hour while shaking at 15- 
minute intervals. The quantities of reagents used in this protocol varied according to the 
fluorescent dye in question. Although it is usual to have a 4: 1 molar ratio o f dye to 
peptide for each coupling reaction, this ratio could not be achieved with the BODIPY FL 
CASE/peptide reaction due to the cost and therefore lack o f availability o f BODIPY. 
Hence a ratio o f  1: 1 was used for BODIPY. 2 mg o f BODIPY was added to 250 pi of 
DMF in an eppendorf, after which equivalent molar quantities o f the coupling reagents 
were added followed by the peptide on dry resin. The reaction was left overnight on a 
shaker. The coupling efficiencies o f each reaction are shown in table 3.1.
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Peptides Biotin BODIPY FL ADMP
Penetrating 5 - + + H—1—1—h
Penetratin + + + + + + + + + +
Penetratin mutant + + + + + + + + + +
Table 3.1 shows the efficiencies ( + ) o f the various coupling reactions. These pluses (+) 
were allocated arbitrarily. Four (+) indicated 100% coupling. Two (+) indicated 50% 
coupling.
The following tests were carried out to confirm that the fluophore had been linked to the 
peptide, as evidenced by the absence o f amine groups. A sample o f the resin was washed 
with dimethylformamide (DMF), dichloromethane (DCM) and methanol (MeOH) in 
succession prior to the following two tests.
A) Kaiser Test
The most widely used qualitative test for the presence or absence o f free amino groups 
was devised by Kaiser et al., 1970. The following solutions were prepared:
1. Dissolve 5 g o f ninhydrin in 100 ml ethanol
2. Dissolve 80 g o f liquefied phenol in 20 ml o f ethanol.
3. Add 2 ml o f a 0.001 M aqueous solution o f potassium cyanide to 98 ml pyridine.
A few resin beads were washed several times with ethanol. The resin was transferred to 
a small glass tube and two drops o f each of the above solutions were added. The 
solutions were mixed well and then heated in an oven to 120°C for 4-6 minutes. Blue 
resin beads indicated a positive test for the presence o f amines.
B) 2, 4, 6-trinitrobenzenesulfonic acid (TNBS) test
In an eppendorf, the following were added: 0.5 ml DMF, 50 jil Diisopropylethylamine 
(DIPEA) and two drops o f 2, 4, 6-trinitrobenzenesulfonic acid (SigmaAldrich, UK). A
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sample of resin beads was placed on a white ceramic tile. A few drops o f test solution 
were placed over the resin. A positive result was a distinct red colour indicating the 
presence o f amines while a lack o f colour change indicated the absence o f amines 
(Hancock and Battersby, 1976). The percentage o f beads that change colour gave an 
indication o f how far the coupling has gone.
If these tests proved negative, dry nitrogen gas was bubbled through the reaction mixture 
for about a minute to keep the atmosphere dry, the eppendorf was then immediately 
covered with parafilm and foil, and the mixture was left to proceed overnight. If tests 
were positive, the resin was cleaved and the peptide purified as described in chapter 2 .
3.2.2 Confocal Microscopy
3.2.2.1 Preparation o f samples
To facilitate the examination o f B16 mouse melanoma cells under the microscope, the 
cells were grown on glass coverslips. These glass coverslips 22 cm x 22 cm, were 
thoroughly cleaned by soaking them in distilled water overnight, rinsing them twice in 
96% ethanol and then finally drying in air. The coverslips were then sterilized by 
autoclaving for 15 minutes at 121°C before using them in cell culture. A single sterile 
coverslip was placed into each well o f a six-well plate and the wells filled with 2 ml o f  
MEM containing FCS and lacking phenol red. B 16 cells were plated onto the coverslips 
at a density o f 2 x 105 cells and the plates were placed in an incubator overnight. During 
this period, the cells were allowed to adhere to the coverslips and become about 60% 
confluent. After 24 hours, the used medium was removed and the cells were then washed 
twice in PBS. Fresh MEM (1.5 ml) but without phenol red was placed in each well to 
replace the old medium. For addition to B16 cells, the peptides were diluted in MEM 
supplemented with 10% FCS, to a volume of 500 pi. Following addition o f the peptides, 
the cells were returned to the incubator for a fixed time. At the end o f this time course, 
the cells were washed three times in MEM and then fixed for five minutes with 100% 
ethanol at -20°C. The cells were then washed three times in PBS, and incubated for 30
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minutes with fluorescein-linked streptavidin which was diluted 10 times into PBS 
containing 10% FCS. At the end of the incubation the cells were washed three times in 
PBS. To prepare cells for visualizing under the microscope, the coverslip was placed, 
cells facing downwards, onto a dimple microscope slide (Fisher). An antioxidant, 
DABCO (100 mg/ml, SigmaAldrich, UK) in 10% PBS/90% glycerol had already been 
spotted onto the dimple so that the cells were bathed in this solution. The excess 
DABCO solution was removed from around the edges o f the coverslips, which were 
sealed with clear nail polish. The slides were left for 24 hours to dry.
3.2.2.2 Peptide visualization
Fluorescence images were obtained with a Zeiss LSM-510 confocal laser-scanning 
microscope (Zeiss LSM-510 system with inverted Axiovert 100M microscope) equipped 
with a krypton-argon laser. Excitation was set at 488 nm for fluorescein isothiocyanate, 
and the emitted light was filtered with an appropriate filter set at 510 nm. 
Photomultiplier gain and laser power were identical within each experiment to allow 
comparison o f samples against untreated samples.
3.2.3 Transmission Electron Microscopy (TEM)
3.2.3.1 Preparation o f cell sections for visualization by TEM
TEM processing involved a number of steps, which needed to be completed in order to 
prepare the cell specimens for TEM investigation. The main steps included fixation, 
dehydration, infiltration/embedding, sectioning, staining and viewing under the 
microscope. Two replicates o f each sample were prepared, as a result o f the difficulties 
of cell adhesion and growth on filter wells. After several preliminary experiments, B16 
mouse melanoma cells were grown on cell culture inserts incorporating polyethylene 
terephthalate (PET) track-etched membranes, with a pore size o f  0.4 pM (Becton 
Dickinson). Both sides o f the membrane were tissue culture treated. B16 cells were 
cultured in MEM containing 10% FCS and one insert was placed in each well o f a
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multiwell cell culture insert six-well plate with centering ribs. The top (apical surface) of 
each filter insert was filled with 1.5 ml o f medium while the basolateral compartment was 
filled with 2.6 ml o f MEM medium. Cells were seeded at a density o f 2 x 105 cells per 
well and allowed to reach 85% confluence. Cells were then incubated with the 
appropriate amounts o f biotinylated peptide and then immediately followed with gold- 
labelled streptavidin in HBS for four hours at 37°C, which revealed the presence o f the 
biotinylated peptide. The cells were washed with PBS and then fixed with 2.5% 
glutaraldehyde in 2 x PBS overnight at 37°C to ensure that cells had enough time to 
adhere to the filters. The fixative was added to the inside and outside o f the insert. The 
cells were then washed three times (5 minutes each) with PBS. Post-fixation was done in 
1% osmium tetraoxide in PBS for one hour at room temperature. This was followed by 
another stage o f washing in triple distilled water. At this point the filter membranes were 
cut out from the culture insert. This procedure was carried out in the presence o f PBS to 
prevent the filters from drying out. Each filter was placed in vials to facilitate the 
dehydration stage. This involved exposing the filters to an acetone dehydration gradient: 
50%, 70%, 80%, 90%, 95% (three changes for each were made and each change lasted 
10 minutes) and 100% dry acetone. This final change was made six times for 20 minutes. 
The dry acetone was then replaced by 100% propylene oxide with two changes for 15 
minutes. Infiltration/embedding initially involved replacement o f 100% propylene oxide 
with 3: 1 propylene oxide to epoxy resin for an hour. Subsequently, this mixture was 
replaced with 1: 1 propylene oxide to epoxy resin for an hour. Then the filters were 
completely embedded in 100% epoxy resin overnight at 60°C so that the resin was 
allowed to completely surround the cells. The resin was used as a premix kit (TAAB) 
which included the resin and hardener already mixed to give medium hardness. After 24 
hours, the filters were rolled around a cocktail stick and placed into a capsule mould 
prefilled with fresh resin. These were allowed to set overnight at 60°C. Following 
curing the blocks were trimmed, faced and sectioned to produce thin sections o f  
approximately 50 nm (silver colour). Sectioning was carried out on an OmU3, Reichert 
(Austria) ultramicrotome using both glass, and finally diamond knives. The sections 
were placed onto palladium sprayed copper grids (300 mesh, Agar Scientific) coated with 
pioloform using 0.3% w/v pioloform solution in chloroform as described by Robards and
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Wilson, 1989. Sections were then washed in distilled water and left to dry. The grids 
were then placed, sections facing downward, onto drops o f Reynold’s lead citrate for 5 
minutes. The Reynold’s lead citrate was freshly filtered and surrounded by a few sodium 
hydroxide pellets to absorb carbon dioxide and prevent the conversion o f lead citrate to 
the carbonate precipitate. The sections were given a final wash and left to dry on filter 
paper ready for examination. Specimen grids were examined using a Jeol 1200EX II 
transmission electron microscope operating at an accelerated voltage o f 80 kV. 
Photographs were taken o f the areas on the grid showing cell ultrastructure and gold 
particles.
3.2.4 Cell culture preparation for ABMP-peptide conjugates
B16 melanoma cells were grown for 24 hours on coverslips in six-well plates as in 
section 3.2.2.1. ADMP-penetratin and ADMP-mutant penetratin were incubated with 
B16 cells both for two different time points, five minutes and three hours. After these 
respective time points, the cells were washed twice with PBS and then treated for 15 
minutes with CellScrub buffer (Gene Therapy Systems, San Diego, CA) to remove 
extracellular conjugates. Cells were then fixed with 100% ethanol for 5 minutes and 
mounted on slides using the antibleaching agent DABCO for viewing with a low light 
microscope.
3.2.4.1 Low light microscopy fo r viewing ADMP-peptide conjugates
Cells were examined with an Olympus 1X70 fluorescence microscope incorporating a 
100W Hg lamp and an Olympus PlanApo x40 water immersion objective. The samples 
were exposed to only a small percentage o f the fluorescent light due to the presence of 
neutral density filters in the light path. The excitation was recorded between 330 -  385 
nm and the emission wavelength was at 420 nm. The microscope was also equipped with 
a PentaMax cooled digital intensified CCD (charge-coupled device) camera system 
(Princeton Instruments). Images were captured by using Improvison Openlab v2.2.1 
image analysis software.
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3.2.5 Membrane preparations for investigation of peptide interactions
The fluorescent dye l-(3-Sulfonatopropyl)-4|j6[2-(di-«-octylamino)-6-naphthyl]vinyl] 
pyridinium betaine (di-8-ANEPPS) was purchased from Molecular Probes, Inc. Egg 
phosphatidylethanolamine (PE) was purchased from SigmaAldrich, UK. 
Fluoresceinphosphatidylethanolamine (FPE) was purchased from Molecular Probes, Inc.
3.2.5.1 Labelling membranes with FPE and Di-8-ANEPPS
Phosphatidylcholine dissolved in chloroform and di-8-ANEPPS (as required) were mixed 
in a round bottom flask, and the solution was dried under a stream o f nitrogen to deposit a 
thin lipid film on the inside o f a glass tube. Large unilamellar vesicles (LUV) were 
prepared by hydrating the dried lipid film with the sucrose buffer (280 mM sucrose, 10 
mM Tris, pH 7.5), then repeatedly freezing and thawing the suspension five times, and 
finally extruding it ten times through two polycarbonate filters o f pore size 0.1 pm 
(Nucleopore Corp., Pleasanton, CA) using an extruder (Lipex Biomembranes Inc., 
Vancouver, Canada) according to the extrusion procedure o f Mayer et a l., 1986. LUVs 
were labelled exclusively in the outer bilayer leaflet with FPE using the following 
procedure. LUVs were incubated with FPE dissolved in ethanol at 37°C for one hour in 
the dark. Any remaining unincorporated FPE was removed by gel filtration on a PD10 
sephadex column equilibrated with the appropriate buffer. FPE-liposomes were used 
immediately and any remaining FPE was stored at 4°C for up to two weeks.
3.2.5.2 Fluorescence measurements and analysis
Fluorescence time courses were obtained by adding the desired amount o f  peptide to 2 ml 
lipid suspensions (200 pm lipid) on an SLM-Aminco model spectrofluorimeter. For FPE 
experiments excitation and emission wavelengths were set at 490 nm and 518 nm, 
respectively. For di-8-ANEPPS measurements, excitation and emission wavelengths 
were set at 460 nm and 520 nm.
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3.3 RESULTS
3.3.1 Fluorescent labelling of peptides using BODIPY FL CASE, Biotin and 
ADMP
33.1.1 Labelling with BODIPY
The Kaiser test and the TNBS test for the presence o f free amines, both showed positive 
results for the labelling reaction as evidenced by the absence o f free amines. The labelled 
peptide was then cleaved from the resin and purified by methods described in chapter 2 . 
BODIPY FL CASE is a water-soluble succinimidyl (N-hydroxysuccinimide or NHS) 
ester o f BODIPY FL cysteic acid with a molecular weight o f 641. Its fluorescence 
excitation spectrum has an excitation at 504 nm with an extinction o f 72300 M^cm' 1 and 
an emission centred at 511 nm.
Me
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Figure 3.1. Structure o f BODIPY FL CASE.
BODIPY FL CASE contains a sulphonated spacer that appears to decrease the interaction 
between the fluophore and the protein to which it is being conjugated. The reaction 
between a protein and BODIPY FL CASE results in split o f the N-hydroxysuccinimide 
(NHS) ester part o f the molecule, which acts as a leaving group, creating the formation o f  
an amide bond with the protein.
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The fluorescence spectrum of BODIPY alone and BODIPY linked to a peptide in this 
study indicated a significant shift in the excitation wavelength from 504 nm to 460 nm. 
Also, there was a dramatic reduction in the absorbance maximum in comparison to 
BODIPY. Three separate measurements confirmed that the absorbance of the fluophore 
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Figure 3.2. Fluorescence spectra of BODIPY FL CASE (dark blue line), BODIPY FL 
CASE conjugated to a peptide (red line) and peptide without fluorescence label (light 
blue line). The concentration of each sample was 1 mg/ml. These spectra are 
representative of three evaluations carried out on different occasions.
These observations of significant differences in the fluorescence spectra of BODIPY 
samples compared to BODIPY-peptide samples led to an investigation of the mass 
spectrometry of these samples by electrospray. Figure 3.3 indicates the mass 
spectrometry of BODIPY alone. The spectrum indicated a significant reduction in the 
observed mass compared to the expected mass of BODIPY. Cysteic acid succinimidyl 
esters are water-soluble and can undergo hydrolysis releasing either the carboxylic acid 
or more likely the succinimide alcohol accounting for the difference of 199 from the mass 
spectrometry results. The mass spectrometry of BODIPY linked to penetratin is shown in 
figure 3.4. There also appeared to be a reduction in the mass observed compared to that 
expected for the structure. This is discussed in section 3.4.1.
6 0
Figure 3.3. Electrospray mass spectrometry of BODIPY FL CASE.
Expected mass = 641 Observ ed mass = 442
Figure 3.4. Electrospray mass spectrometry of BODIPY-penetratin. 
Expected mass = 2688 Observed mass = 2623
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The mass spectrum is a plot o f abundance (the relative amounts of the different positively 
charged fragments) against the mass-charge ratio of the fragments. Each major peak 
(numbered) in the spectrum represents a fragment o f the molecule. The smaller peaks 
represent impurities from the sample. The fragments are scanned so that the peaks are 
arranged by increasing mass-charge from left to right in the spectrum. The intensities o f  
the peaks are proportional to the relative abundance o f the fragments, which in turn 
depends on their relative stabilities.
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3.3.1.2 Labelling with ADMP and Biotin
1 G O . O
■tHt* I i m l  j} Ht’t ’*'
i'H'H’Hfi'H'Hiii'tttithriirnr-^




| f  r H  If  !V 1!TTTTTTf!\ §
MEM10. 0,40. 04 0 .  0 .
mU\
2 0 . 028. O
0. G0 . 0
Figure 3.5. UV-VIS scan of ADMP at a concentration of l mg/ml. The spectrum shows 
an emission of 429 nm and an excitation wavelength of 345 nm. An initial UV scan 
employed water as a standard to confirm that the equipment was suitably calibrated.
For all labelling reactions with ADMP and Biotin, the amine tests always proved 
negative, as evidenced by the absence of amine groups indicating a fully coupled peptide 
(section 3.2.1.2). The peptides were cleaved from the resin and then purified before 
further analysis was undertaken. The peptides are labelled with both ADMP and biotin 
selectively at their N-termini. The fluorescence properties o f the labelled peptides were 
compared to the unmodified fluorescent labels to ensure that the process of labelling did 
not have a detrimental effect on the spectral properties of the fluophores. Figure 3.5 and
3.6 show observed spectral properties of unmodified ADMP and ADMP coupled to 
peptide.
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Figure 3.6. UV-VIS scan of ADMP linked to penetratin at a concentration o f 1 mg/ml. 
The spectrum shows an emission of 429 nm and an excitation of 345 nm.
The UV scan for ADMP-penetratin confirmed that the labelling process was successful 
since the labelled peptide exhibited the same spectral properties as the unmodified 
fluophore.
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Figure 3.7. Electrospray mass spectrometry for ADMP linked to K2 5 penetratin. 
Expected mass = 5725 Observed mass = 5723
Figure 3.8. Electrospray mass spectrometry for ADMP linked to penetratin. 
Expected mass = 2520 Observed mass = 2521
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The expected masses were calculated from the carbon skeleton and functional groups of  
samples. The observed masses shown in Figure 3.7 and 3.8 are both equivalent to the 
average o f the main peaks obtained for each sample.
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3.3.2 Visualization of intracellular peptides using confocal microscopy
To follow the cellular entry and fate of penetratin as a translocating peptide, confocal 
microscopy was employed. B16 murine melanoma cells were exposed to biotin-labelled 
penetratin or mutant penetratin, which has been reported to be poorly translocated. Cells 
were exposed for four hours, after which the peptides were removed by rinsing with 
several washes using PBS. The cells were then fixed and the presence of biotin revealed 
with fluorescein isothiocyanate-labelled streptavidin.
Figure 3.9. Confocal image showing B16 melanoma cells, which were not incubated 
with either peptide or streptavidin FTTC. Excitation at 488 nm, FITC emission filter. 
Scale bar: 20 pm.
The control image shown in Figure 3.9 indicates the level of auto fluorescence observed 
under the FITC filter set of the microscope. A comparison in peptide distribution was 
achieved by maintaining fixed conditions for all scans. The confocal images displayed in 
Figure 3.9 - 3.12 are representative of B16 cell sections observed using replicates of 
slides (n > 2).
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Figure 3.10. Confocal images showing B 16 cells that have been incubated for different 
times with the biotin-labelled mutant penetratin [22 pM] for up to four hours at 37°C and 
subsequently treated with FITC-streptavidin. Image A (5 minutes), B (30 minutes), C (2 
hours), D (4 hours). Excitation at 488 nm, FITC emission filter. Scale bar: 20 pm.
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Figure 3.11. Confocal microscopy visualisation of biotin-labelled penetratin [22 |iM] 
incubated with B16 cells for up to four hours at 37°C and subsequently treated with 
FITC-streptavidin. Image A (5 minutes), B (30 minutes), C (2 hours), D (4 
hours).Excitation at 488 nm, FTTC emission filter. Laser power and photomultiplier gain 
is identical within each experiment. Scale bar: 20 p.m.
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BFigure 3.12. Confocal microscopy images of B16 cells incubated with biotin-labelled 
mutant penetratin (A) and penetratin (B) for four hours at 4°C with subsequent detection 
using FITC-streptavidin.
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3.3.3 Transmission electron microscopy examination of peptide uptake.
The use of the transmission electron microscopy (TEM) provides a very powerful tool for 
examining cells at the ultrastructural level. In addition to confocal microscopy, TEM was 
employed to further evaluate the cellular mechanisms of uptake and trafficking of 
penetratin and its derivative. These techniques, used in conjunction, are more powerful 
than either technique alone. The final results achieved with TEM can be very dependent 
on the methods of sample preparation. All the stages of sample preparation need to be 
optimised as much as possible to ensure that the images are free from artefacts and that 
there is homogeneity between sample populations. Direct methods of detection can be 
achieved using colloidal gold particles, which act as very electron-dense markers and can 
easily be observed under an electron beam. Gold particles form complexes with proteins 
such as streptavidin by means of a non-covalent interaction. Colloidal gold particles of 
10 nm in diameter were chosen for these experiments to ensure easier visibility in low 
magnification electron micrographs. The following representative EM images were 
eventually obtained after transfection and the EM process was repeated two occasions. 
Consequently, 30 sections were prepared and repeatedly studied on numerous occasions 
under the microscope.
Figure 3.13. Electron micrograph showing an untreated B16 murine melanoma cell (N = 





Figure 3.14. Electron micrographs showing sections of B16 cells which were treated 
with streptavidin colloidal gold particles without biotinylated peptide. The cells were 
fixed in glutaraldehyde, post-fixed in osmium tetroxide, dehydrated and embedded and 
finally stained with uranyl acetate and lead acetate. (A) Electron micrograph with no 
evidence of gold particles inside the cell, (x 20,000). (B) Cluster of gold particles at cell 
surface, (x 30,000). Arrows pinpoint gold particles.
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AFigure 3.15. Uptake of streptavidin-gold labelled transferrin molecules by B16 cells. 
Cells were fixed 4 hours post-incubation. After fixation in glutaraldehyde, postfixation in 
osmium tetroxide, dehydration and embedding, the sections were stained with uranyl 
acetate and lead citrate. (A) Electron micrograph of gold labelled particles moving 
through vesicular structures immediately beneath the cell surface, (x 30,000). Scale bar 
200 nm. (B) Intracellular vesicular structures containing gold-labelled transferrin 
particles (x 40,000). Both images show cytoplasmic cell sections.
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Figure 3.16. Electron micrographs showing B16 cells incubated with biotinylated 
mutant penetratin, after which cells were rinsed several times and incubated with 
streptavidin gold-labelled particles. Cells were fixed and stained four hours post­
incubation. Gold particles (pinpointed by arrows) remain on the surface of the cells. No 







Figure 3.17. Uptake of gold particles with biotinylated penetratin by B16 cells. The 
arrows indicate gold particles internalized by cellular vesicles in the cytoplasm (C). 
There were no gold particles visible in the nucleus (N). Cells were fixed four hours post­
incubation. (A) Cell projections engulfing gold-labelled peptide particles. (B), (C) and
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(D) represent sections that have been incubated with biotinylated penetratin. All have 
gold particles enclosed in vesicular vacuoles within the cytoplasmic regions. These 
images were not seen with other samples including the biotinylated mutant penetratin. 
However, no gold particles were observed in nuclear compartments o f the images taken. 
The TEM images shown in this chapter are representative sections for each sample tested. 
Hence, the distribution pattern o f gold particles for each sample was consistently 
observed in all batches o f cells examined.
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3.3.4 Visualization of ADMP-peptide conjugates
All images of B16 cells incubated with ADMP-conjugates were taken using identical 
settings with the microscope. The detector gain remained at 49.9 for all pictures.
Figure 3.18. B16 cells that have not been exposed to labelled peptides (untreated). Cells 
were washed after incubation, with PBS and examined with a microscope equipped with 
a UV laser and a CCD camera system.
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Figure 3.19. Microscopic images showing B 16 cells which were incubated with ADMP- 
labelled conjugates after a 5-minute incubation period. (A) represents cells that were 
exposed to ADMP-mutant penetratin and (B) shows cells exposed to ADMP-penetratin. 
Both images were taken using the same settings.
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Figure 3.20. Microscopic images showing B16 cells, which were incubated with 
ADMP-labelled conjugates after a three-hour incubation period. (A) displays cells that 
were incubated with ADMP-mutant penetratin while (B) shows cells that were exposed to 
ADMP-penetratin. Pictures were taken at identical detector gain.
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Scale bar 1Opm
Figure 3.21. Images represent cells exposed to ADMP-penetratin conjugates for five 
minutes (A) and three hours (B). The images on the right side are corresponding contour 
analysis of the amount of fluorescence. A x 60 oil immersion objective was used to take 
these images.
Cells treated with ADMP-penetratin conjugates consistently revealed intense cellular 
staining. Staining was predominantly surface-associated after short, 0 - 5  minutes 
incubation period with progressive accumulation in intracellular staining up to three 
hours.
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3.3.5 Interactions of penetratin and its derivatives with phospholipid vesicles
The measurements o f fluorescence changes can indicate a clear interaction between 
charged peptides and the lipid membranes. The technique involved labelling membranes 
with small amounts of FPE, which is sensitive to the membrane surface electrostatic 
potential. Addition or removal of a charged peptide resulted in a corresponding increase 
or decrease in the fluorescence intensity of the probe. The response observed on 
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Figure 3.22. The introduction of Calcium ions [5 mM] to phospholipid vesicles, which 
have been labelled with FPE, caused a fluorescence change due to the ionisation of 
fluorescein. Total lipid concentration was typically 200 pM. The liposomes had a 
diameter o f approximately 100 nm after preparation. Fluorescence measurements were 
made using an SLM-Aminco model spectrofluorometer. Excitation and emission 
wavelengths were set at 490 nm and 518 nm, respectively. This Ca2+ profile acted as a 










Figure 3.23. Typical fluorescence changes after introduction o f penetratin to FPE- 
labelled phosphatidylcholine vesicles. Lipid concentration was 200 pM and the sample 
volume was 2 ml. Fluorescence measurements were made on an SLM-Aminco 
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Figure 3.24. Time course o f the interaction of mutant penetratin with 100 nm diameter 
phospholipid vesicles as revealed by fluorescence of FPE-labelled membranes. 
Fluorescence measurements were made under similar experimental conditions as in 
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Figure 3.25. FPE measurements: The lipid concentration was 200 pM. FPE- 
phospholipid vesicles were subjected to various concentration of peptide with a single 
excitation wavelength o f 490 nm and emitted light recorded at 520 nm. The relative 
magnitude of the initial change in fluorescence was plotted against concentration of 
peptide to produce an adsorption isotherm for each peptide. The fluorescence changes 
were measured against increasing peptide concentrations.
The equation used to fit the data is as follows: y = (a x)/(b + x)
Table 3.2 below shows the corresponding a and b values for each peptide.
Peptide a b
Penetratin 0.945 0.100 5.250 1.200
Phe-penetratin (mutant) 0.879 0.162 6.940 2.790
Penetratin-biotin 1.310 0.060 1.370 0.269
Phe-penetratin-biotin (mutant) 1.420 0.067 0.405 0.098
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Figure 3.26. Di-8-ANEPPS measurements: Phospholipid vesicles labelled with di-8- 
ANEPPS were subjected to fluorescence investigation with a stopped-flow 
spectrophotometer. The plot shows the effect of peptide concentration on the 
fluorescence signal amplitude following normalization by background subtraction. Lipid 
concentration was 200 pM. Increasing volumes of peptide were added to the suspensions 
containing the vesicles to achieve the desired final concentration.
The data obtained from the measurement of R (460/520) in the di-8-ANEPPS 
measurements and the fluorescence at 518 nm for the FPE measurements, as a function of 
peptide concentration was fitted to a hyperbolic function equivalent to those which 
describe the single site binding model curves;
R = capacity. [peptide]/(Kd + [peptide])
8 8
Where Kd is the dissociation constant and the capacity corresponds to the maximum 
value o f R.
From both graphs, the equation o f each curve is given by:
Y = (a x)/(b + x)
where a = capacity, a value which is proportional to the number o f binding sites and b = 
Kd, the dissociation constant for the binding process, a measure o f the affinity o f the 
peptide for the membrane. The smaller the constant, the higher the affinity. Sigma 




3.4.1 Fluorescent labelling of peptides
Although fluorescein isothiocyanate (FITC) remains one o f the most popular fluorescent 
labelling reagents, the green fluorescent BODIPY FL CASE, was first choice as a 
fluorescent label in this study for a number o f reasons. Some o f the characteristics 
BODIPY displayed that made it potentially superior to fluorescein include:
• A higher fluorescent intensity per dye molecule.
• Insensitivity to solvent polarity and pH. It was important that no quenching of  
fluorescence occurred once the label was within the intracellular environment.
• Labelling with BODIPY should not adversely affect the properties o f the molecule in 
question since it is not a charged fluophore.
• Greater photostability.
BODIPY FL was purchased as a succinimidyl ester of BODIPY FL cysteic acid. 
Succinimidyl esters form amide bonds, with free amine groups. The fluorescence spectra 
obtained after linking BODIPY to the peptide indicated that there was a detrimental 
effect on the fluorescence intensity o f BODIPY. A significant shift in the excitation 
wavelength occurred as well, which indicated a chemical change after coupling. This 
problem was probably due to the cleaving conditions, which were required to deprotect 
and detach the peptide from the resin. It was desirable to conjugate the fluophore to the 
N-terminus o f a resin-bound peptide before the removal o f other protecting groups and 
release o f the peptide from the resin. This removed any ambiguity about the position of 
the coupling, which could only occur at the N-terminus. The cleavage mixture always 
required the presence of trifluoroacetic acid (TFA) 95%, a reagent used for the 
deprotection o f peptides, which are synthesized using fmoc chemistry, creating relatively 
harsh conditions, which were assumed to cause the breakdown o f BODIPY. This 
hypothesis was supported by the electrospray mass spectrometry results for the labelled 
peptides, which indicated the loss o f chemical groups equivalent to the breakdown o f the
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chromophore structure o f BODIPY. Appendix A shows electrospray mass spectrometry 
results for the peptides alone confirming their high level o f purity. Unfortunately the 
electrospray mass spectrometry result for BODIPY coupled to peptide indicated a loss of 
mass. It seems certain that some degradation occurred judging from the fluorescence 
spectrum o f BODIPY-peptide.
The labelling problems encountered with BODIPY encouraged the introduction of 
ADMP as an alternative fluophore. ADMP is a coumarin-based amino acid derivative. 
The coumarin itself is not fluorescent but the addition o f various electron-donating 
substituents on the molecule results in increased fluorescence intensity. The advantages 
o f using ADMP include its relatively similar structure and size with amino acids (MW = 
264). This fluophore has been used to label peptides in experiments aimed at 
determining how the structures o f peptides influence their alveolar permeability (Dodoo 
et al., 2000). ADMP is relatively small compared with other fluorescent probes, being 
only slightly larger than tryptophan. ADMP also absorbs at longer wavelengths than the 
naturally occurring amino acids. More significantly, ADMP was found to be stable to 
repetitive treatment with TFA during peptide cleavage. The synthetic route o f ADMP 
allowed the products of each stage of synthesis to be easily checked for yield and purity. 
Each stage had to be optimized to ensure that the final product was o f a high yield and 
purity. The coupling o f ADMP to a peptide did not have any detrimental effects on the 
structural stability o f the peptide. The spectral properties o f the labelled peptide were 
identical to the spectral properties o f ADMP. The integrity o f the fluophores were further 
confirmed by electrospray mass spectrometry data which yielded equivalent observed 
masses to the expected masses of the labelled peptides.
3.4.2 Peptide internalization and trafficking.
Confocal laser scanning microscopy confirmed that the internalization o f penetratin led to 
its intracellular localization rather than a non-specific association with extracellular 
membranes. B16 cells generally have dendritic morphology. However, some o f the cells 
appeared to be more rounded after the internalization experiments. This effect was seen 
clearly in images showing cells that had extended incubation with penetratin for up to
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four hours. There are two possible explanations for this observation. Despite the 
versatility o f B16 cells, the process of preparation for microscopy and incubation for as 
long as four hours may have caused them to change structurally leading to this rounded 
state. Also, the presence o f these peptides may have induced cytotoxicity. Fawell et al., 
1994 reported that Tat conjugates showed some cytotoxicity when HeLa cells in culture 
were found to round up with incubation o f these conjugates. During the four-hour 
incubation period, most o f the fluorescence was cytoplasmic in distribution although only 
a few cells showed nuclei fluorescence. Cells incubated with penetratin showed very 
bright halos in the cytoplasmic regions and around the nuclear membranes o f cells. This 
was more evident at four hours where fluorescence appeared as distinct rings around the 
nuclei and plasma membranes. In addition, the distribution o f fluorescence in the cell 
images was o f a punctate appearance. This was indicative o f an endocytotic movement 
through the cell by the peptides. Other investigators have described this appearance, 
which is characteristic o f endocytotic vesicles using confocal microscopy (Thierry and 
Dritschilo, 1992; Thierry et a l., 1997). Nuclear staining in cells incubated with penetratin 
did not appear as widespread as cytoplasmic staining. It is likely that a longer incubation 
period was needed to see more fluorescence in the nuclei as was reported by other groups 
including Zelphati et al., 1999. The nucleoli were strongly stained in cells incubated with 
penetratin compared to control cells and cells incubated with the mutant penetratin. The 
confocal images presented here show cell sections that were incubated at 37°C. There 
was little or no fluorescence (background levels) when the peptides were incubated at 
4°C. The fluorescence intensity o f cell images was more widespread and brighter at 
37°C. Similar findings were reported by Derossi et al., 1994. At 4°C, most cellular 
metabolic processes shut down or take place at very slow rates. Hence, only binding 
tends to take place since diffusion occurs at a very low rate. The results demonstrate the 
importance o f membrane fluidity and active metabolism in the cellular transport o f  
penetratin.
Transmission electron microscopy was employed as a further confirmation o f  the mode 
of cell entry undertaken by penetratin and its derivatives. Similar controls were used in 
these experiments as those o f confocal microscopy. In addition biotin-labelled transferrin 
was employed in TEM, as it is a well-known marker for receptor-mediated endocytosis
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(Zabner et a l., 1995). In all the images taken o f cells without peptide incubation, all the 
streptavidin gold particles observed always appeared on the surface o f  the cells (Figure 
3.14). There were no gold particles seen inside any cell. A similar pattern was also 
observed with cells incubated with mutant penetratin, where all the gold particles 
remained on the cell surface at the end of the incubation time o f four hours (Figure 3.16). 
There was a very obvious difference seen in cells incubated with biotin-labelled 
penetratin. Firstly, there was clear cell entry o f penetratin-gold particles with a few seen 
also on the cell surface (Figure 3.17). It was possible to capture an image o f particles on 
the cell surface being engulfed by cellular projections (Figure 3.17A). A significant 
observation was that penetratin-gold internalized particles were consistently found in 
vesicular structures in the cytoplasm of cells. This pattern o f distribution was also 
observed in cells incubated with biotin-labelled transferrin-streptavidin gold particles 
(Figure 3.15) and was indicative of endocytosis taking place. These data contradict the 
suggestions for mechanism of internalization proposed by Derossi et al., 1996. Although 
there appeared to be a small amount of fluorescence reaching the nucleus in the confocal 
images, it was not possible to see any peptide-gold particles in the nucleus o f cells from 
TEM. It is thought that a longer incubation and a higher concentration o f peptide may be 
necessary to observe nuclear uptake.
The images obtained from the ADMP-labelled conjugates clearly showed uptake of 
penetratin in a short time, 5 minutes (figure 3.19B, 3.20B and 3.21A). Then there was a 
gradual increase in intracellular trafficking between 5 minutes and three hours (figure 
3.19A, 3.20A and 3.2IB). Hence, penetratin does not appear to undergo instant 
intracellular trafficking. This is consistent with the data obtained from confocal 
microscopy with the streptavidin fluorescein and biotinylated peptides.
3.4.3 Peptide-membrane interaction
It is o f significant interest to gain an understanding o f some o f the factors, which 
predispose the interactions o f peptides with membranes. Previous studies investigating 
the ability o f these translocating peptides to bind to membranes have involved the 
conjugation o f a chromophoric indicator to the peptides or the synthesis o f radio
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derivatives (Rapaport and Shai, 1994; Shai, 1995). The localization of 
fluoresceinphosphatidylethanolamine (FPE) at the membrane surface can present the 
possibility o f measuring in real time, the interactions o f peptides with membranes in a 
sensitive and virtually non-invasive manner (Wall et a l., 1995). This technique relies on 
the fact that most peptides possess a net charge and, as the charged peptide comes into 
contact with the membrane surface, it interferes with the electrostatic potential o f the 
membrane surface. By locating a fluophore, which is sensitive to the membrane surface 
potential precisely at the membrane-solution interface, it is possible to monitor the 
binding and insertion o f the peptide into the membrane to very high sensitivity and in real 
time. Figure 3.23 and 3.24 represented typical patterns o f fluorescence changes: an 
increase in fluorescence followed by a gradual decrease in fluorescence. The change in 
fluorescence may be positive or negative depending on the resulting change in the 
microenvironment at the surface of the membrane. The initial rapid phase which leads to 
an increase in fluorescence intensity is consistent with the addition of positive charge to 
the membrane surface. This phase has been previously established as the binding o f the 
peptide to the membrane surface (Golding et al., 1996). The much slower decay o f the 
fluorescence intensity indicates loss or removal o f positive charge from the membrane 
surface and represents peptide insertion of its charged parts into the interior of the 
membrane. Once immersed in the hydrophobic core o f the membrane, these charges are 
effectively insulated from the electrical double layer o f the membrane surface and do not 
further influence the protonation state o f FPE or the surface potential upon which the 
latter depends. This phase could also indicate a change in the conformational state o f the 
peptide. The fluorescence changes with mutant penetratin (reported not to undergo 
internalization) showed a quick recovery in fluorescence around the insertion phase 
compared to penetratin, which displays a gradual decrease in fluorescence. The 
significance o f these findings is such that mutant penetratin binds very quickly to the 
membrane surface but undergoes little or no insertion probably due to its amino acid 
mutations. This in turn implies the importance o f tryptophan in the penetratin sequence, 
which is crucial in the internalization process o f penetratin.
The FPE and di-8-ANEPPS measurements (figure 3.25 and 3.26 respectively) both 
indicate that biotin-penetratin binds to the membrane with a higher affinity than
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penetratin. The FPE results show the binding of all the penetratin peptides tested (native, 
mutant and biotinylated o f both) bind to the membrane surface. There is no great 
difference between the binding o f the native sequence and that o f mutant penetratin, 
whereas biotinylated penetratin peptides enhance the binding clearly in terms o f affinity. 
The Di-8-ANEPPS dye measures changes in the “dipole potential”, originated by 
molecular dipoles present mainly at the water-membrane interface, such as the dipole of 
the carbonyl group o f the ester bond from the phospholipid headgroup. This potential is 
different from the surface potential and is positive towards the interior o f the membrane. 
The results show that only the native sequence (biotin-labelled and unlabelled) causes a 
variation o f the dipole potential. This implies that the wild type causes a higher 
perturbation o f the membrane than the mutant sequence, which appears to only mostly 
bind. The higher disturbance caused by native penetratin suggests insertion o f the 
peptide into the membrane.
3.5 SUMMARY
The use of BODIPY FL as a fluorescent probe proved problematic due to its big size and 
unstable characteristic. ADMP provided an alternative, which was found to reduce 
interference caused by bulky and unstable fluophores.
The uptake and intracellular movement of penetratin and its mutant version was 
investigated using electron and confocal microscopy. Both techniques exhibit data to 
confirm that penetratin peptides were taken up into B16 cells by endocytosis as seen 
clearly by the presence o f gold particles engulfed by vesicular cell structures as well as 
the punctate cytoplasmic distribution of fluorescence. The mutant penetratin showed 
some entry into B16 cells, which was not as intense as penetratin.
The peptide membrane measurements only indicate that the peptides bind to the 
membrane, that is, a clear interaction between charged peptides and the lipid membranes. 
The fluorescence variation as a function o f peptide concentration gave an accurate 
measure o f the affinity these peptides have for the membranes but does not exhibit 
information as to whether the membrane is being penetrated.
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CHAPTER 4
INTERCELLULAR SPREAD OF VP22 IN ANIMAL TISSUE.
4.1 INTRODUCTION
The introduction o f nucleic acids, peptides/proteins, and small molecules into the 
appropriate target cells and tissues is being developed as a therapeutic approach to a 
range o f diseases. Currently, the potential uses o f biotherapeutic agents are compromised 
by problems o f achieving intracellular delivery in vivo. It has been previously reported 
VP22 exhibits the unusual property o f transport between cells (Elliott and O’Hare, 1997). 
Transport was observed after introduction o f the VP22 gene by several routes, including 
transfection or microinjection o f the isolated gene in plasmid constructs or by infection 
with a non-replicating herpesvirus encoding the native VP22 gene. One o f the features of 
transport was that in cells actively synthesizing the protein, VP22 was located 
predominantly in the cytoplasm, where it could be observed in filamentous arrays 
colocalizing with bundled microtubules (Elliott and O’Hare, 1998), while in the 
surrounding cells, VP22 was observed mainly in the nucleus, where it could also be 
observed colocalizing with chromatin in mitotic cells. A short C-terminal deletion 
mutant o f VP22 lacking 34 residues was expressed normally and exhibited unaltered 
cytoplasmic localization in the primary cells expressing VP22 but failed to spread to 
surrounding cells (Brewis et a l., 2000).
This chapter investigates the ability o f VP22 to spread out into many cells in cell culture 
and animal tissues, namely muscle and tumour.
96
4.2 MATERIALS AND METHODS
4.2.1 Plasmid constructs
The reporter plasmids used during the course o f the animal work were pRSVlacZ and 
pVP22. The pRSVlacZ is a 7.8 kb plasmid where the E.coli lacZ gene is under the 
transcriptional control o f the Rous sarcoma virus (RSV) promoter/enhancer sequence. 
The pVP22 (kindly provided by Jeff Drew, Marie Curie Institute) incorporated two 
expression cassettes, one for the lacZ gene and the other for VP22. The plasmid maps for 
both plasmids may be found in appendix D.
4.2.2 Preparation of plasmid DNA/PEI complexes for in vitro studies
The concentration o f DNA was monitored using the absorbance o f DNA at 260 nm. PEI 
was used at an optimum and suboptimal N/P ratio (+/- 9.0 and +/- 3.0 respectively) as 
necessary. Appropriate mixtures o f PEI were prepared prior to DNA complexation and 
diluted to a final volume o f 250 pi with Hepes buffered saline (HBS). 3 pg o f both 
plasmids was diluted to a volume o f 250 pi with HBS. In each case the PEI solution was 
added to the DNA solution and immediately mixed by vortexing. The mixture was left to 
incubate for 20 minutes prior to addition to the cells. Transfection was carried out in the 
presence o f serum-free media for four hours at 37°C after which time the transfection 
medium was replaced with fresh complete culture medium and cells were cultured for a 
further 48 hours before harvesting, fixed and stained for immunohistochemical analysis.
4.2.3 Formulation of DNA for animal studies
Following extraction and purification o f DNA, the quantification revealed on a number of  
occasions a DNA concentration too dilute for use for animal studies. The required 
concentration o f DNA for injection is usually 50 pg in 20 pi or 2.5 mg/ml. However, the 
volume injected also had to be isotonic and therefore a DNA concentration closer to 3 
mg/ml was required to allow a small amount of dilution with NaCl. Since a minimum
97
volume o f Milli-Q water must be added to the pelleted DNA to achieve complete 
dissolution, a poor DNA yield from the maxi kit will result in a DNA solution not 
sufficiently concentrated.
4.2.4 Animal administrations
Animal experiments were conducted under the supervision o f Dr Pauline Wood, the 
Home Office license holder. Female C3H mice were obtained from Charles River at 6-7 
weeks age and then allowed to acclimatize for a further two weeks prior to experiments. 
Before implanting murine fibrosarcoma RIF-1 cells (Twentyman et al., 1980) the fur 
from the lower half o f the mouse back was removed using clippers. The RIF-1 cells were 
previously cultured in RPMI 1640 (Roswell Park Memorial Institute) medium 
supplemented with 15% foetal calf serum, penicillin and streptomycin, and were not 
passaged more than 7 times prior to trypsinization for implantation. RIF-1 cells were 
injected intradermally mid way along the back o f the mouse. To obtain an acceptable 
tumour implant care was taken to ensure that the cell suspension left a spherical bump at 
the implant site, devoid o f any tracks caused by the leakage o f cell suspension on needle 
removal. Tumours were visible after approximately seven days and were ready for gene 
delivery experiments 12-14 days post-implantation. One day before treatment with DNA 
the mice were weighed and the dimensions of the tumour recorded. The average tumour 
was approximately 6-9 mm in diameter and 270 mg in weight.
The intramuscular injections were made into the right hind leg o f each mouse. The 
expression levels resulting from the two different tissues could then be directly 
compared. These intramuscular injections were carried out five days before 
intratumoural injections, so that tumour dosing occurred on day five o f a typical 
experiment. Tissues were harvested following the killing (cervical dislocation) of the 
mice on day seven. To facilitate intramuscular injection the mice were anaesthetized 
using a combination o f Hypnovel (midazolam 5 mg/ml) and Hypnorm (1 ml o f Hypnovel 
+ 1 ml o f Hypnorm + 2 ml sterile water, inject 0.1 ml intraperitoneally) and the right 
thigh shaved with an electric shaver. Muscle injections were made using a sterile 
Hamilton syringe fitted with a 31 G, lA inch needle and calibrated dosing clamp. This
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clamp insured that each mouse was injected with 20 pi o f formulation. The needle was 
left in place for a few seconds to prevent formulation being expelled by the tissue. The 
same procedure was carried out for the dosing o f the implanted tumour five days later but 
without anaesthetizing the mice prior to injection. Each 20 pi injection contained 35 pg 
o f DNA alone.
4.2.5 Tissue preparation and immunohistochemical analysis
Muscle and tumour specimens were frozen to cork blocks in Tissue-Tek mounting 
medium (Miles, Elkhart, Indiana) by immersion in liquid nitrogen-cooled isopentane. 
Four-pm sections were then cut in a Bright OTF/AS-OOl motorized cryostat (Bright, 
Huntingdon, UK). Sections were mounted on glass slides before air-drying at room 
temperature for one hour. The staining procedure for frozen sections was then followed. 
Sections were fixed with acetone after which the slides were transferred into PBS buffer 
for 5 minutes. Sections were incubated for 20 minutes with diluted normal horse serum 
and then incubated for one hour in primary antibody in 0.05% w/v BSA at room 
temperature. The two primary antibodies used were monoclonal anti-p-galactosidase 
(SigmaAldrich) and polyclonal anti-VP22 (kindly donated by O’Hare at the Marie Curie 
Institute). Slides were washed for 5 minutes in PBS buffer. Sections were then 
incubated with biotinylated horse anti-mouse solution for 30 minutes, rinsed five times 
with PBS, and then incubated for 30 minutes with VECTASTAIN® ABC reagent 
(horseradish peroxidase-conjugated ABC). Sections were again washed in PBS and then 
developed using either diaminobenzidine (DAB) or fast-red (SigmaAldrich), until desired 
stain intensity develops. Both are substrate solutions for DAB (horseradish peroxidase) 
and fast-red (alkaline phosphatase) respectively. Sections are then rinsed in tap water and 
counterstained with haematoxylin and mounted.
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4.3 RESULTS
4.3.1 Transfection of B16 cells in vitro using pRSVlacZ and pVP22
In vitro transfection was performed with complexes of plasmid DNA (2 pg per well) and 
PEI at two different N/P ratios. Expression levels following a two-day transfection 
period were evaluated using immunohistochemistry.
i
Figure 4.1. B16 cells were not transfected with expression vectors. Post transfection, 
the cells were fixed with 100% ethanol and stained with the monoclonal antibody to (3- 
galactosidase using Sigma fast-red to develop staining for alkaline phosphatase. When 
the degree of staining intensity was reached, the reaction was terminated by washing in 
distilled water.
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Figure 4.2. B16 cells were transfected with a complex o f pRSVLacZ and PEI (N/P = 
3.0). Forty-eight hours after transfection, the cells were fixed and processed for detection 
o f (3-galactosidase expression. A x40 objective was used for examination.
Figure 4.3. B16 cells were transfected with a complex o f pRSVLacZ and PEI (N/P = 
9.0). Cells were processed for p-galactosidase expression 48 hours post transfection. A 
x40 objective was used for examination.
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Figure 4.4. Untransfected B16 cells were fixed and processed for detection o f pVP22 
expression using DAB to develop staining for peroxidase, hence the brown colour.
Figure 4.5. B16 cells transfected with PEI (N/P = 3.0) and pVP22 were fixed after 48 
hours, and immunofluorescence carried out with a rabbit anti-VP22 polyclonal antibody. 
A x63 objective was used for examination.
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Figure 4.6. Plasmid expressing VP22 was transfected with PEI (N/P = 9.0), into B16 
cells and 48 hours after transfection, the cells were fixed with 100% ethanol. Transfected 
monolayers were subsequently stained with a rabbit anti-VP22 polyclonal antibody. For 
horseradish peroxidase, cells were incubated with diaminobenzidine (Sigma) according to 
the manufacturer's instructions. When the desired degree o f staining intensity was 
reached, the reaction was terminated by washing in distilled water. A x40 objective was 
used for examination.
Untransfected cells were used as suitable controls for visualisation o f expression levels 
using immunofluorescence. Expression was detected in all transfected cells. Expression 
levels o f  both (3-galactosidase and VP22 were estimated at only 50% in cell monolayers 
transfected with sub-optimal doses o f PEI, but were almost doubled in cells transfected 
with optimal PEI doses.
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4.3.2 Introduction of pRSVlacZ and pVP22 in vivo
Figure 4.7. Histochemical staining of tumour tissue with X-gal. A section o f mouse 
tumour tissue was fixed in 4% paraformaldehyde, washed three times in PBS and then 
developed for 36 hours in X-gal.
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Figure 4.8. Uninjected tumour tissue fixed with acetone and stained with haematoxylin 
and eosin (H&E).
Figure 4.9. Mouse tumour tissue fixed with acetone and subsequently stained with a 
rabbit anti-VP22 polyclonal antibody. Expression o f pVP22 was detected using DAB to 
develop staining for horseradish peroxidase followed by H&E stain.
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4.4 DISCUSSION
Elliott et al., 1997 observed transport o f VP22 between cells after introduction o f the 
gene by several routes including transfection or microinjection o f the isolated gene in 
plasmid constructs.
The aim o f this study was to detect the distribution o f VP22 in vivo using 
immunohistochemistry techniques. Initially, in vitro testing o f the VP22 and P-gal 
plasmids was performed using B 16 cells to confirm that the method o f detection worked. 
Transport of VP22 has not been found to be restricted to distinct cell types or species. 
Wybranietz et al., 1999 reported the spread o f VP22 in fifteen commonly used 
mammalian cell lines. In addition, the use o f primary and secondary antibodies provided 
high levels o f detection in B16 cell line defining the proportion of cells containing VP22 
or p-gal following transfection. This observation was also recognized in experiments 
carried out by other groups such as Fang et al., 1998 and Elliott and O’Hare, 1999. 
These groups demonstrated significant increases in the sensitivity o f detecting spread o f  
VP22 fusion proteins with the use o f antibodies although Fang et al., 1998 did not 
observe the dramatic increase in the intercellular trafficking o f a VP22 fusion protein in 
transfection experiments. This was explained by differences in the methods o f fixation 
leading to different concentration effects and/or removal o f interfering or quenching 
components. Brewis et al., 2000 found evidence to suggest that the use o f  
paraformaldehyde for fixing cells resulted in the significant quenching o f  fluorescence in 
recipient cells although this was partially but incompletely restored on rehydration with 
PBS. The distribution o f VP22 in B16 cells appeared as foci o f VP22-containing cells as 
evidenced by the brown clusters surrounded by patches o f blue cells (Figure 4.5). A 
similar pattern o f distribution was also seen in the mouse tumour tissue (Figure 4.9). The 
brown clusters represent intensely stained cells with a largely cytoplasmic distribution 
and some nuclear staining surrounded by less intensely stained cells. This pattern was 
observed in all the batches o f tumour tissues injected with the VP22 vector. Apart from 
this pattern observed in tumour tissue sections, the distribution o f VP22 was not detected 
in mouse muscle tissue. One explanation might be the fact that only a very small 
proportion of muscle tissue was transfected. Hence, it is possible that this area of
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transfected tissue was missed during sectioning and processing o f the tissue for staining. 
Work done by Davies et al., 1993 using plasmid DNA for direct gene transfer into mouse 
muscle reported only 1-2% o f muscle was transfected and these areas was restricted to 
the injection site. Similar findings were reported by Winegar et al., 1996 with an 
intramuscular plasmid vaccine. In addition, conditions optimal for the tumour cells may 
be different from those for the muscle cells. Compared to muscle cells, tumour cells 
divide rapidly implying expression is more likely in tumour cells. The VP22 expression 
protein may have a more stable half-life than P-gal as well as the fact that p-gal is located 
intracellularly (and not secreted) as opposed to VP22, which is distributed intercellularly. 
Hence, VP22 may be easier to detect.
Detection o f p-galactosidase was attempted by histochemical staining with X-gal. 
Unfortunately, little or no expression o f p-gal was observed in any o f the tumour and 
muscle tissue sections except tumour tissue which had VP22 injected into it (Figure 4.7). 
The presence o f blue parts o f the tissue sections as seen in figure 4.7, is indicative of 
background staining, which becomes blue after prolonged incubation with X-gal. X-gal 
incubations for as long as 36 hours resulted in this blue wash, suggesting that the tissue 
expressed relatively small amounts o f the gene or more likely this implies a low level of  
non-specific activity. The lack o f p-gal expression can possibly be due to the lack o f  
plasmid stability within the tissue. However, considering that the half-life o f p- 
galactosidase is eight hours, it is unlikely that protein instability within the tissue is the 
cause. Also, since muscle cells are nondividing compared to tumour cells, one would 
expect more plasmid persistence in the muscle. Wolff et al., 1992 made this observation 
during experiments to study expression in mouse muscle. The expression o f pRSVluc 
reporter gene was sustained for 19 months.
A more likely explanation for a lack o f performance o f both VP22 and p-gal plasmids in 
vivo is the fact that since only 30 pg of plasmid DNA was injected into the tissue, the 
chances o f detecting gene expression would be overall very low. Although, the decision 
to use 30 pg o f plasmid arose from low yields constantly achieved during plasmid 
preparations as well as cost and time available, it was expected that this dose o f DNA  
would be sufficient to detect expression. Yang and Huang, 1996 carried out intratumour 
injections with 30 pg o f free DNA and reported protein expression levels (1.9 ng o f
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protein) as high as those expressed in skeletal muscle observed by W olff et al., 1990. 
Lack o f in vivo expression may also be caused by differences in the plasmid promoter 
component as well as slow DNA transport. Luby-Phelps et al., 1987 found that 
cytoplasmic diffusion o f macromolecules is slow. For instance, a molecule o f molecular 
weight 500000 would take an approximate time o f 4 days to diffuse 1 mm. Also, 
intramuscular injection through the skin without observation o f the exact injection site 
may result in administration to non-muscle tissue such as adipose or other muscle groups. 
Insufficient penetration o f the needle may also yield poor distribution as well as 
localizing the injected DNA mainly in the interfascicular muscle space. Occasionally, 
some sample got lost during the injection procedure.
Another possibility is that the relatively small injection volume o f 20 pi used in these 
experiments may not achieve high enough expression. Davies et al., 1993 observed less 
variability and higher gene expression in muscle tissue when they injected a larger 
volume o f plasmid DNA. Yang et al., 1996 confirmed that gene expression in BL6 
tumour was almost four-fold higher with 100 pi o f injection volume compared with 10 pi 
o f injection volume, although the former resulted in tissue toxicity. A higher injection 
volume would spread the injected DNA to a wider area at the injection site, achieving a 
greater number o f transfected cells. In addition, it was found that there was poor 
diffusion o f complexes within the tumour mass post injection with a syringe. Hence, the 
mode o f delivery may require modifications to incorporate a micropump, which would 
enable slow injection. Cells in vivo can be considered to be in a quiescent state, entry o f  
DNA into cell nuclei becomes problematic since cell division aids uptake o f DNA as is 
evident from in vitro transfection data.
4.5 SUMMARY
This study attempted to observe distribution of VP22 in animal muscle and tumour tissue. 
Although the spread o f VP22 was observed only in tumour tissue sections, these data 
show the marked levels o f experimental variability, which needs to be taken into account 
when interpreting in vivo studies. There was a lack o f obvious |3-galactosidase 
expression above background levels.
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CHAPTER 5
RELATIVE MOBILITY OF MEMBRANE TRANSLOCATING 
PEPTIDES.
5.1 INTRODUCTION
Drug delivery to selected cells and tissues remains an area o f active research. One 
potential way to improve the efficacy o f gene therapy is to construct plasmids, which 
express fusions o f therapeutic proteins with membrane translocating peptides (MTPs).
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Such fusion proteins may be able to translocate from transfected cells to other cells in the 
vicinity, producing a bystander effect, or generally improve the biodistribution o f the 
gene product within the target tissue. The mechanism whereby these MTPs are able to 
target and to traverse lipid membranes currently remains unknown and though there are 
several putative MTPs in the literature it is difficult to assess which are the most 
promising for use in gene therapy. One published protein, the Drosophila pAntennapedia 
(pAntp) a homeotic transcription factor, has a cationic domain, which is known to include 
an MTP, (-RQIKIWFQNRRMKWKK-). This MTP is able to carry linear polypeptides 
across biological membranes, though the limits to the size o f the payload have only been 
studied qualitatively.
This chapter investigates the generation o f two fusion constructs with the enhanced green 
fluorescent protein (EGFP-N1), one consisting o f the gene coding for the native pAntp 
MTP and the other carries a mutated version o f pAntp MTP. These fusion constructs 
could show pAntp’s ability to promote transfection in mammalian cells in culture and 
possibly protein transduction to other surrounding cells. The mutant version (- 
RQIKIFFQNRRMKFKK-, where two amino acid residues have been changed) may 
share this transduction ability but only to a smaller extent, interrupting the translocation 
functions o f native pAntp.
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5.2 MATERIALS AND METHODS
This work was done in collaboration with Dr Mick Amott, a postdoc at the Department of 
Pharmacy, University o f Bath.
5.2.1 Materials
The oligonucleotides required for the fusion constructs incorporated EcoRl sites at the 5’ 
end and BamHl sites at the 3 ’ end, both o f which were digested. The oligonucleotides 
were ordered from Sigma Genosys on a 3 OD scale and were phosphorylated before use.
Native pAntp MTP Sense Primer
5 ’ AATT CAT gCgCC AgAAT AAAgATTT ggTT CC AgAAT CggCgC AT gAAgT ggAAgA 
Agggg 3’
Native pAntp MTP Antisense Primer
5 ’ gAT CCCCCTT CTT CC ACTT CAT gCgCCgATT CT ggAACC AAAT CTTTAT CT ggCg 
CATg 3’
Mutant pAntp Sense Primer
5 ’AATT CAT gCgCC AgAT AAAg ATTTT CTT CC AgAAT CggCgC AT gAAgTT C AAgAA 
gggg 3 ’




5.2.2 Phosphorylation and annealing of oligonucleotides
To achieve optimal cloning efficiency the oligonucleotides were phosphorylated using 
the following reaction mix:
The kinase reaction was incubated at 37°C for one hour and heat inactivated by boiling at 
100°C for two minutes. The reaction was allowed to cool slowly to room temperature.
To anneal the oilgonucleotides together, the wild type sense and antisense primers were 
mixed together in a microcentrifuge tube while the mutant sense and antisense primers 
were also mixed in a separate reaction. Both reactions were carried out in the presence o f  
10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM EDTA, at pH 7.9 and left at 95°C 
for 2 minutes. The oligonucleotide mix was allowed to cool to room temperature 
gradually overnight. To confirm that the annealing occurred a 15% acrylamide gel was 
set up.
5.2.3 Preparation of the cloning vector pEGFP-Nl
A large-scale digest o f pEGFP-Nl with EcoRl and BamHl was performed overnight at 
37°C to ensure optimum digestion o f the vector. The vector was digested sequentially 
with EcoRl and BamHl restriction enzymes, and then run on a 1% agarose minigel. The 
single band was excised from the gel and purified.
Nuclease free water
137 pmoles oligo 
ATP, 0.1 mM (Boehringer)
T4 Polynucleotide Kinase (10 U/pl, Promega) 









The following ligation reaction mixture was used:
Vector pEGFP-Nl (digested with BamHl and EcoRl) 1.3 jul
Wild type/Mutant annealed oligos 20 pi
lOx ligation buffer 2.5 pi
Ligase 1 pi
Ligations were left for 2 hours at 37°C.
Dr. P. Jones carried out DNA sequengihg at the automated sequencing facility at the 
University o f Bath using d-Rhodamine 'terminator dye chemistry (labeled ddNTP’s) and 
FS Taq polymerase (PE Applied Biosystems). The AB1377 DNA sequencer and cycle 
sequencer used were both from PE Applied Biosystems. The DNA samples for 
sequencing were supplied in PCR tubes containing 10 pmoles o f primer, made up to final 
volumes o f 6 pi with Milli-Q water.
5.2.5 Cell culture and transfection of cells
One cell line was employed in this study. B16 cells were routinely cultured as adherent 
monolayers in MEM as described in chapter 2. Complexes o f pEGFP-Nl fusions with a 
sub-optimal dose o f PEI (N/P = 4) were prepared 30 minutes prior to use. These 
complexes were then incubated with 3 pg DNA per well (in 0.5 ml Opti-MEM™) on B16 
cells grown on coverslips in six-well plates, in the presence o f 1.5 ml Opti-MEM™. 
After 4 hours, the transfection medium was removed and replaced with 2 ml growth 
medium.
5.2.6 Immunofluorescence analysis
Immunofluorescence analysis for transfected cells was performed. After 48 hours o f  
transfection, cells were washed with PBS, fixed for 10 minutes at room temperature with
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100% methanol. The samples were then blocked with 10% foetal calf serum in PBS for 
15 minutes at room temperature. Rabbit anti-GFP polyclonal antibody was added to the 
same solution at a concentration o f 1: 500, as recommended by the manufacturer (Insight 
Biotechnology Ltd). The samples were then incubated for 20 minutes, washed three 
times with PBS, and incubated for another 10 minutes with blocking solution containing 
an anti-rabbit IgG antibody labeled with Rhodamine red (Insight Biotechnology Ltd). 
Samples were then washed three times with PBS. The coverslips were mounted on slides 
using DABCO antibleaching agent. Fluorescence images were obtained with a Zeiss 
LSM-510 confocal laser-scanning microscope (Zeiss LSM-510 system with inverted 
Axiovert 100M microscope) equipped with a krypton-argon laser. Excitation was set at 
488 nm, and the emitted light was ^ filtered with an appropriate filter set at 510 nm. 
Photomultiplier gain and laser power'were identical within each experiment to allow 
comparison o f samples against untreated samples.
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5.3 RESULTS
5.3.1 Sequencing of wildtype pAntp clone.
The sequence is shown below in Figure 5.1. The EcoRl site o f the wildtype pAntp is 
underlined in the sequence.
5 ’
TTTTAANTTTCNGTTTNGNGTTCCCCAGATCCGCTANCGCTCCGGACTCAGAT
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Figure 5.1. Sequencing report for wild type pAntp clone.
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5.3.2 Sequencing of mutant pAntp clone.
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Figure 5.2. Sequencing report for mutant pAntp clone.
Both the wildtype and mutant pAntp genes were cloned into the vector pEGFP-Nl 
successfully as seen from the sequencing information (Figure 5.1 and 5.2).
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5.33  Transfection of EGFP-pAntp clones.
Fusions of the N-terminus of EGFP retain the fluorescent properties of the native protein 
allowing the localization of the fusion protein in vitro and in vivo. The target gene is 
cloned into pEGFP-Nl so that it is in frame with the EGFP coding sequences.
For these results, cells were examined only with a x 40 oil immersion objective. It was 
not possible to obtain images of the cells at lower magnification (using a x 10 objective) 
because of a lack of fluorescence. No transfected cells were detected in cells exposed to 
pEGFP-N 1 only and complexes of pEGFP-N 1 and PEI. Both samples displayed similar 
levels of fluorescence (figures 5.3 and 5.4 respectively). Images obtained of cells 
exposed to complexes of the wildtype pAntp fusions displayed higher levels of 
fluorescence than those exposed to mutant pAntp fusions (figure 5.5).
20 pm
Figure 5.3. Confocal images (split display) of untransfected cells.
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Figure 5.4 (top and bottom panels). Images of cells transfected with pEGFP-N 1/PEI 
only. A x 40 oil immersion objective was used to captured these images.
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Figure 5.5. Images of cells incubated with wildtype EGFP-pAntp fusion (top) and 







Figure 5.6. Confocal images of transfected cells using the mutant EGFP-pAntp/PEI 
complexes. Images were captured with a x 40 oil immersion objective.
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Images taken o f cells incubated with complexes o f the mutant EGFP-N1 and PEI 
displayed few transfected cells. Figures 5.6A to D show some o f these transfected cells, 
which were situated far apart from each other. The distances between transfected cells 
were too great to obtain a full view o f them on the same image, hence it was only 
possible to take pictures o f isolated transfected cells. Figure 5.6A shows a cell where 
transfection has occurred as seen only in the cytoplasmic region. Figure B represents an 
image where a dual channel (rhodamine/fluorescein) filter image o f a transfected cell has 
been superimposed on a transmitted light image o f the same cell. This superimposed 
attempt gives a clear picture o f the proximity o f surrounding cells around the transfected 
cell. Figure 5.6C and D display more cells that express EGFP (seen using the fluorescein 
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Figure 5.7. A panel of images taken from cells that were incubated with wildtype EGFP- 
pAntp fusion complexed with PEL A x 40 oil immersion objective was used.
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Figures 5.7A to D represent images o f  cells that were exposed to complexes o f wildtype 
EGFP-N1 pAntp fusion with PEL As with the mutant, images show a few transfected 
cells obtained from different fields o f view from the slides. However, there seemed to be 
a few cells transfected by the wildtype complexes as evident from figure 5.7A where two 
cells are transfected. Figure 5.7D also displays more than one transfected cell in the 
same field, one cell (bottom right o f the picture) has cytoplasmic distribution of EGFP 
whereas the centrally displayed cell exhibits transfection in the nucleus. In addition, 
there appeared to be a spread o f EGFP fluorescence in the immediate vicinity (top) of this 
centrally placed transfected cell (figure 5.7D). The cell showed in figure 5.7B is yet 
another cell with nuclear expression o f EGFP and spread o f EGFP around it.
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5.4 DISCUSSION
In order to get a reasonable visual impression o f the number o f  transfected cells in a 
population o f cells, it was intended to obtain images at low magnification. However, this 
proved difficult to achieve since the overall fluorescence o f the cells was too low to allow 
images o f the cells to be detected. The lowest magnification possible and applied was 
x40. This level o f magnification was sufficient to observe individual cells that had been 
transfected. In the case o f wildtype EGFP-pAntp, it was possible to detect an image with 
two isolated transfected cells in the same field. Generally, the proximity o f the 
transfected cells detected was too far apart with both the mutant EGFP-pAntp and 
wildtype EGFP-pAntp. The low fluorescence seen with the EGFP fusions implies an 
overall low transfection efficiency, which may be enhanced by the use o f higher N/P 
ratios o f PEI close to ratios required for optimum transfection. Another possible 
explanation for the low fluorescence detected may be due to the fact that the fusion of 
these translocating sequences to the N-terminus of EGFP, may reduce their ability to 
perform their intended duties, namely to transduce proteins. Although over 20 different 
oligonucleotides and a similar number of peptides have been linked to pAntp, there is a 
strong size constraint whereby fusions with the pAntp translocating sequence appears 
only to be active in proteins with less than 100 residues. This is a significant contrast to 
other protein-transduction domains including TAT and VP22, which have been shown to 
transduce much larger molecules, including P-galactosidase (>1000 amino acids) (Fawell 
et al., 1994). Schwarze et al., 1999 delivered a biologically active enzyme to all cells and 
tissues o f mice by intraperitoneal delivery of the 120-kDa p-galactosidase protein, fused 
to the protein transduction domain from the HIV TAT protein. This resulted in readily 
detectable p-gal activity in all tissues assayed, such as the bone marrow. Phelan et al., 
1998 transfected a VP22-p53 fusion expression vector and observed transduction o f the 
VP22-p53 protein to the surrounding tumour cells as well as subsequent induction of 
apoptosis. Apoptosis o f tumor cells was induced as a result o f this intercellular delivery 
of p53 by VP22.
Recently, it has been suggested that transduction o f GFP fusions across the cellular 
membrane is an inflexible process, which requires the partial or complete unfolding of a
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protein and this in turn needs refolding once in vivo. Mammalian cells do not appear to 
have the ability to refold the GFP protein into its enzymatically active conformation 
(Schwarze et al., 2000). This cellular handicap results in a significant loss o f GFP 
emission. Hence, it is also conceivable that the process o f translocating cell membranes 
can result in the denaturation o f the protein. Bonifaci et al., 1995 observed that 
transduction o f full-length TAT-protein transduction domain fusion proteins across the 
cell membrane results in an inactivation o f the protein. In this latter study, TAT was used 
to ferry dihydrofolate reductase into cells and results implied that unfolding o f the protein 
might be necessary.
An alternative approach to improve the ability o f pAntp to transduce proteins in 
mammalian cells may be to generate a construct using a bacterial expression vector. For 
instance, a fusion between TAT and herpes simplex virus TK protein will transduce into 
cells and has its highest enzymatic activity when purified from the soluble bacterial 
fraction. This protocol has been successfully used to transduce green fluorescent protein 
(Schwarze et al., 2000). However, since the expression o f some proteins are poor in 
bacteria combined with the fact that some may require posttranslational modifications, 
other systems such as yeast and baculovirus may provide better transduction efficiency.
5.5 SUMMARY
From the data obtained in this study, it can be deduced that no evidence yet exists to 
confirm that translocation by pAntp occurs from a transfected cell to other surrounding 
cells in the immediate vicinity. The threshold of detection o f transfected cells may be too 
low to observe this. In addition, the emission o f EGFP may decrease as it goes through 
the membrane. Hence, another method o f marking transfection may be required such as 
use o f alkaline phosphatase or (3-gal in immunohistochemistry.
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PART II




GENE TRANSFER USING A BIFUNCTIONAL PEPTIDE 
COMPRISING A MEMBRANE TRANSLOCATING SEQUENCE 
COUPLED TO A CATIONIC DNA-BINDING DOMAIN.
6.1 INTRODUCTION
Current self-assembly gene delivery systems are only moderately efficient methods for 
gene transfer to mammalian cells and consequently efficient uptake into the nucleus, 
leaving much scope for improvement. In general, particulate gene delivery systems 
achieve cellular gene delivery by the process o f endocytosis, which involves 
internalisation by membrane vesicles. There are several intracellular barriers for gene 
transfer and it is well established that escape from the endosomal compartment following 
internalisation o f transfection complexes is one o f the rate-determining steps (Zabner et 
al., 1995). Hence, various groups have reported the use o f endosomolytic agents 
including chloroquine (Erbacher et al., 1996) or fusogenic peptide sequences such as 
influenza haemagglutinin subunit 2 (Schoen et al., 1999), to achieve endosomal escape. 
Two gene delivery vectors, which were reported to have endosomolytic activity, were 
employed in these experiments: polyethyleneimine (PEI) and K25HA2 .
This chapter investigated the use of penetratin in gene delivery. The uptake mechanism 
of this translocating peptide is by an alternative pathway to endocytosis. This is of 
particular interest since endocytosis by differentiated cells in vivo is appreciably slower 
than dividing cells in culture (Matsui et al., 1997; Fasbender et al., 1997). The 16 amino 
acid sequence from pAntp has been used as an internalization vector for peptides and 
oligonucleotides (Schutze-Redelmeier et al., 1996) but has not yet been fully evaluated 
for plasmid DNA delivery. This chapter evaluates the ability o f penetratin and its 
derivative to interact with plasmid DNA, display membrane activity and modulate gene 
expression in a variety o f cultured cell lines.
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6.2 MATERIALS AND METHODS
6.2.1 Cationic vectors employed
6.2.1.1 Penetratin and its derivative
All peptides were synthesized using solid phase peptide synthesis as described in chapter 
2. The penetratin sequence was synthesized as follows:
h 2n - r q ik t w f q n r r m k w k k - c o o h
The penetratin derivative with an oli^o-lysyl chain, K2spenetratin, was synthesized as 
follows:
h 2n -k 25- r q ik iw f q n r r m k w k k - c o o h
6.2.1.2 Polylysine (K25)
This oligolysine chain was synthesized and used as a control for these experiments. The 
peptide appeared as a white fluffy lyophilized solid, which was stored at -20°C prior to 
use.
6.2.1.3 Influenza haemaglutinin subunit 2 (HA2)
This fusogenic peptide sequence was a kind gift from Alfred Agyeman (School of 
Pharmacy, University o f Bath, UK). It was synthesized such that the native sequence 
was coupled to an oligolysine chain (K25), which was at the amino terminal end o f the 
HA2 sequence. The peptide was presented as a white fluffy lyophilised solid which was 




This gene delivery vector was commercially available and was supplied by SigmaAldrich 
Chemical Company. It appeared as a viscous solution. PEI average molecular weight 
25000 (average degree o f polymerisation 580 assuming a MW of 43 Da for the repeating 
unit) was used to prepare a 20 mM aqueous stock solution. The stock solution was 
neutralised with hydrochloric acid and filtered through a 0.2 pm Millipore filter. PEI 
stock solutions were stored at 4°C and used within one month o f preparation.
6.2.2 Mammalian cell lines
The cell lines used in this study were as follows;
B16 cells, a murine melanoma cell line, was donated by L.R. Kelland, Institute o f cancer 
research, Sutton.
A549 cells, a human adenocarcinoma cell line derived from the alveolar region of the 
lungs (alveolar type II), was obtained from M. Watson, School o f Pharmacy, University 
of Bath, UK. For routine culture, cells were subcultured 1 in 4 twice weekly.
16HBE14o- cells, an SV40 transformed human bronchial epithelial cell line was obtained 
from D. Greunert, University of California, San Francisco, USA. For routine culture, 
cells were subcultured 1 in 2 weekly.
FEK4 cells, a human foreskin primary cell line, was obtained from J. Brown, School of  
Pharmacy, University o f Bath, UK. For routine culture, cells were subcultured 1 in 4 
weekly.
HeLa cells, a human epithelial carcinoma cell line, was obtained from the European 
Collection o f Animal Cell Cultures (ECACC, Porton Down, Salisbury, UK). For routine 
culture, cells were subcultured 1 in 10 weekly.
HEK293 cells, a human embryonal kidney cell line, was obtained from ECACC, UK. 
For routine culture, cells were subcultured 1 in 10 weekly.
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6.2.3 Transfection of mammalian cells
6.2.3.1 Preparation o f  transfection complexes
Plasmid DNA (6.4 pg o f pCMVluc, pCMV/? or pEGFP-N 1 where appropriate) was 
diluted to 800 pi with HBS in a sterile polystyrene tube (Costar, UK). Variable quantities 
of the GDV (gene delivery vector) were separately diluted to 800 pi with HBS. 
Complexes were prepared by adding the 800 pi o f GDV solution to the 800 pi o f DNA. 
Gentle mixing o f the two solutions was executed by pipetting the solution up and down 
five times using a 1 ml Gilson pipette.
6.2.3.2 Exponentially growing cells
For transfection o f exponentially growing cultures, cells were seeded at a density such 
that at the time o f transfection monolayers were 70% confluent. For the various cell 
types studied, seeding densities on 35 mm well plates were as shown in table 6.1; 
Following seeding, cells were grown for 16 - 20 hours under standard conditions in the 
appropriate culture medium prior to transfection.
Cell line Cell number per 35 mm 
well plate
B16 1 x 105
16HBE14o- 5 x  105
HEK293 2 x 10s
FEK4 2 x 105
A549 2 x 105
HeLa 1 x 105
Table 6.1. Seeding densities for various cell lines.
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6.23.3 Peripheral Mononuclear Cell Preparation
This standard method described by Favour, 1964 was employed to isolate lymphocytes.
6.2.4 Methods for quantifying expression
The transfection efficiency was calculated as a mean value o f luciferase activity (ng) per 
quantity o f protein in mg (Chapter 2).
6.2.4.1 FACS analysis ofE G F P  expression
At 24 hours post transfection, adherent cells were washed twice with 1.0 ml o f PBS and 
then detached using 0.02% w/v EDTA in PBS. Cells were transferred to a 1.5 ml micro­
centrifuge tube, collected by centrifugation, washed and resuspended in 1.0 ml o f PBS. 
Control cells were untransfected. Cell fluorescence intensity relative to control cells was 
measured at each time point. The fluorescence analysis o f cell populations was 
performed using a Becton Dickinson FACSVantage instrument at an excitation o f 488 
nm and an emission wavelength o f 530 nm (±15 nm) using an argon ion laser. A 
minimum o f 104 cellular events was analysed for each sample. Cell viability was 
assessed with propidium iodide and dead cells were excluded from analysis.
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6.2.4.2 Cytochemical staining fo r  /3-galactosidase activity
The determination o f the efficiency o f (3-galactosidase expression employed 5-bromo-4- 
chloro-3-indolyl-p-D-galactosidase (X-Gal), (Melford Laboratories Ltd, Ipswich, 
England). Staining for (3-galactosidase activity in whole cells was carried out as 
described by MacGregor et al., 1991. The distribution o f expression within a cell 
population can be determined with histochemical staining using the substrate 5-bromo-4- 
chloro-3-indoly-(3-D-galactoside (X-gal). Cells expressing p-gal hydrolyze this substrate 
to galactose and soluble indolyl substances, which undergo oxidation to insoluble blue 
precipitates. The solutions required were as follows;
Phosphate buffered saline (pH 7.3)
Fixative solution 1% (v/v) glutaraldehyde
ImM magnesium chloride 
0.1M sodium phosphate pH 7.3 
X-gal solution 0.2% (w/v) 5-bromo-4-chloro-3-indolyl-p-galactoside (X-
gal) in dimethylformamide 
ImM magnesium chloride 
150mM sodium chloride 
3.3mM potassium ferrocyanide, K4Fe(CN)6 
3.3mM potassium ferricyanide, K3Fe(CN)6 
0 .1M sodium phosphate
Forty-four hours post transfection, cell monolayers were rinsed twice with 2 ml o f PBS 
and then permeabilised by overlaying with 2 ml o f fixative solution followed by a 5 
minute incubation at 4°C. The fixative solution was aspirated, the cells were rinsed once 
with PBS and then overlaid with 1 ml o f X-gal solution, followed by incubation 
overnight at 37°C in the dark. Cells were then washed twice with PBS and viewed under 
an inverted light microscope. Cells expressing the p-galactosidase enzyme were stained 
blue against a background o f unstained cells. Where appropriate, photographs were taken 
using a Nikon F-301 camera with fujichrome 200 or 400 DX film.
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6.2.5 Determination of cell viability.
A modified MTT assay (Mosmann, 1983) was used to establish the toxicity o f penetratin, 
K25penetratin, K25 and PEI. B16 cells were plated into 96-well tissue culture plates at a 
density o f 4000 cells per well in 100 pi media. Peptides to be tested were made up in 100 
pi o f PBS and added to the wells. After treatment and a three day incubation, the 
medium was removed by inversion and the cells washed twice with serum free Opti- 
MEM™. A 200 pi aliquot o f 1 mg/ml MTT formazan, (SigmaAldrich, UK) was added to 
each well, and the plate incubated at 37°C for 3 hours. After this time, the MTT solution 
was removed. 200 pi DMSO was added to each well followed by agitation on an orbital 
mixer for 10 minutes. Plates were.,rea,  ^ at 540 nm on a Titre plate reader (Dynatech MR 
580). The optical density in wells containing treated cells was compared with that of 
control wells containing untreated cells to allow the percentage viability to be 
established.
6.2.6 Gel mobility shift assay
This assay was used to assess the interaction between penetratin and DNA. Plasmid 
DNA (3 pg pCMVluc) were diluted to 125 pi HBS in a sterile micro-centrifuge tube. 
Variable quantities o f the peptide were separately diluted to 125 pi in sterile micro­
centrifuge tubes. Hence different charge ratios were prepared. All micro-centrifuge 
tubes were subsequently pulse centrifuged (Jouan microfuge, France) to concentrate 
samples to the bottom of the tube. The peptide was then added to the DNA solution by 
gentle mixing. The mixture was then incubated at room temperature for 25 minutes. 
After this time, 40 pi o f solution were diluted to 50 pi with electrophoresed loading 
buffer. Ten to 12 pi o f this sample were then loaded on to a 1% (w/v) agarose gel in lx  
TAE and electrophoresed at 80 volts for one hour in lx  TAE. The agarose gel was then 
viewed under an ultra-violet transilluminator and photographed using a Polaroid 55 film 
fitted into a Polaroid CU-5 camera.
136
6.2.7 Ethidium Bromide Exclusion Assay
The fluorescent properties o f ethidium bromide (figure 6.1) allow it to be used as a 
fluorescent probe, following intercalation between double-stranded DNA.
Figure 6.1. Structure o f ethidium bromide: 2, 7-diamino-9-phenyl-10- 
ethylphenanthridinium bromide.
The peptide-DNA complexes were prepared and complexation was analysed using a 
method adapted from Gershon et al. , 1993. Six pg o f pCMVluc was diluted to 125 pi 
with HBS in a sterile micro-centrifuge tube. Variable quantities o f the peptide were 
separately diluted to 125 pi in sterile micro-centrifuge tubes. Samples were mixed, 
incubated for 15-30 minutes and then diluted to 3 ml with 20 mM sodium chloride 
solution. The fluorescence was monitored at AeXcitation 260 nm and Admission 600 nm 
immediately following addition o f 3 pi o f a 0.5 mg/ml solution o f ethidium bromide 
(final concentration o f 0.5 pg/ml), on a RF-540 spectrofluorimeter (Shimadzu, UK) using 
1 cm cuvettes with slit settings o f 5 nm for both the excitation and emission 
monochromators. The degree o f complexation was reported as a percentage o f the 
fluorescence obtained from a control sample containing 6 pg o f uncomplexed DNA. The 
fluorescence o f the control sample was normalised to 100%. A reduction in fluorescence 
was seen relative to the control as the intercalation o f ethidium bromide between base 
pairs o f DNA was prevented by complexation with the peptide.
137
6.2.8 Erythrocyte lysis assay
The method o f Plank et al., 1994 was followed. Freshly prepared human erythrocytes 
were washed with HBS and resuspended in a 2 x assay buffer o f pH 5 or 7 (300 mM
n
NaCl, 30 mM sodium citrate) at a concentration o f approximately 5 x 1 0  cells/ml. An 
aliquot o f 75 pi was added to 75 pi o f a serial dilution o f the peptide in water in a 96-well 
microtitre plate and incubated for 1 hour at 37°C with constant shaking. After removal of 
the unlysed erythrocytes by centrifugation (1000 x g, 5 min), 100 pi o f the supernatant 
were transferred to a new microtitre plate, and haemoglobin absorption was determined at 
450 nm (background correction at 750 nm). 100% lysis was determined by adding 1 pi 
of a 10% Triton-X solution prior to. cerprifugaition.
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6.3 RESULTS
6.3.1 Gel Mobility shift assay
The interaction between penetratin and DNA was first analyzed by agarose gel 
electrophoresis using the gel mobility shift assay. Following incubation of the peptide 
with DNA, the electrophoretic movement of complexes across the agarose gel was 
examined after staining with ethidium bromide. As the quantity of penetratin increased, 
the mobility of plasmid DNA decreased. The plasmid DNA was neutralised at the lowest 
charge ratio where the DNA was completely immobilised within the well origin. At 
charge ratios above 3.0, penetratin completely immobilised DNA at the well origin 
(Figure 6.2).
Figure 6.2. Determination of charge ratio of penetratin required to neutralize pCMV/wc 
using the gel mobility shift assay. The DNA/penetratin complexes were run against a 
Molecular weight marker (M) and free DNA (D) with increasing charge ratios as shown 
from left to right.
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6.3.2 Ethidium bromide/DNA Fluorescence assay
The interaction o f the various cationic peptides with plasmid DNA was more extensively 
studied using a fluorescence assay. DNA neutralisation was taken to be the charge ratio 
at which fluorescence first reached a minimum. This point varies with each of the 
peptides tested. In the case of polylysine ( K 2 5 ) ,  this point occurred at a charge ratio (+/-) 




Figure 6.3. The effect on ethidium bromide fluorescence on complexing pCMY luc  with 




Figure 6.4. The effect on ethidium bromide fluorescence on complexing pCMV/wc with 
K2 5 penetratin. The data points represent the mean of three replicate evaluations.
141
The interaction of DNA with the bifunctional peptide, K2 5 penetratin is shown in Figure 
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Figure 6.5. The effect on ethidium bromide fluorescence on complexing pCMVluc with 
penetratin. Each data point is the mean of three replicate evaluations.
K^spenetratin appeared to show a stronger binding ability with DNA compared with 
penetratin where larger mass excess was needed. The critical point of DNA 
neutralization for penetratin was at a charge ratio o f 3.5 (Figure 6.5).
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Figure 6.6. Complexation of DNA using K^spenetratin and BODIPY-K2 5 penetratin. The 
pCMVluc was mixed separately with increasing quantities of unlabelled K^penetratin or 
with K2 5 penetratin linked to BODIPY. The degree of complexation was measured as a 
decrease in fluorescence relative to the control, which was free DNA. The exclusion o f 
ethidium bromide is plotted against charge ratio o f the DNA complexes (peptide: DNA). 
Each data point represents the mean ± SD of three replicate evaluations.
To investigate whether labelled peptide molecules were interacting with DNA in a similar 
manner to unlabelled peptides, their abilities to complex plasmid DNA were examined 
using the ethidium bromide exclusion assay. Labelling with BODIPY resulted in a 
reduction in the peptide’s ability to interact with DNA (Figure 6.6). K2 spenetratin
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complexed DNA in a similar manner to K2 5 . Fluorescence dropped to 10% at a charge 
ratio between 1.0 and 2.0. There was little exclusion o f ethidium bromide by the labelled 






Figure 6.7. Complexation of DNA using ADMP-K2 spenetratin. The pCMVluc was 
mixed with increasing quantities o f ADMP linked to K.2 5 penetratin. The degree of 
complexation was measured as a decrease in fluorescence relative to the control, which 
was free DNA. The exclusion of ethidium bromide is plotted against charge ratio of the 
DNA complexes (labelled peptide: DNA). Each data point represents the mean ± SD of 
three replicate evaluations.
Figure 6.7 indicates that ADMP-K.2 5 penetratin was able to exclude ethidium bromide 
causing a decrease in the fluorescence intensity similar to the unlabelled peptide.
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Figure 6.8. Comparative transfection efficiency of unlabelled K^penetratin and 
K2 5penetratin labelled with BODIPY FL CASE. Luciferase expression following 
transfection of B16 murine melanoma cells using pCMV/wc (2 pg) alone or complexed 
separately at various charge ratios (+/-), with labeled (LI, L2, L3 and L5) and unlabelled 
K2 5 penetratin (1, 2, 3, and 5). At the same time, cells were also treated with DNA 
complexed with a 50: 50 mixture of labelled and unlabelled K^penetratin (LU). 
Transfection was carried out for four hours in the presence of 100 pM chloroquine. 
Expression was assayed 24 hours post transfection. Data points represent the mean ± SD 
of three replicates. Free DNA was used as a negative control.
A transfection experiment (figure 6.8) helped to confirm that there was very poor binding 
occurring between the labelled peptide and plasmid DNA. At all charge ratios tested for 
the labelled peptide, there was little evidence of gene expression compared to the 
reasonably high transfection efficiency displayed by the unmodified peptide. The data 
also shows the marked reduction in transfection efficiency when the labelled peptide is
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combined with the unlabelled peptide in the same ratio. This was assumed to be due to 
poor or imcomplete condensation of the plasmid DNA by the labelled peptide.
6.3.3 Optimisation of chloroquine
B16 cells were transfected with K^spenetratin at an optimum charge ratio (+/-) o f 2.0 in 
the presence of increasing concentrations of chloroquine. The optimum concentration of 
chloroquine that gave high transfection levels of K^penetratin was found to be 100 pm 
(Figure 6.9). This concentration was used in subsequent transfection experiments with 
the gene delivery vectors, where appropriate.
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Figure 6.9. Optimisation of chloroquine concentration for transfection o f B16 cells with 
K2 5penetratin at a charge ratio (+/-) o f 2 .0 . B16 cells were transfected with 2  pg of 
pCMV/wc complexed with K2 spenetratin (+/- 2.0) for four hours and cells harvested 24 
hours post initiation of transfection for analysis. Data represent the mean of triplicate 
samples ± SD.
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6.3.4 Charge ratio of transfection complexes
For the transfection experiments, the optimum charge ratio o f all cationic gene delivery 
systems tested was determined in B16 cells. Table 6.2 gives an overview o f the optimum 
charge ratios. Plasmid DNA, 2 pg o f pCMV/wc was complexed with various quantities 
of the gene delivery vectors and transfected for four hours. Chloroquine at 100 pM was 
added where appropriate, prior to each transfection experiment.
Gene delivery 
system
Optimum charge ratio 
(+/-)
Penetratin V  3-5
K25penetratin 2.0
k 25 1.5
PEI 1.0 (= N/P ratio o f 6.0)
K25HA2 1.0
Table 6.2. Optimum charge ratios for various gene delivery systems for transfections in 
cell culture. The cationic vectors were transfected in the presence o f chloroquine.
6.3.5 Transfection of penetratin and its derivative
The transfection efficiency o f K25penetratin was about six times higher than that o f  
penetratin alone, although the level of luciferase expression was very low. Both 
penetratin and K25 showed little efficacy, even in the presence o f chloroquine. Cells 
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Figure 6.10. Transfection of B16 cells with various peptides. Luciferase expression 
following transfection using 2 pg pCMVluc complexed with K^penetratin (+/- 2.0), 
penetratin (+/- 3.5) and polylysine (K2 5  +/- 1.5) in the presence or absence of 100 pM 
chloroquine (c). Expression was assayed 24 hours after transfection. Data points 
represent the mean ± SD of three replicates.
6.3.6 A comparison of penetratin with endosomolytic agents in different 
mammalian cell lines
Also, in all cell lines employed, transfection of the various gene delivery vectors was 
carried out in the presence of 100 pM chloroquine. The conditions optimized in B16 
cells were used in all other cell lines and each vector was used at its optimum charge ratio 
for transfection. Naked DNA was used as a negative control in all cases.
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6.3.6.1 B16 cells
The efficiency of transfection in B16 cells is shown in Figures 6 .11A and B. All the gene 
delivery vectors were able to mediate gene expression in this cell line. PEI gave the 
highest transfection efficiency, especially without the presence of chloroquine, displaying 
twice as much activity as K2 5 HA2  and about three times as much efficiency as 
K2 5 penetratin with chloroquine. However, the efficiency o f PEI seemed to decrease in 
the presence of chloroquine. The activity of K2 5 penetratin in the presence of chloroquine 
was significantly higher than that of K^spenetratin alone, which was higher than K2 5 . 
Polylysine (K2 5 ) had little measurable activity, even in the presence of chloroquine. 
Naked DNA showed no measurable luciferase activity.
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Figures 6.11A and B. Both graphs show the same data for the transfection of B16 cells 
except that graph B is a log plot. Luciferase expression following transfection of 
pCM\ l u c  (2 pg) complexed with various gene delivery vectors at their respective 
optimum charge ratios (+/-). Complexes were transfected in the absence and presence of 
100 pM chloroquine (c). Expression was assayed 24 hours post initiation of transfection.
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Data points represent the mean ± SD of three replicates. Free DNA was used as a 
negative control.
Histochemical staining of B16 cells with X-gal was used to assess the percentage of B16 
cells expressing (3-galactosidase after transfection with pCMV(3 complexed with PEI, 
K:sHA2 and K0 5  penetratin at their optimum charge ratios (Figure 6.12). The cell 
population transfected with the cationic polymer, PEI, had markedly higher expression 
levels than those observed for the peptides. The influenza haemagglutinin peptide 
derivative, K2 5 HA2 , also gave high numbers of (3-gafve cells compared to K:5 penetratin.
A B
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EFigure 6.12. Histochemical staining of B16 cells with X-gal. (A) Cells incubated with 
naked DNA only. Complexes were formed between pCMVp and (B) Kispenetratin, (C) 
K:5 penetratin in the presence of chloroquine, (D) K:5 HA2 , (E) PEI. All complexes were 
incubated at 37°C for four hours and cells were treated with X-gal stain 48 hours post 
transfection, p-galactosidase expressing cells were stained blue.
This method of analysis involves counting the number of cells that are stained and 
therefore can be subject to error. Hence, expression was quantified more accurately 
using flow cytometry analysis or fluorescence activated cell sorting (FACS), which 
proves to be a more sensitive method. Figure 6.13 shows that Kospenetratin alone 
achieved only about 1% expression compared to 30% in the presence of chloroquine. It 
is noteworthy that with FACS analysis, chloroquine displays small amounts of 
auto fluorescence and this should be taken into account when interpreting expression 
levels in the presence of chloroquine. PEI achieved over 55% of expression without the 
need for chloroquine, almost twice as much as K^penetratin with chloroquine. Both 
methods of determining the percentage of cell expression levels exhibited similar trends 
in B16 cells with all the delivery vectors tested.
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SAMPLE % Gated (Ml)
Untransfected cells 0 . 0 2
Chloroquine only 0.69
K:5 penetratin 0 . 1 1
K.:5 penetratin+ chloroquine 33.96
PEI 1 58.95
PEI + chloroquine 51.23
Figure 6.13. FACS analysis of B16 cells transfected with K^penetratm and PEI at their 
optimum charge ratios. The pEGFP-Nl (2 jig) was complexed with the gene transfer 
agents and incubated at 37°C for four hours in the presence of 100 jiM chloroquine where 
necessary. FL-l-FIeight on the x-axis represents the fluorescence intensity at 530 nm ± 
15 nm and Events on the y-axis represents the cell counts. Table shows the percentage 
values for gated cells.
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6.3.6.2 HEK293 cells
The transfection efficiency in HEK293 cells for the various gene transfer agents was, in 
most cases, about twice the activity obtained in B16 cells with all vectors (with or 
without chloroquine) including K2 5  alone. PEI transfected with chloroquine in this cell 
line gave high expression levels similar to PEI alone.
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Figure 6.14A. Comparative transfection studies in HEK293 cells. Luciferase expression 
following transfection o f pCMV/wc (2 pg) complexed with various gene delivery vectors 
at their respective optimum charge ratios (+/-). Complexes were transfected in the 
absence and presence o f 100 pM chloroquine (c). Expression was assayed 24 hours post 
initiation of transfection. Data points represent the mean ± SD of three replicates. DNA 
only was used as a negative control.
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Figure 6.14B. Comparative transfection studies in HEK293 cells in a log representation.
6.3.63 HeLa cells
Figure 6.15 shows comparative transfection results in HeLa cells. PEI and K2 5 HA2  were 
very efficient transfection agents although PEI achieved about two times the transfection 
activity o f K2 5 HA2 . Expression levels were similar to those obtained in HEK293 cells. 
However, there was a marked decrease in the transfection activity o f PEI in the presence 
of chloroquine while the transfection of K2 5 HA2  was enhanced by chloroquine. 
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Figure 6.15A and B. Transfection in HeLa cells. Luciferase expression following 
transfection of pCMV/wc (2 pg) complexed with various gene delivery vectors at their
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respective optimum charge ratios (+/-). Complexes were transfected in the absence and 
presence of 100 pM chloroquine (c). Expression was assayed 24 hours post initiation of 
transfection. Data points represent the mean ± SD of three replicates. DNA only acted as 
a negative control. B is a log plot o f the data.
6.3.6.4 A549 cells
Generally, the levels of luciferase expressed in this cell line were lower than in previous 
cell lines studied. PEI proved to be the best efficient transfection agent without the 
presence of chloroquine. The difference in transfection efficiency between K2 5 HA2  and 
PEI was much greater, with the latter almost three times more efficient than the former. 
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Figure 6.16A and B. Transfection in A549 cells. Luciferase expression following 
transfection of pCMV/wc (2 pg) complexed with various gene delivery vectors at their 
respective optimum charge ratios (+/-). Complexes were transfected in the absence and 
presence of 100 pM chloroquine (c). Expression was assayed 24 hours post initiation of 
transfection. Data points represent the mean ± SD of three replicates. Free DNA was 
incorporated as a negative control. B is a log representation of the data.
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6.3.6.5 16HBE14o cells
In this cell line the levels of luciferase activity were relatively very low. The gene 
transfer agents, including PEI, displayed about half as much expression as with previous 
cell lines. Luciferase activity was two-fold higher in PEI transfected cells compared with 
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Figure 6.17A and B. Transfection in 16HBE14o' cells. Luciferase expression following 
transfection of pCMV/wc (2 pg) complexed with various gene delivery vectors at their 
respective optimum charge ratios (+/-). Complexes were transfected in the absence or 
presence of 100 pM chloroquine (c). Expression was assayed 24 hours post initiation of 
transfection. Data points represent the mean ± SD of three replicates. Free DNA only 
was used as a negative control. B represents a log plot of the transfection data.
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6.3.6.6 FEK4 cells
A comparative transfection study in FEK4  cells is shown in Figure 6.18. The transfection 
levels were relatively very low. Both PEI and K2 5 HA2  proved to be more efficient with 
PEI displaying the highest activity by an appreciable margin. Transfection with 
K.2 5penetratin in the presence of chloroquine gave similar activity to that of PEI and 
chloroquine.
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Figure 6.18A and B. Transfection in F E K 4  cells. Luciferase expression following 
transfection o f pCMV/wc (2 pg) complexed with various gene delivery vectors at their 
respective optimum charge ratios (+/-). Complexes were transfected in the absence or 
presence o f 100 pM chloroquine (c). Expression was assayed 24 hours post initiation of 
transfection. Data points represent the mean ± SD of three replicates. DNA alone served 
as a negative control. B is a log plot representation of the transfection data.
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6.3.7 Multi-component transfection systems
The gene transfer agents, PEI and K2 5 HA2  employed in this study, were both co- 
complexed with penetratin or K^penetratin. The combination o f PEI with either 
K2 5 penetratin or penetratin reduced transfection activity o f the polymer. However, the 
combination of K2 5 HA2  with either K2 spenetratin or penetratin appeared to enhance 
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Figure 6.19. Transfection of multi-component systems in B16 cells. Luciferase 
expression following transfection of pCMWluc (2 pg) complexed with two gene delivery 
vectors at the same time. Expression was assayed 24 hours post initiation of transfection. 
Data points represent the mean ± SD of three replicates. Naked DNA was used as a 
negative control.
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6.3.8 Effect of centrifugation on transfection efficiency in B16 cells
The effect o f centrifugation (300 g  for 5 minutes) on the efficiency o f transfection 
mediation by gene transfer agents was investigated in B16 cells and is shown in Table 
6.3. The gene delivery vectors were complexed with pCMYluc and transfected at their 
optimum charge ratios with or without centrifuging the cell culture plates. The results 
showed that this process of spinning the culture plates before incubation proved to be 
beneficial for all the gene transfer agents. However, the increase o f transfection 
efficiency due to spinning was only significant for K^penetratin.
Gene delivery 
vector
Mean transfection efficiency 
(ng luc/mg protein)




K25penetratin 343.98 2275.13 84.9 0.0062
K25penetratin + c 7918.79 9641.97 17.9 0.3000
K25HA2 16996.01 23564.25 27.9 0.0790
K25HA2 + c 28199.19 34088.21 17.3 0.1600
PEI 37855.63 38749.72 2.3 0.8800
Table 6.3. Effect o f centrifugation on transfection in B16 cells. Luciferase expression 
following transfection o f pCMV/wc (2 fig) complexed with various gene delivery vectors 
at their respective optimum charge ratios. Transfection o f B16 cells was carried out with 
or without centrifugation. Data points represent the mean ± SD o f three replicates. Free 
DNA (+/-spin) only was used as a negative control. P values < 0.05 are significant.
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6.3.9 Toxicity of polymer/peptides.
The MTT assay was used to determine levels of toxicity of various gene delivery agents. 
Figure 6.20 shows a comparison of the percentage of B16 cells viable after 3 hours with 
the peptides and PEI. The peptides, K2 5 , K^spenetratin and penetratin all displayed 
similar levels of percentage cell viability, especially at lower peptide concentrations. 
K.2 5 penetratin showed slightly lower cell viability than K2 5  and penetratin at higher 
concentrations of peptides. PEI displayed the highest level of toxicity. The charge ratio 
calculated for PEI is only theoretical and is based on its protonation outline where one in 







charge ratio of polym er/peptide (+/-)
Figure 6.20. Determination of toxicity of uncomplexed gene delivery agents in B16 
melanoma cells. Various additions of peptides/polymer were made to the wells 
equivalent to concentrations similar to that used in transfection experiments. Cell 
viability was determined by comparison with a control population of cells, plated out 16 
hours before the MTT assay, using the calibration curve (Appendix G). Data points 
represent an average of triplicate evaluations.
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All peptides displayed comparable toxicity levels, with higher charge ratios giving higher 
toxicity. The polycations were found to be non-toxic at concentrations giving optimum 
transfection efficiency: B16 cells exhibited over 60% viability at the range o f charge 
ratios tested, for all peptides. PEI showed a higher toxicity level in comparison at a 
similar range in the absence of DNA. However, levels o f PEI toxicity on B16 cells was 
generally low and occurred at charge ratios higher than that required for optimal 
transfection efficiency. This can be explained by the fact that the cationic charges are not 
neutralized under these conditions.
6.3.10 Particle size analysis
A comparative analysis o f particle size exhibited by peptide-DNA complexes at their 
respective optimum charge ratios used for transfection is shown in Table 6.4. The 




1 2 3 Mean diameter 
(nm)
Polylysine (K25) 1.5 87.7 85.3 115.5 96.2
K25penetratin 2.0 99.5 88.0 91.0 92.8
Penetratin 3.5 104.1 89.1 112.4 101.9
Table 6.4. Determination o f particle size analysis o f polycation-DNA complexes. 
Complexes were prepared using pCMV/wc and appropriate quantities o f peptides 
equivalent to their optimum charge ratios used for transfection experiments. Complexes 
were incubated for 20 minutes at room temperature. Measurements were made at 20°C 
and five runs were recorded per sample, n = 3.
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6.3.11 Erythrocyte Lysis Assay
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Figure 6.21. Erythrocyte leakage activity of K.2 5penetratin and K2 5 HA2 . The absorption 
of haemoglobin is plotted using 10% Triton X-100 to give 100% lysis. Values are 
normalised to 1 0 0 %. n =  1 .
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6.4 DISCUSSION
6 . 4 . 1  D N A  b i n d i n g
P l a s m i d  D N A  h a s  d i f f i c u l t y  g a i n i n g  a c c e s s  t o  t h e  c y t o p l a s m  a n d  n u c l e u s  o f  e u k a r y o t i c  
c e l l s  b e c a u s e  o f  i t s  l a r g e  s i z e  a n d  p o l y a n i o n i c  p r o p e r t y .  H e n c e ,  i t  i s  n e c e s s a r y  t o  
n e u t r a l i s e  t h e  e x c e s s  n e g a t i v e  c h a r g e s  o f  D N A  a s  w e l l  a s  c o n d e n s e  D N A  t o  a  s i z e  t h a t  
f a c i l i t a t e s  c e l l  e n t r y .  T h e  n e u t r a l i s a t i o n  o f  e x c e s s  n e g a t i v e  c h a r g e s  o n  D N A  w i t h  
p o l y c a t i o n s  h a s  b e e n  i n v e s t i g a t e d  b y  v a r i o u s  t e c h n i q u e s  s u c h  a s  g e l  m o b i l i t y  s h i f t  a s s a y  
( W a g n e r  et al., 1 9 9 0 ,  V i t i e l l o  et al., 1 9 9 6 )  a n d  t h e  e t h i d i u m  b r o m i d e  s p e c t r o f l u o r i m e t r i c  
a s s a y  ( G e r s h o n  et al . ,  1 9 9 3 ) .  T h e ,  i n t e r a c t i o n  b e t w e e n  p e n e t r a t i n  d e r i v a t i v e  a n d  p l a s m i d  
D N A  i n  t h i s  s t u d y  w a s  i n v e s t i g a t e d  u s i n g  b o t h  t e c h n i q u e s .
I t  h a s  b e e n  p r e v i o u s l y  s h o w n  t h a t  t h e  i n t e r a c t i o n  b e t w e e n  c a t i o n i c  p o l y m e r s / p o l y c a t i o n s  
a n d  p l a s m i d  D N A  i s  e l e c t r o s t a t i c  ( B l o o m f i e l d ,  1 9 9 6 ) .  T h e  e x t e n t  o f  p l a s m i d  D N A  
b i n d i n g  b y  p e n e t r a t i n  w a s  d e t e r m i n e d  b y  g e l  m o b i l i t y  a s s a y .  T h i s  r e q u i r e m e n t  f o r  a  h i g h  
c h a r g e  r a t i o  i m p l i e s  t h a t  p e n e t r a t i n  d o e s  n o t  h a v e  a  s t r o n g  e l e c t r o s t a t i c  i n t e r a c t i o n  w i t h  
p l a s m i d  D N A .  T h i s  w a s  s u p p o r t e d  b y  d a t a  o b t a i n e d  u s i n g  t h e  e t h i d i u m  b r o m i d e  
f l u o r e s c e n c e  a s s a y .  T h e r e  i s  a  d i s t i n c t  f l u o r e s c e n c e  e n h a n c e m e n t  w h e n  e t h i d i u m  b r o m i d e  
i n t e r c a l a t e s  w i t h  d o u b l e - s t r a n d e d  D N A .  T h e  d y e  b i n d s  a t  a  s t o i c h i o m e t r y  o f  o n e  d y e  p e r  
4 - 5  b a s e  p a i r s  o f  D N A  a n d  i t s  f l u o r e s c e n c e  i s  e n h a n c e d  b y  2 0 -  t o  3 0 - f o l d .  U l t r a v i o l e t  
r a d i a t i o n  i s  a b s o r b e d  b y  t h e  D N A  a n d  t r a n s m i t t e d  t o  t h e  b o u n d  d y e ,  t h e  e n e r g y  b e i n g  r e ­
e m i t t e d  i n  t h e  r e d - o r a n g e  r e g i o n  o f  t h e  v i s i b l e  s p e c t r u m  ( S a m b r o o k  et al. ,  1 9 8 9 ) .  
S p e c t r o f l u o r i m e t r i c  q u a n t i t a t i o n  o f  d i s p l a c e m e n t  f r o m  i t s  i n t e r c a l a t i o n  s i t e  w a s  u s e d  t o  
q u a n t i t a t e  t h e  c h a r g e  r a t i o  a t  w h i c h  t h e s e  p e p t i d e s  c o m p e t i t i v e l y  d i s p l a c e  e t h i d i u m  
b r o m i d e  f r o m  D N A .  C o m p a r a t i v e  s t u d i e s  w i t h  K 2 5 p e n e t r a t i n  s h o w e d  t h a t  t h e  
e l e c t r o s t a t i c  i n t e r a c t i o n  w i t h  p l a s m i d  D N A  p r o v e d  t o  b e  s t r o n g e r  t h a n  t h a t  o f  p e n e t r a t i n .  
A  r e l a t i v e l y  l o w  m a s s  o f  K 2 5 p e n e t r a t i n  w a s  r e q u i r e d  t o  n e u t r a l i s e  D N A .  T h i s  s u g g e s t s  
t h a t  t h e  a t t a c h m e n t  o f  t h e  p o l y l y s i n e  c h a i n  ( K 2 5 )  t o  p e n e t r a t i n  c r e a t i n g  a  p e p t i d e  w i t h  a  
c l u s t e r  o f  p o s i t i v e l y  c h a r g e d  a m i n o  p r o m o t e d  a  1 :  1  i n t e r a c t i o n  w i t h  D N A  p h o s p h a t e  
g r o u p s .  T h u s  K 2 s p e n e t r a t i n  b i n d s  m o r e  s t r o n g l y  p r o b a b l y  r e s u l t i n g  i n  a  s m a l l e r  a n d  m o r e  
c o m p a c t  s t r u c t u r e ,  w h i l e  p r o m o t i n g  e f f e c t i v e  D N A  u p t a k e  i n t o  t h e  c e l l .  O l i n s  et a l . ,  1 9 6 8
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h a v e  s h o w n  t h a t  a  m i n i m u m  o f  e i g h t  l i n e a r  l y s i n e s  i s  r e q u i r e d  i n  o r d e r  t o  i n d u c e  t h e  
b i p h a s i c  m e l t i n g  b e h a v i o u r  o n  c o m p l e x a t i o n  o f  D N A  t h a t  i s  c h a r a c t e r i s t i c  o f  p o l y l y s i n e s .  
T h e  a d v a n t a g e  o f  u s i n g  K 25  i s  t h a t  i t  a v o i d s  p o o r l y  d e f i n e d  h e t e r o g e n e o u s  c o m p l e x e s  t h a t  
a r e  d i f f i c u l t  t o  c h a r a c t e r i s e  o n  a  m o l e c u l a r  b a s i s ,  o f t e n  a c h i e v e d  w i t h  c o m m e r c i a l  
p o l y l y s i n e s  t h a t  h a v e  b e e n  f o u n d  t o  b e  p o l y d i s p e r s e .  T h i s  i s  a  l o n g e r  o l i g o l y s i n e  c h a i n  
t h a n  t h a t  u s e d  b y  G o t t s c h a l k  et a l . ,  1 9 9 6  w h o  d e v e l o p e d  a  p e p t i d e  w i t h  1 0  l y s i n e s ,  w h i c h  
a p p a r e n t l y  s t i l l  b i n d s  t o  D N A .  I n  t h i s  s t u d y ,  K 25  p r o v i d e d  a  g o o d  c o m p a r i s o n  w i t h  t h e  
e n d o s o m o l y t i c  a g e n t ,  K 2 5 H A 2 . D i f f e r e n c e s  w e r e  s e e n  b e t w e e n  t h e  a m o u n t s  o f  e a c h  
p e p t i d e  r e q u i r e d  t o  a c h i e v e  p l a s m i d  D N A  c o n d e n s a t i o n .  P r o f i l e s  w e r e  r e l a t e d  t o  t h e  n e t  
c h a r g e  o f  e a c h  p e p t i d e  a s  w e l l  a s  t h e  a c c e s s i b i l i t y  o f  t h e i r  c h a r g e d  r e s i d u e s  t o  i n t e r a c t  
w i t h  p l a s m i d  D N A .  C o n d e n s a t i o n  o f  D f s T A  i s  a n  i m p o r t a n t  f a c t o r  a s  i t  n o t  o n l y  e n h a n c e s  
e x p r e s s i o n  i n  t h e  p e n e t r a t i n  s y s t e m ,  b u t  h a s  b e e n  s h o w n  t o  i m p r o v e  g e n e  d e l i v e r y  a n d  
e x p r e s s i o n  i n  v a r i o u s  o t h e r  s y s t e m s  ( W a g n e r  et al., 1 9 9 1 ;  F o m i n a y a  a n d  W e i s ,  1 9 9 6 ) .  
T h e  l y s i n e  c h a i n  m a y  c o n t r i b u t e  t o  a  r e s i s t a n c e  t o  d e g r a d a t i o n  o f  t h e  D N A - p e p t i d e  
c o m p l e x  b y  c e l l u l a r  p r o c e s s e s ,  p o s s i b l y  d u e  t o  a  l a c k  o f  a c c e s s i b i l i t y  o f  t h e  D N A  t o  
l y s o s o m a l  n u c l e a s e s  b e c a u s e  o f  t i g h t  b i n d i n g  t o  t h e  l y s i n e  m o i e t y .
T h e  e t h i d i u m  b r o m i d e  e x c l u s i o n  p r o f i l e s  o n  D N A  c o m p l e x a t i o n  w e r e  i n v e s t i g a t e d  i n  a n  
a t t e m p t  t o  c o n f i r m  t h a t  b o t h  t h e  l a b e l l e d  a n d  u n l a b e l l e d  p e p t i d e s  w e r e  b e h a v i n g  i n  a  
s i m i l a r  m a n n e r .  T h e  a b i l i t y  o f  K 2 5 p e n e t r a t i n  t o  c o n d e n s e  D N A  w a s  d r a m a t i c a l l y  r e d u c e d  
b y  t h e  p r e s e n c e  o f  B O D I P Y  F L  ( F i g u r e  6 . 6 ) .  B O D I P Y - l a b e l l e d  K 2 s p e n e t r a t i n  c a u s e d  a  
m u c h  l o w e r  r e d u c t i o n  i n  f l u o r e s c e n c e  a n d  w a s  u n a b l e  t o  e x c l u d e  e t h i d i u m  b r o m i d e  f r o m  
p l a s m i d  D N A  e v e n  a t  h i g h e r  c h a r g e  r a t i o s  c o m p a r e d  t o  t h e  p e p t i d e  a l o n e .  T h e  d i f f e r e n c e  
i n  t h e  i n t e r a c t i o n  w i t h  p l a s m i d  D N A  b e t w e e n  t h e  l a b e l l e d  a n d  u n l a b e l l e d  p e p t i d e s  w a s  
f u r t h e r  c o n f i r m e d  i n  t r a n s f e c t i o n  s t u d i e s .  T h e  a b i l i t y  t o  t r a n s f e r  D N A  i n t o  c e l l s  w a s  
t o t a l l y  a b o l i s h e d  i n  t h e  p r e s e n c e  o f  B O D I P Y  ( F i g u r e  6 . 8 ) .  O n e  e x p l a n a t i o n  f o r  t h e s e  
d i f f e r e n c e s  i n  b e h a v i o u r  i s  t h e  f a c t  t h a t  t h e  p r e s e n c e  o f  B O D I P Y  p r e v e n t s  t h e  p e p t i d e  
f r o m  i n t e r a c t i n g  w i t h  p l a s m i d  D N A .  B O D I P Y  i s  a  m o l e c u l e  o f  r e l a t i v e l y  l a r g e  s i z e  ( M W  
=  6 4 1 . 5 ) ,  w h i c h  e x e r t s  s i g n i f i c a n t  s t e r i c  h i n d r a n c e  o n  t h e  i n t e r a c t i o n  w i t h  p l a s m i d  D N A .  
T h e  u s e  o f  B O D I P Y  a s  a n  e x t r i n s i c  p r o b e  p r o v e d  t o  b e  i n t r u s i v e  a n d  l e d  t o  c h a n g e s  i n  t h e  
f u n c t i o n a l  a n d  s t r u c t u r a l  p r o p e r t i e s  o f  t h e  l a b e l l e d  p e p t i d e .  I t  w o u l d  b e  t o  g r e a t
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advantage to have a chemically and biologically stable, non-intrusive fluophore, which 
could be incorporated in a peptide.
6.4.2 Endosomal release
For efficient transfection, escape from the endosome and delivery to the cytoplasm are 
required. Various groups have observed similar approaches to cytoplasmic delivery 
involving the endosomal pathway, where the endosome is disrupted and allows DNA 
access to the cytoplasm prior to fusion o f the endosome with the lysosome (Behr et al., 
1994; Gao and Huang, 1995). In the presence o f chloroquine, cultured cells expressed 
the reporter gene following transfection with peptide-condensed plasmid DNA. The 
luciferase activity was maximal when the transfection was conducted in the presence o f  
100 p.M chloroquine. This result was in agreement with those obtained for transfections 
of an erythroblast cell line HD3 using plasmid/transferrin-polylysine complexes (Zenke 
et al., 1990).
Although the mode o f action o f chloroquine is not clear, it is thought that apart from 
neutralizing the pH o f endocytotic vesicles as a weak base (Poole and Okhuma, 1981), it 
prevents fusion o f endosomes with the lysosomes where complexes get degraded. Its 
buffering o f the endosomal pH causes a rise in the osmolarity o f the vesicle such that 
lysis may take place leading to the release o f DNA into the cytoplasm. Chloroquine has 
also been shown to induce dissociation o f plasmid DNA/peptide complexes in vesicular 
compartments (Erbacher et al., 1996). This may help explain why the activity o f the 
bifunctional peptide, K^penetratin, was dramatically enhanced when chloroquine was 
present in the transfection stage. The critical requirement for chloroquine is a significant 
finding as it implies that most o f the K2spenetratin/DNA complexes enter the cells by 
endocytosis. Chloroquine has been shown to increase the egress o f complexes from 
endosomes and mediate efficient gene transfer by several other groups (Hedin and 
Thyberg, 1985; Taxman et a l., 1993; Midoux et al., 1993; Cotten et al., 1990). Cell lines 
differ considerably with respect to the need for chloroquine for efficient transfection, 
implying that there are variations in the integrity o f endosomal membrane components.
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Other groups have demonstrated the use o f membrane-active peptides in enhancing DNA 
delivery (Midoux et al., 1993; Haensler and Szoka, 1993). K25HA2 is a membrane-active 
amphipathic helical peptide. The membrane-disrupting action is demonstrated in the 
erythrocyte lysis study, which had a strong correlation with luciferase gene transfer 
efficiency. These results are in line with those reported by Plank et al., 1994. Penetratin, 
on the other hand, is only very partially amphipathic, and amphiphilicity is not a 
requirement for its internalization (Prochaintz et al., 1996). K^spenetratin displays little 
measurable lytic activity at pH 5 and 7 despite the fact that binding o f penetratin to the 
membrane will occur since the membrane o f erythrocytes possess negatively charged, 
sialic acid-modified glycoproteins. Investigations by Joliot et al., 1991b reported clear 
interactions o f penetratin with polysialic acid groups present on neuronal membrane 
surfaces. Singh et al., 1992 also studied the interaction o f polycations with negative 
charges on epithelial cell surfaces, which appears to be due to carboxylic acids o f the 
sialic acid o f glycoproteins and sulphate groups o f proteoglycans. Schutze-Redelmeier et 
al., 1996 reported data that suggest polysialic acid groups bind penetratin through 
electrostatic interactions, concentrating the peptide at the cell surface and protecting it 
from proteolytic degradation. This may help explain why penetratin has been found to 
exhibit very efficient translocating properties. Although the mode o f action of penetratin 
is yet to be confirmed, preliminary studies have reported that cell entry does not involve 
endocytosis as it occurs at both 37°C and 4°C (Derossi and Prochiantz, 1995). This 
deviates from transfection results achieved in this study as the delivery o f penetratin was 
enhanced significantly in the presence o f chloroquine, implying endosomal uptake. 
Among peptide vectors that have been proposed for intracellular delivery, those involving 
receptor-mediated mechanisms have been successful in gene delivery (Perales, 1994). It 
is noteworthy that preliminary studies done to establish a mechanism of action for 
penetratin have not assessed interactions with plasmid DNA, that is complexed systems, 
which creates a different molecular environment compared to the peptide on its own. 
Polycation-mediated gene transfer is thought to involve DNA aggregation and binding o f  
the resulting particles to anionic residues on the plasma membrane (Behr et al., 1994). 
The complexes should exhibit an overall net positive charge to be efficient. PEI 
consistently proved to be the best gene delivery agent in all experiments and all cell lines
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t e s t e d  i n  t h i s  s t u d y ,  w i t h o u t  t h e  n e e d  f o r  c h l o r o q u i n e .  T h e  b u f f e r i n g  c a p a c i t y  o f  P E I  i s  
s u b s t a n t i a l  a t  a n y  p H  m a k i n g  i t  a  h i g h l y  e f f i c i e n t  v e c t o r  f o r  d e l i v e r i n g  p l a s m i d s  in vitro 
a n d  in vivo  ( B o u s s i f  et a l . ,  1 9 9 5 ) .  T h e  p e n e t r a t i n  p e p t i d e  s h o w e d  n o  s i g n i f i c a n t  e f f e c t  o n  
P E I  t r a n s f e c t i o n ,  p e r h a p s  d u e  t o  a  s a t u r a t i o n  o f  p o s i t i v e  c h a r g e s ,  a n d  h e n c e  a c h i e v e s  n o  
a d d i t i o n a l  b e n e f i t .  T h e  i n t e r a c t i o n  b e t w e e n  p e n e t r a t i n  a n d  P E I  i s  n o t  a  c o v a l e n t  o n e ,  
h e n c e  i t  i s  d i f f i c u l t  t o  c o n c l u d e  i f  p e n e t r a t i n  c a n  a c t u a l l y  e x e r t  a n  e n h a n c e m e n t  o f  P E I  
a c t i v i t y .
6.4.3 Transfection efficiency of gene delivery vectors
P r e l i m i n a r y  t r a n s f e c t i o n  d a t a  w i t h  p e n e t r a t i n  i n  B 1 6  c e l l s  s h o w e d  t h a t  t h e r e  w a s  l i t t l e  
g e n e  e x p r e s s i o n  a t  a l l  c h a r g e  r a t i o s  t e s t e d ,  a l t h o u g h  i t  w a s  a b l e  t o  c o n d e n s e  p l a s m i d  D N A  
a t  h i g h  c h a r g e  r a t i o s .  T h e  i m p r o v e m e n t  i n  t r a n s f e c t i o n  e f f i c i e n c y  a c h i e v e d  w i t h  
K 2 5 p e n e t r a t i n  w a s  d u e  t o  t h e  i n c l u s i o n  o f  a  c h a i n  o f  l y s i n e s .  F r i t z  et a l . ,  1 9 9 6  o b s e r v e d  a  
s i m i l a r  r e s u l t ,  w h i c h  i n v o l v e d  g e n e  t r a n s f e r  u s i n g  a  l y s i n e - r i c h  h i s t o n e / D N A  c o m p l e x  i n  
t h e  p r e s e n c e  o f  c h l o r o q u i n e .  P r e s u m a b l y ,  K 25 p e n e t r a t i n  d e r i v e s  i t s  D N A  t r a n s f e c t i o n  
e f f i c i e n c y  f r o m  b o t h  t h e  p e n e t r a t i n g  a b i l i t y  o f  p e n e t r a t i n  a n d  t h e  k n o w n  p r o p e r t i e s  o f  t h e  
a d d e d  p o l y l y s i n e  c a t i o n i c  p e p t i d e .  A p a r t  f r o m  t h e  f a c t  t h a t  H E K 2 9 3  c e l l s  h a v e  w e a k e r  
e n d o s o m a l  m e m b r a n e s  m a k i n g  t h e m  m u c h  m o r e  r e a d i l y  t r a n s f e c t e d .  W o l f e r t  a n d  
S e y m o u r ,  1 9 9 8  a l s o  o b s e r v e d  t h a t  H E K 2 9 3  w e r e  r e a d i l y  t r a n s f e c t e d  w i t h  
p o l y l y s i n e / D N A  c o m p l e x e s  in vitro. I n  a l l  o t h e r  c e l l  l i n e s  t e s t e d ,  t h e  e x p r e s s i o n  l e v e l  o f  
P E I  w a s  d r a m a t i c a l l y  r e d u c e d  w i t h  c h l o r o q u i n e .  I n  p a r t i c u l a r ,  H e L a  c e l l  l i n e  w e r e  m u c h  
m o r e  s e n s i t i v e  t o  t o x i c i t y  a n d  m a y  r e q u i r e  < 1 0 0  p M  c h l o r o q u i n e  a s  t h i s  a m o u n t  o f  
c h l o r o q u i n e  p l u s  P E I  p r o v e d  t o o  t o x i c .  T h e  t r a n s f e c t i o n  e f f i c i e n c y  o f  t h e  e n d o s o m o l y t i c  
p e p t i d e ,  K 2 5 H A 2 ,  w a s  i n c r e a s e d  w i t h  c h l o r o q u i n e  i n  a l l  c e l l  l i n e s  w i t h  t h e  e x c e p t i o n  o f  
A 5 4 9 s  a n d  F E K 4  c e l l s .  A l t h o u g h  i t  i s  p o s s i b l e  t h a t  < 1 0 0  p M  o f  c h l o r o q u i n e  m a y  r e s u l t  
i n  b e t t e r  t r a n s f e c t i o n  o f  K 2 5 H A 2  i n  t h e s e  c e l l s ,  t h e  t r a n s f e c t i o n  e f f i c i e n c y  o f  
K 2 5 p e n e t r a t i n  w a s  c o n s i s t e n t l y  i m p r o v e d  w i t h  c h l o r o q u i n e  a t  t h i s  c o n c e n t r a t i o n .  T h e  
t r a n s f e c t i o n  e f f i c i e n c y  o f  K 25 p e n e t r a t i n  a l o n e  w a s  r e l a t i v e l y  s i m i l a r  i n  a l l  c e l l  l i n e s  
a l t h o u g h  F E K 4 S , A 5 4 9 s  a n d  1 6 H B E 1 4 o -  c e l l s  g e n e r a l l y  p r o v e d  t o  b e  m o r e  r e s i s t a n t  t o  
t r a n s f e c t i o n .  T h e  t r a n s f e c t i o n  o f  t h e s e  d e l i v e r y  p e p t i d e s  i n  p r i m a r y  c e l l s  p r o v e d  v e r y
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inefficient implying the very high resistance these groups o f cells have to transfection 
probably due to decreased cell binding. Bahnson et a l., 1995 observed refractory 
transfection efficiency with peripheral blood mononuclear cells because they lack cation- 
binding surface components. These cationic vectors bind to anionic sugars present on the 
membrane o f adherent cells only. Derossi and Prochiantz, 1995 reported the significance 
of these interactions in permitting or facilitating the internalization process o f various 
polypeptides. Labat-Moleur et al., 1996 showed the difficulty in transfecting peripheral 
blood mononuclear cells due to the absence o f these membrane components. Wyman et 
al., 1996 reported a lack o f transfection mediation in primary epithelial cells using the 
cationic amphipathic peptide KALA. A variation in transfection efficiency in cell lines 
tested may be the result o f differences iri cell surface composition that affect the binding 
of complexes.
Transfection efficiency was further improved in B16 cells when the culture plates were 
centrifuged after the delivery vectors have been added to the wells. Transfection o f cells 
in culture involves the random movement of complexes in suspension to the close 
proximity o f the cell surface. Spinning the culture plates allows smaller polycation/DNA 
complexes to come into closer proximity with the surface o f the cells. This makes a 
greater amount o f these complexes available for uptake into the cells, which in turn 
results in higher expression levels. Similar data were observed by Boussif et al., 1996 in 
a study to optimize conditions used in transfection. There was no beneficial effect on 
PEI/DNA complexes probably due to their bigger particle population most o f which settle 
on to the cells without the need for centrifugation. Swaney et al., 1997 reported a 
synergistic effect in the transfection efficiencies o f cationic complexes when combined 
with centrifugation.
6.4.4 Characterization studies
Particle size analysis o f polycation/DNA complexes demonstrated that the complexes 
were between 90 -  101 nm mean diameter. The use o f 5% glucose in these experiments 
provides isotonic conditions found in vivo. It is necessary to control the size o f  
complexes such that they are small enough to access target cells. Most forms o f triggered
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membrane penetration act via the endosomal membrane following endocytosis, and 
pinocytic internalization is usually limited to materials o f less than 100 nm diameter 
(Wagner et al., 1991, Perales et al., 1994a). Receptor-mediated gene transfer was found 
to be far more effective when DNA was condensed into particles o f approximately 80 -  
100 nm (Ogris et al., 1998). Preliminary measurements were carried out in HBS in an 
attempt to mimic transfection conditions as close as possible. However, the 
measurements with HBS proved to be problematic as extremely large (>1600 nm) 
aggregated particles were formed. A similar observation was also found by Tang and 
Szoka, 1997. Sometimes it was not possible to interpret results with HBS, as the 
interference o f the light scattering path was too great.
6.5 SUMMARY
Penetratin has considerable potential for delivery o f small polypeptides (and possibly 
oligonucleotides) by direct transfer o f the molecule across the plasma membrane. 
Fahraeus et al., 1996 observed entry into S phase o f HaCaT cells was blocked by a p i6- 
derived peptide when it was coupled to penetratin. Although K25penetratin is capable of 
mediating transfection in a variety o f cell lines, this internalization process is not efficient 
for larger species such as plasmids used in this study. The K25 moiety helps to anchor 
penetratin to DNA, which does not display as high endosomolytic activity as amphipathic 
helical peptides. K2spenetratin appears to be membrane-active but most o f the DNA is 
taken up primarily by endocytosis, which contradicts results from other groups (Derossi 
and Prochiantz, 1995). The cationic polymer, polyethyleneimine shows very effective 
DNA-binding, mediating efficient gene transfer, without the addition o f chloroquine.
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CHAPTER 7
SYNTHETIC VIRUS-LIKE PARTICLES FOR INTEGRIN- 
MEDIATED TARGETING
7.1 INTRODUCTION
Cationic polyplexes interact in a non-specific manner with most cells. If formulated with 
an endosomolytic polymer, such as PEI, cationic polyplexes are adequate for transfection 
in vitro. There are practical problems with the use o f such polyplexes in vivo. When 
injected directly into solid tissues "they tend to bind to any negatively charged surfaces 
causing them to be immobilised close to the injection site. One way to circumvent this 
problem may be to design negative or neutral particles, which use a selective ligand to 
promote uptake into target cells. This chapter investigates the design and assembly o f  
polyplexes (or virus-like particles) for non-viral gene delivery. In their core polyplexes 
must contain the appropriate condensed DNA, and their design must include a 
mechanism for endosome escape. This chapter explores whether targeting o f neutral or 
negative polyplexes could be achieved, and how the efficiency o f targeting related to 
their total polycation content. Hart et al., 1994 showed that particles in the form o f  
filamentous phage could be targeted to cells using cyclic RGD peptides. Later an 
integrin-binding RGD peptide was coupled to polylysine (Hart et al., 1996) to produce a 
polymer which was capable o f targeting DNA to cells which expressed appropriate 
integrins. This study aims to combine an RGD peptide with PEI, a polymer that was first 
identified as a transfection reagent by Boussif et al., 1995 and has been regarded as the 
reagent o f choice for transfection o f cells in vitro and in vivo (Coll et al., 1999). The 
objective was to partly-neutralise the DNA with PEI, to mediate endosome escape, and 
then to add cationic peptides with or without a targeting function to the system. The 
integrin-binding moiety GACDCRGDCFCA (Pasqualini et al., 1997) was used as a 
model ligand for this purpose.
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7.2 MATERIALS AND METHODS
7.2.1 Materials
Cyclic-GRGDSPA was obtained from Bachem, UK and was employed in inhibition 
experiments.
T h e  o t h e r  m a t e r i a l s  u s e d  i n  t h i s  s t u d y  i n c l u d e  t h e  r e p o r t e r  p l a s m i d  p C M V / w c ,  PEI, K 25  
a n d  K 2 5 R G D ,  w h i c h  h a v e  a l r e a d y  b e e n  d e s c r i b e d  i n  d e t a i l  i n  c h a p t e r  2 .  T h e  s e q u e n c e  o f  
K 2 5 R G D  w a s  a s  f o l l o w s ;
H 2N - K 2 5 - G A C D C R G P C F C A - C O O H
7.2.2 Preparation of complexes
Appropriate mixtures o f PEI and K25 or PEI and K25RGD were prepared prior to DNA 
complexation and diluted to a final volume o f 250 pi with Hepes buffered saline (HBS). 
3 pg pCMV/wc was diluted to a volume of 250 pi with HBS. In each case the 
PEI/peptide solution (or PEI alone for controls) was added to the DNA solution and 
immediately mixed by vortexing. For experiments involving DNA/PEI/peptide 
complexes the PEI content was kept constant at two N/P ratios o f 4 and 2. Complexes 
were labeled according to the additional charge resulting from the cationic peptide 
content [ratio o f lysine groups added per phosphate; equivalent to the additional charge 
ratio (+/-)]. The additional charge ratio relating to the K25 or K25RGD content was varied 
within the range 0.1 to 1.0 (+/-) to produce DNA/PEI/peptide complexes with net 
negative as well as net positive charge.
7.2.3 Cell culture and transfection of cells
Two cell lines were employed in this study. Cos7 and B16 cells were routinely cultured 
as adherent monolayers in MEM as described in chapter 2. Cos7 cells, a fibroblast-like 
cell line established by SV40 transformation of CV-1 African green monkey kidney cells,
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were obtained from the European Collection o f Animal Cell Cultures (ECACC), UK. 
For routine culture, cells were subcultured 1 in 5 twice weekly. Cells were seeded onto 
six-well plates in 2 ml growth medium 24 hours before transfection. Complexes o f  
pCMV7wc with polycations were prepared 30 minutes prior to use, then transfections 
were carried out with 3 pg DNA per well (in 0.5 ml HBS) in the presence o f 1.5 ml Opti- 
MEM. For competitive inhibition experiments, the cells were first incubated with 600 pg 
of cyclic-GRGDSPA per well, for 5 minutes, prior to addition o f complexes. After 4 
hours, the transfection medium was removed and replaced with 2 ml growth medium. 
Cells were harvested 24 hours after transfection and analysed using the Promega 
luciferase assay system. Luminescence generated in each sample was determined over 
10 seconds using a Turner Design 20/20 luminometer. The concentration o f protein in 
cell extracts was measured using the Bio-Rad Dc protein assay kit.
7.2.4 Zeta potential measurements
Zeta potential measurements o f PEI-K25RGD-DNA and PEI-DNA complexes formed 
were determined using an electrophoretic light scattering technique in the form of a 
Brookhaven ZetaPALS (zeta phase analysis light scattering), Zeta Potential Analyser 
(Brookhaven Instruments Corporation, USA). Measurements were made on PEI 
complexes formed in a tris 0.01 M solution pH 7.0. All sample vials, glass and 
plasticware were washed using prefiltered water to reduce particulate contamination. 
Measurements were made in a micro-electrophoresis cell thermostatically controlled at 
25°C. The model or method o f calculating zeta potential from the measured mobility 




Complexes o f pCMV7«c with PEI transfected B16 (figure 7.1) and Cos7 (figure 7.2) cells 
spontaneously with N/P ratios between 6  and 9 showing the most efficiency. The 
transfection data showing the optimum N/P range was in agreement with published 
results Boussif et al., 1995, and this is equivalent to a range of charge ratio (+/-) between 
1 -  1.5.
2 S’
nitrogen/phosphate ratios of PH
Figure 7.1. Luciferase expression in B16 cells as a function o f the PEI content of 
polyplexes (mean + sd, n=3). Complexes were formed between pCMV/wc and PEI in the 
absence of additional peptide. PEI content is expressed as the nitrogen/phosphate (N/P) 
ratio within the complex. An N/P of 6  is approximately equivalent to charge- 
neutral isation. At N/P ratios < 6  the particles were expected to be anionic. At the N/P 
ratio o f 9 the particles were cationic.
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Figure 7.2. Luciferase expression in Cos7 cells as a function o f the PEI content of 
polyplexes (mean + sd, n=3). Complexes were formed between pCMV/wc and PEI in the 
absence of additional peptide.
This study employed a longer oligolysine chain (K2 5 ) as opposed to a Ki6 used by Hart et 
al., 1997 to ensure that DNA binding was strong. K2 5 RGD was shown to condense DNA 
stochiometrically using the ethidium exclusion assay in a similar manner to K2 5  (figure 
7.3). Polyplexes formed by co-condensing pCMV/wc with K2 5 RGD were in all cases 
more active in Cos7 cells than the corresponding complexes containing K2 5  as evident in 
figures 7.4a and 7.5a. Figure 7.4a and 7.4b represent the biological activity of complexes 
prepared with slightly positive and substantially positive excesses. The activity o f 
complexes prepared with lower peptide contents, exhibiting negative charge excesses is 
shown in figures 7.5a and 7.5b. Complexes containing K2 5 had similar activities in Cos7 
cells irrespective of their net charge excess, whereas those containing K2 5 RGD resulted in 
5 - 1 0  fold higher levels of gene expression. In each graph, the suffix in each case 
represents the additional charge ratio (+/-) conferred by the peptide
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Figure 7.3. Ethidium bromide exclusion assay for K25RGD and K2 5 .
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DNA K 250.3 K25RGD K 250.5  K25RQ0 K 251 .0  K25ROD 
0.3 0 .5  1.0
Corrplex corrposition
Figure 7.4a. Luciferase expression after transfection of Cos7 with polyplexes formed by 
complexation of pCMV/wc with PEI/peptide mixtures (mean + sd, n=3). PEI content was 
constant at N/P = 4. PEI/K2 5  or PEI/K2 5 RGD = polyplexes produced with mixtures of 
PEI and K2 5  or PEI and K2 5 RGD. Complexes with additional 0.3 (+/-) had negative 
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Figure 7.4b. Luciferase expression after transfection o f B16 cells with polyplexes 
formed by complexation of pCMV/wc with PEI/peptide mixtures (mean + sd, n = 3).
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Figure 7.5a. Luciferase expression after transfection of Cos7 cells with polyplexes 
formed by complexation of pCMV/wc with PEI/peptide mixtures (mean + sd, n = 3). 
Complexes with additional 0.1 and 0.2 (+/-) had negative charge excess; 0.4(+/-) = close 
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Figure 7.5b. Luciferase expression after transfection of B16 cells with polyplexes 
formed by complexation of pCMV/wc with PEI/peptide mixtures (mean + sd, n=3).
Complexes with higher additional cationic charge, particularly those with cationic charge 
excess generally resulted in the highest levels of gene expression, but this was not always 
the case in some experiments. For example, the data shown in figure 7.5a suggests that 
transfection with PEI/K2 5 RGD 0.1 (which had negative charge excess) resulted in a very 
high level of gene expression in Cos7 cells. This is indicative of variability that is 
inherent in using partially complexed systems. There was no significant advantage in 
using RGD peptides for transfection of B16 cells, whether the polyplexes had excess 
anionic or cationic charge, despite the reported expression of integrins by B16 cells 
(figures 7.4b and 7.5b). The optimum gene expression in B16 cells appeared to occur at 
net (total) charge ratios (+/-) o f approximately 1.0 -  1.2 (complexes denoted 




Figure 7.6 shows the inhibition of integrin-mediated uptake in the presence of the 
synthetic cyclic oligopeptide, GRGDSPA. This is consistent with the increase in gene 
expression conferred by use of K25RGD. In the presence of the competitive inhibitor the 
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Figure 7.6. Inhibition of transfection of Cos7 cells with RGD-polyplexes in the presence 
of free cyclic RGD peptide formed by complexation o f pCMV/wc with PEI/peptide 
mixtures (mean + sd, n=3). PEI/K25RGD 0.3 particles comprised DNA, PEI (at N/P ratio 
of 4), and K2 5 RGD at a charge ratio o f 0.3 (+/-).
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7.3.2 Effect of serum on transfection efficiency
The transfection efficiency of polyplexes was tested in the presence o f foetal calf serum 
(FCS) as a model for what might be encountered in biological fluids. Figure 7.7 shows 
the advantage o f using K25RGD for transfection of Cos7 cells was lost in the presence of 
FCS and in all cases the level of gene expression was very much lower than in the 
absence of FCS.
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Figure 7.7. Luciferase expression after transfection o f Cos7 cells with polyplexes in the 
presence of fetal bovine serum (mean + sd, n=3). PEI content was constant at N/P = 4. 
PEI/K25 or PEI/K25RGD = polyplexes produced with mixtures of PEI and K25 or PEI and 
K25RGD. The suffix in each case represents the additional charge ratio (+/-) conferred by 
the peptide. Complexes with additional 0.1 and 0.2 (+/-) had negative charge excess; 0.4 
(+/-) = close to charge neutralisation/slightly positive.
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7.3.3 Zeta potential studies
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Figure 7.8. Effect of N/P ratio on the zeta potential measurements of PEI/DNA 
complexes. Complexes were incubated for 30 minutes at room temperature. Zeta
potential was determined using an electrophoretic light scattering technique.
Measurements were made in a thermostatically controlled electrophoresis cell
equilibriated to 25°C. Each value represents the mean ± standard deviation for three
replicate measurements.
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The binding o f nucleic acids to PEI shifts its protonation profile. Recent reports by 
Erbacher et al., 1999a suggest that particles were neutral at an N/P (PEI nitrogen atoms to 
DNA phosphates) ratio = 3.5 -  4.0. This ratio differs from previous published data that 
showed particles were neutral at an N/P ratio o f 6.0 (Boussif et al., 1995). Based on 
these new data, zeta potential measurements were carried out on complexes formed using 
PEI at an N/P ratio of 2.0.
-15 J-----------------------------------------------------------------
0.1  0 .2  0 .3
C h a r g e  r a t i o  o f  K 2 5 R G D in a d d i t i o n  t o  PEI N/P  
r a t i o  o f  2 . 0
Figure 7.9. The zeta potential measurements of PEI/K2 5 RGD complexes at an N/P ratio 
o f 2.0 while varying peptide charge ratios. The suffix in each case represents the 
additional charge ratio (+/-) conferred by the peptide. Complexes with additional 0.1 (+/-) 
had negative charge excess and 0.2 (+/-); 0.3 (+/-) = slightly positive
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7.3.4 Transfection efficiency of polyplexes using PEI at N/P of 2.0
Based on the data on the zeta potential measurements identifying negative complexes at 
PEI N/P ratio o f 2.0, Cos7 cells were transfected with polyplexes with PEI at an N/P ratio 
of 2 .0 , which was shown to give negative charge particles.
C m  K250.1 K25RGD0.1 K 2502 K25RGD0.2 K250.3 K25RGD0.3 PB NKPZO
Conrptexconrpositkm
Figure 7.10. Luciferase expression after transfection o f Cos7 cells with polyplexes 
(mean + sd, n=3). PEI content was constant at N/P = 2. PEI/K2 5  or PEI/K2 5 RGD = 
polyplexes produced with mixtures of PEI and K2 5  or PEI and K2 5 RGD. The suffix in 
each case represents the additional charge ratio (+/-) conferred by the peptide. Complexes 
with additional 0.1 (+/-) had negative charge excess and 0.2; 0.3 (+/-) = close to charge 
neutralisation and slightly positive excess.
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7.4 DISCUSSION
Establishing a negative or neutral surface is a key objective in polyplex design in order to 
avoid parasitic interactions, a problem typical o f  positively charged complexes. The 
protonation o f PEI occurs over a wide pH range, unlike other polycations such as 
polylysine, and is very sensitive to change at pH values close to neutrality. This makes it 
impractical to calculate precise charge ratios for complexes formed at neutral pH. The 
estimation o f net charge excess was initially based on the assumption that most samples 
of PEI are approximately one-sixth protonated at pH 7.4. This implies that the most 
effective complexes o f PEI and DNA (figure 7.1) are formed just above charge 
neutralisation when the particles will have a positive zeta potential. Transfection is 
optimal when complexes are positively charged since anionic cell-surface proteoglycans 
of adherent cells mediate their attachment and spontaneous endocytosis. At high N/P 
ratios the activity typically decreases in a similar manner to polyplexes formed by other 
polycations, whether or not they have endosomolytic potential (Lucas et a l., 1999). This 
may possibly be due to the fact that after a certain ratio o f PEI nitrogens to DNA 
phosphates, no more anionic charge remains for PEI to bind. Another suggestion may be 
changes in particle size or aggregation state which affect the biological activity o f the 
complexes. Also, there may be direct toxic effect on the cells. The moderate activity o f  
complexes formed by PEI complexes at N/P = 3 in both B16 cells and Cos7 cells is 
interesting (Figures 7.1 and 7.2). Polylysine complexes are completely inactive, even in 
the presence o f chloroquine, until the charge ratio (+/-) exceeds unity and the zeta 
potential becomes positive (Lucas et al, 1999). One hypothesis is that complexation o f  
polylysine with DNA is a random process, and that condensation is required for 
biological activity. Thus complexes which are half-neutralized are inactive. If 
complexation o f PEI with DNA was random then one would expect that at N/P = 3 the 
DNA would have been uniformly in a state o f half-neutralization, and partial 
condensation. This implies that cells took up partially condensed complexes, and that 
they delivered enough PEI to the endosome to allow endosomolysis to occur. However 
an alternative explanation is that the binding of PEI to DNA was co-operative, such that
187
a t  a  N / P  r a t i o  o f  3 ,  t h e  r e s u l t i n g  m i x t u r e  c o n s i s t e d  o f  s o m e  5 0 %  f u l l y  c o n d e n s e d  p l a s m i d s  
a n d  5 0 %  f r e e  D N A  ( N w a c h u k u  a n d  P o u t o n ,  m a n u s c r i p t  i n  p r e p a r a t i o n ) .
T h e  z e t a  p o t e n t i a l  m e a s u r e m e n t s  o f  P E I / D N A  c o m p l e x e s  g a v e  a  s i m i l a r  t r e n d  t o  z e t a  
p o t e n t i a l  d a t a  f r o m  E r b a c h e r  et al., 1 9 9 9 .  F o r  P E I / D N A  p a r t i c l e s  b e t w e e n  N / P  =  2  a n d  
N / P  =  5 ,  t h e  s u r f a c e  c h a r g e  v a r i e d  f r o m  - 2 5  m V  t o  + 1 7  m V  r e s p e c t i v e l y .  T h e  
e m p l o y m e n t  o f  K 2 5 R G D  a s  a  t a r g e t i n g  m o i e t y  w a s  s h o w n  t o  b e  a d v a n t a g e o u s  i n  t h e  
t r a n s f e c t i o n  o f  C o s 7  c e l l s .  I n  s o m e  c a s e s  t h e r e  w a s  u p  t o  1 0 - f o l d  i n c r e a s e  i n  t r a n s f e c t i o n  
e f f i c i e n c y  i n  C o s 7  c e l l s  o v e r  n o n - t a r g e t e d  D N A  ( f i g u r e s  7 . 4 a  a n d  7 . 5 a ) .  E r b a c h e r  et al., 
1 9 9 9  f o u n d  t h a t  g r a f t i n g  a n  R G D - c o n t a i n i n g  p e p t i d e  t o  P E I  i m p r o v e d  t r a n s f e c t i o n  i n  
H e L a  c e l l s  b y  t w o  o r d e r s  o f  m a g n i t u d e .  S u c h  r e s u l t s  c o u l d  m a k e  a  s i g n i f i c a n t  d i f f e r e n c e  
t o  t h e  f e a s i b i l i t y  o f  n o n - v i r a l  g e n e  d e l i v e r y '  s y s t e m s  in vivo  i f  a n  i d e n t i c a l  b e n e f i t  w a s  
o b t a i n e d .  T h e r e  w a s  s t i l l  a n  a d d e d  a d v a n t a g e  t o  b e  g a i n e d  i n  C o s 7  c e l l s  e v e n  w h e n  
p o l y p l e x e s  w e r e  s t r o n g l y  p o s i t i v e  a s  e v i d e n t  i n  t h e  h i g h  e f f i c i e n c y  s h o w n  b y  
P E I / K 2 5 R G D  1 . 0  c o m p l e x e s .  I n  s u c h  c a s e s ,  i t  i s  p o s s i b l e  t h a t  l i g a n d - m e d i a t e d  b i n d i n g  i s  
f a c i l i t a t e d  b y  i o n i c  i n t e r a c t i o n  b e t w e e n  t h e  p a r t i c l e s  a n d  t h e  c e l l  s u r f a c e ,  a l l o w i n g  c l o s e r  
a c c e s s  t o  i n t e g r i n s .  H o w e v e r ,  i n  t h e  t r a n s f e c t i o n  o f  B 1 6  c e l l s ,  t h e  a c t i v i t y  o f  i n t e g r i n -  
t a r g e t e d  p o l y p l e x e s  w e r e  n o t  s t r o n g e r  t h a n  c o r r e s p o n d i n g  n o n - t a r g e t e d  p o l y p l e x e s .  I t  h a s  
b e e n  e s t a b l i s h e d  t h a t  v a r i a t i o n s  i n  t r a n s f e c t i o n  d a t a  i n  v a r i o u s  c e l l s  m a y  a r i s e  f r o m  
d i f f e r e n c e s  i n  c e l l u l a r  m e m b r a n e  i n t e g r i t y  a n d  i n t e r n a l  e n d o s o m a l  c o n d i t i o n s .  A l t h o u g h ,  
c e l l  l i n e  v a r i a b i l i t y  i s  o f t e n  s e e n  i n  n u m e r o u s  t r a n s f e c t i o n  e x p e r i m e n t s ,  t h i s  w a s  
u n e x p e c t e d  c o n s i d e r i n g  t h a t  B 1 6  c e l l s  a r e  i n t e g r i n - e x p r e s s i n g  c e l l s .  I t  i s  n o t  c l e a r  a t  
p r e s e n t  w h a t  p r o p o r t i o n  o f  c e l l s  e x p r e s s i n g  i n t e g r i n s  w i l l  r e s p o n d  f a v o u r a b l y  t o  a  
t a r g e t i n g  s y s t e m  s u c h  a s  R G D  p e p t i d e .  B 1 6  c e l l s  t a k e  u p  c a t i o n i c  p a r t i c l e s  m o r e  r e a d i l y  
t h a n  m o s t  c e l l s ,  w h i c h  i n  t h i s  c a s e  m a y  h a v e  r e d u c e d  t h e  s i g n i f i c a n c e  o f  t h e  t a r g e t i n g  
l i g a n d .  B 1 6  c e l l s  s h o w e d  e x t e n s i v e  g e n e  e x p r e s s i o n  e v e n  w h e n  t h e y  w e r e  t r a n s f e c t e d  
w i t h  P E I / K 25  c o m p l e x e s ,  s o  i t  i s  p o s s i b l e  t h a t  in vitro  t h e  o u t p u t  o f  B 1 6  c e l l s  w a s  
s a t u r a t e d ,  e v e n  a f t e r  t r a n s f e c t i o n  w i t h  l e s s  f a v o u r a b l e  d e l i v e r y  s y s t e m s .  A n  a d d i t i o n a l  
e x p l a n a t i o n  f o r  t h i s  v a r i a b i l i t y  i s  t h e  f a c t  t h a t  d i f f e r e n t  i n t e g r i n  r e c e p t o r s  a r e  p r e s e n t  o n  
d i f f e r e n t  c e l l  l i n e s .  F o r  i n s t a n c e ,  C o s 7  c e l l s  e x p r e s s  a 5  i n t e g r i n s  b u t  n o t  a 4  i n t e g r i n s .  
R G D  p e p t i d e s  t a r g e t  a 5  i n t e g r i n s .  H e n c e ,  t h e  r e s u l t s  o b t a i n e d  i n  t h i s  s t u d y  a r e  i n  l i n e  
w i t h  t h e  r e c e p t o r  e x p r e s s i o n  p a t t e r n  f o r  C o s 7  c e l l s .  I t  i s  p o s s i b l e  t h a t  t h e  t y p e  o f  i n t e g r i n s
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present on B16 cells are not responsive to the specific RGD peptide used here. The 
specificity o f integrin peptides, and their affinity o f binding, has been found to be 
influenced by the amino acid sequences flanking the -RGD- group (Hart et a l., 1997). 
Overall, a broad range o f cell lines would need to be investigated to determine the 
significance o f integrin-mediated endocytosis.
Facilitating tissue dispersion after intramuscular or intratumoral injection and preventing 
tissue sequestration close to the injection site are issues that can be overcome with the 
formulation o f negatively charged or neutral particles. However, the beneficial effects 
shown by the RGD targeting moiety in Cos7 cells may be reduced when polyplexes come 
into contact with plasma proteins. Still, the possibility o f co-operative condensation 
between PEI/DNA and K25 or K2 5 RGD'remains.
7.5 SUMMARY
This study has shown that targeting o f neutral or negative polyplexes to cell surfaces can 
be achieved. Combining the high transfection potential o f PEI with the efficient and 
specific mechanism of receptor-mediated endocytosis improves gene transfer efficiency 
and offers the possibility for specific targeting o f gene delivery.
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CHAPTER 8
CONCLUDING REMARKS AND FURTHER WORK
One o f the main goals o f continuing research in gene delivery is the work on the barriers 
that hamper the development o f efficient gene delivery vectors. The first hurdle that 
delivery systems need to overcome is getting across the plasma membrane o f living cells, 
which may be problematic in the gene therapy o f some inherited or acquired diseases, for 
example, solid tumours. The plasma membrane o f eukaryotic cells is inherently 
impermeable to peptides and proteins < that lack specialized membrane receptors or 
transport proteins. The hydrophdbic nature o f the lipid bilayer makes it difficult for 
hydrophilic compounds to target the cytoplasm and nucleus o f cells. Some proteins are 
endowed with properties to cross the plasma membrane and gain entry into the living 
cell. These include the homeodomain of Antennapedia (pAntp), the Herpes virus 22 
protein VP22 and the Tat protein o f HIV (Prochiantz, 1996; Phelan et a l., 1998; 
Schwarze et al., 1999). The identification of these proteins and their respective abilities 
to undergo internalization into cells has opened new possibilities for the study o f 
intracellular functions.
The work discussed in this thesis focussed on investigating the behaviour and properties 
of these membrane-translocating sequences in an attempt to determine their mode o f  
internalization while assessing their potential for gene therapy and as a general means of 
introducing proteins into cells.
Chapter three presented significant data on trafficking o f labeled peptides in B16 cells. 
Initially, confocal microscopy employing fluorescently labeled peptides revealed that 
most o f the pAntp (penetratin) particles were taken up into endocytotic-type vesicles. In 
addition, EM images using gold-labeled pAntp have revealed an entry process typical o f 
endocytosis. The results gave an indication of how long these peptides take to get into 
cells. The use o f ADMP, showed that some o f the labeled wildtype pAntp were 
instantaneously internalized up to the first five minutes o f incubation. Plus, intracellular 
staining became more widespread after a further few hours. Fenton et al., 1998 studied
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import of pAntp peptide into primary B and T lymphocytes and found that some o f the 
cells took up the peptide within 10 minutes of its addition to the culture medium. The 
majority of the cells were stained positive after two hours. The work done on the 
interaction o f peptides with lipid membranes reported in chapter two gave evidence o f  
binding affinities o f various peptides. However, further work will need to be done to 
determine which amino acid residues play a role in the mechanism o f entry o f a protein 
into a cell and how conformational changes o f the sequence affects the cellular 
internalization. For instance, some pore-forming proteins undergo a dramatic partial 
unfolding to form an extended, largely helical structure that lies on the surface o f the 
bilayer. Then, under the influence o f the transmembrane potential, a large fraction o f the 
polypeptide chain is translocated into the bilayer where it regroups to form ion channels 
with more than one possible structure (Fernandez and Bayley, 1998).
Elliott and O’Hare, 1997 reported on the potential usefulness o f VP22 in gene therapy by 
studying its distribution in vitro. They showed that VP22 had the remarkable property o f  
intercellular transport, which is so rapid and efficient that following expression in a 
subpopulation the protein spreads to every cell in a monolayer, where it concentrates in 
the nucleus. Phelan et al., 1998 also reported on the widespread delivery o f functional 
p53 protein to a human tumour cell line inducing apoptosis. However, no study o f VP22 
in animal tissues has yet been reported. This was attempted and discussed in chapter 
four. In this study, it was possible to see in vivo activity o f VP22 in tumour where the 
pattern o f distribution appeared similar to that achieved in vitro. Overall, there was a 
lack o f expression in animal tissue compared to transfection o f cells in culture, which 
may explain why there has not been any studies in vivo published yet. This study also 
highlighted how the manipulation o f procedures for animal experimentation is fraught 
with a vast amount o f experimental variability. In vivo experiments performed by other 
groups such as Manthorpe et al., 1993 also reported high variability in gene expression. 
They showed that there was a marked decline of muscle expression up to 14 days post 
injection o f a plasmid containing a CMV promoter, whereas a luciferase plasmid 
containing the RSV promoter maintained an almost constant level o f expression for four 
months. The study also indicated how various injection protocols resulted in high 
variability o f reporter gene expression. For instance, the administration o f luciferase
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plasmid by longitudinal injection mediated 200-fold higher expression levels than 
perpendicular injection (Levy et a l., 1996). Further work on VP22 in vivo should initially 
employ two-fold higher concentration o f expression vector that can be achieved in 
solution.
The ability o f the membrane-translocating peptides to undergo intercellular spread in 
cells in culture was tested using fusions o f pAntp with the enhanced green fluorescent 
protein (EGFP). Such fusions were prepared successfully and shown to transfect cells 
but efficiency was too low to confirm whether pAntp does undergo intercellular spread. 
Also, from the point o f view o f the mutant pAntp, which has been reported not to 
undergo internalization, it is o f great interest to confirm whether the mutant distorts the 
expression levels and spreading efficiency. One potential disadvantage o f this system is 
the reported size limitation o f the fusion peptides that can be introduced by the pAntp 
peptide (Chatelin et a l., 1996). A study in which 30 kDa proteins were linked to the 
pAntp peptide, no uptake was observed confirming the limit to the size and/or constraint 
on the cargo structure that pAntp can translocate (Perez et a l., 1994). However, Rojas et 
al., 1998 reported on another membrane-translocating sequence able to import proteins 
(as a fusion construct) as large as 45 kDa into living cells. These fusion proteins are easy 
to produce, highly stable and have low cytotoxicity. Such a novel technique will find 
widespread use in intracellular functional study and in drug and vaccine development.
The utility o f noninvasive delivery o f membrane-translocating sequences and proteins has 
been established and offers lots o f possibilities in probing and protein-protein and 
protein-DNA interactions. Some o f the limitations inherent in currently used invasive 
methods such as microinjection or the use o f membrane-permeabilizing reagents are 
overcome by advantages o f using cell-permeable peptides that include the speed and ease 
of translocation across the plasma membrane, low immunogenicity, a wide range o f cell 
types, free movement to cytoplasmic target proteins as well as easy detection (Hawiger, 
1999).
Since viral vectors can cause nonspecific inflammation and anti-vector immune 
responses, non-viral systems present a more attractive alternative, as they are more 
amenable to engineering to overcome immune and other toxic effects as well as tackle 
production challenges. However, low efficiency compared to viral systems is a major
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limitation. Non-viral systems are based on DNA compaction by electrostatic interaction 
between the polyanion and cationic polymers (polyplexes). The ability o f the membrane- 
translocating peptide, pAntp peptide (penetratin) to transfer genes to cells in culture was 
examined in chapter six. Initial experiments were performed in which the peptide- 
mediated retardation o f plasmid DNA was examined using ethidium bromide exclusion 
assays. A bifunctional peptide (K2spenetratin) was synthesized that was able to have 
stronger binding affinity for DNA compared to penetratin alone. Above charge ratios o f  
(+/-) 1.5, complexes had mean particle diameters o f between 92 -  102 nm, which 
represents a size range amenable for cellular uptake. Although the transfection efficiency 
o f pAntp peptide was improved by this modification, the gene expression data suggested 
that K.25penetratin was not as efficient' as other endosomolytic peptides such as K25HA2 
and PEI. Results also suggested variations in transfection efficiency, in the presence and 
absence o f chloroquine, with the different cell lines tested. Such observations imply 
differences in the integrity o f cell membranes as well as variations in the endosomal 
environment. Hart et al., 1997 found that transfection with Cos7 cells was enhanced in 
the presence o f chloroquine whereas the same effect on ECV304 cells was achieved 
without chloroquine. Wagner et al., 1992 found that HepG2 cells did not achieve as high 
transfection levels as erythroid leukemic K-562 cells, which are unusual cells, since they 
lack regulation o f endosomal regulation and have a low endosomal pH. Results with 
chloroquine in this chapter suggested that most o f the complexes were taken up by the 
endocytotic process. Further transfection studies on pAntp should include inhibitors o f  
endocytosis such as cytochalasin B. Although preliminary transfection data suggested 
that penetratin might not offer any more benefit to an endosomolytic agent such as PEI, 
penetratin can be chemically linked to PEI perhaps via a disulphide linkage to test 
whether the translocating sequence can infer any additional benefit on the activity of PEI. 
This is important since transfection systems are often poorly characterised mixtures and 
not consistently well-defined. Such systems may facilitate entry o f pAntp peptides to the 
nucleus. It is well established that the entry of plasmid DNA into the nucleus is one o f  
the steps limiting non-viral gene transfer (Dowty et al., 1995). Nuclear pores only allow 
proteins o f < 60 kDa to gain access to the nucleus unless they display a nuclear
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localization signal (NLS) (Jans and Hubner, 1996). Hence, the incorporation o f an NLS 
could be considered for examining nuclear uptake o f pAntp peptides.
On the other hand, the exploitation o f a mutant pAntp (does not accumulate in the 
nucleus) or linking o f proteins to pAntp, may prove useful for the delivery o f proteins to 
non-nuclear locations. Derossi et a l., 1996 reported on various mutants o f pAntp peptide 
including mutants that had one amino acid replaced by a proline residue. This proline 
mutant was concentrated solely in the cytoplasm and not the nucleus compared to the 
native pAntp peptide. Electrostatic cell-membrane binding and entry pathways are 
efficient and extensively exploited for in vitro transfection. In addition to intracellular 
barriers, physical restrictions and immunological barriers have to be overcome for the 
development o f vectors applicable, t o in vivo gene transfer. Ideally, transfection 
complexes should be highly soluble, specific for binding to the target cells, but inert 
against parasitic interactions with body fluids or tissues. The most efficient synthetic in 
vitro DNA delivery systems are dependent on a net positive charge, which is one o f the 
major barriers for targeted in vivo delivery. Positively charged particles prepared for 
transfection can bind in a non-specific manner to cell surfaces as well as activate the 
complement system (Plank et al., 1994). Results from chapter seven showed that PEI 
complexes formed with either cationic or anionic charge excess can be targeted using 
K25RGD, which implies that it will be possible to deliver negatively charged particles by 
ligand-mediated endocytosis. Although the exact mechanism o f PEI remains to be 
elucidated (Godbey et al., 1999), further work should involve testing this system using an 
in vivo model. Arap et al., 1998 showed preferential targeting o f an RGD-containing 
peptide to a toxin o f tumour blood vessels in a mouse model. Such results might become 
applicable to cancer gene therapy. Recently, ligands have been coupled to PEI to 
produce polyplexes, which can target cell surfaces, and as a result are partially selective 
transfection systems (Diebold et al., 1999a, 1999b). Such cell-binding ligands include 
transferrin, which may stabilize complexes in solution around electroneutrality. It may 
be possible to design transfection delivery systems that can target specific integrins that 
are prevalent on certain cell types in an attempt to give integrin-mediated transfection 
complexes a degree o f specificity. Since the cyclic structure o f the peptide is important 
for maintaining affinity by keeping the RGD domain in the correct conformation for
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maximal integrin-binding, the formation o f two pairs o f disulphide bridges between 
flanking cysteine residues in the peptide structure might favour higher binding affinities 
o f transfection complexes. The widespread distribution o f target integrin ligands makes 
in vivo use o f RGD peptides as DNA vectors problematic. However, these vectors can be 
employed for ex vivo gene transfer to tissues such as the cornea.
Barry et al., 1996 used a general and systematic approach for generating phage libraries 
to select peptides that bind and enter several different cell types. Because o f their small 
size, cell-binding peptides such as these could be incorporated into biological or physical 
gene therapy vectors. This process requires no prior knowledge o f the biology o f the 
target cells and hence may be useful for gene therapy and drug-targeting strategies. 
Overall, peptides have many advantages as ligands for transfection complexes. They are 
not only easy to synthesize to a good degree o f purity but sequences can be designed on 
the basis o f known ligands. The functions o f some peptides, such as membrane- 
destabilization by the influenza hemagglutinin HA-2 fusogenic peptide, can be 
incorporated into peptide-targeted transfection complexes.
Further work may include a comparison of all the internalizing sequences and a search 
for conserved structural traits. This should lead to the synthesis o f  peptidomimetic 
molecules, which will be o f interest both in fundamental and applied pharmaceutical 
research.
Although the use o f penetratin may not improve the efficiency o f DNA transfection 
systems with endosomolytic activity such as PEI, constructs consisting o f penetratin and 
established nuclear localization sequences can be assembled to achieve efficient 
transfection to the nucleus. The ability o f penetratin and VP22 to translocate across cell 
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Figure A1: Electrospray mass spectrometry for penetratin. Expected mass -  2246
Observed mass = 2245.10
3CQ W «:
Figure A2: Electrospray mass spectrometry for K^spenetratin. Expected mass — 5451




Ampicillin sodium (Sigma, UK) was prepared as a 100 mg/ml solution in water 
and filter sterilised using a 0.2 pm pore membrane (Millipore, UK) and stored at - 
20°C for up to three months. Working concentration 100 pg/ml.
Tetracycline (Sigma, UK) was prepared as a 25 mg/ml solution in methanol and 
stored at -20°C for up to three months'.
2. Chloroquine
Chloroquine (Baxter, UK) was prepared as a 10 mM aqueous stock solution, filter 




TAE buffer 0 . 0 4  m M  T r i s - a c e t a t e  
0 . 0 1  m M E D T A
TE buffer 1 0  m M  T r i s . C l  ( p H  8 )
1  m M E D T A  ( p H  8 )  ■
Electrophoresis loading buffer (5x) 0 . 2 5 %  b r o m o p h e n o l  b l u e
0.25% X y l e n e  c y a n o l  F F  
1 £ %  F i c o l l  ( t y p e  4 0 0 ,  P h a r m a c i a )
v ,
Electrophoresis loading buffer containing sodium dodecyl sulphate (5x)
N a 2E D T A  6 . 7 %  w / v
G l y c e r o l  5 0 %  v / v
B r o m o p h e n o l  b l u e  0 . 2 %  w / v
S o d i u m  d o d e c y l  s u l p h a t e  1  %  w / v
Luria Bertani Medium (LB)
B a c t o - t r y p t o n e  1 0  g
B a c t o - y e a s t  e x t r a c t  5  g
S o d i u m  c h l o r i d e  1 0  g
D D D W  t o  1 0 0 0  m l
LB Agar
B a c t o - t r y p t o n e  1 0  g
B a c t o - y e a s t  e x t r a c t  5  g
S o d i u m  c h l o r i d e  1 0  g
A g a r  T  e c h n i c a l  1 2  g
D D D W  t o  1 0 0 0  m l
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R e a g e n t s  f o r  p r e p a r i n g  L B  w e r e  o b t a i n e d  f r o m  D I F C O ,  U K .  S o l u t i o n s  w e r e  s t e r i l i s e d  b y  
a u t o c l a v i n g  a t  1 2 1 ° C  a n d  1 5  p s i  f o r  1 5  m i n u t e s  o n  a  l i q u i d  c y c l e  i n  a  s w i n g a t e  T y p e  S F T -  
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Figure D3. Plasmid map for pCMVp.
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10 2 3 4 5 6
Luciferase (ng)
Calibration curve for luciferase by dilution of purified luciferase (Promega) stock with lx  
lysis buffer (Promega). Analysis was performed as described previously in 2.6.2.1. The 
linear regression analysis was as follows:
Gradient (m) = 685.15
Intercept (c) = 0





E  0 . 4
20 4 0  6 0  ?
BovineSerum  Albumin (micrograms)
100
Calibration curve for protein using bovine serum albumin (BSA) as a standard and the 
Bio-Rad Dc protein assay kit. A stock solution of 1 mg/ml o f BSA (SigmaAldrich, UK) 
was prepared from which 100 pi aliquots in 0.1 M sodium phosphate buffer (pH 7.4) 
containing various amounts of protein.
Gradient (m) = 0.0072
Intercept (c) = 0.0159
Correlation coefficient (r) = 0.9961
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APPENDIX G
A calibration curve was constructed for B 16 cells by plating known numbers of cells into 
96-well plates, before using the MTT method. Figure below shows linear regression 








Calibration curve for the MTT assay for B16 cell number. Each data point represents the 
mean absorbance values (540 nm -  690 nm) ± SD of three evaluations.
Gradient (m) = 0.0457
Intercept (c) = 0.0491
Correlation coefficient (r) = 0.9784
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0 .00-  f -   ----------------
1.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00
Minutes
HPLC trace for ADMP. Column: Vydac 218TP53 3.2 cm x 250 mm
Flow rate = 0.5 ml/min X of detection = 230 nm Material pore size = 3 f.im
Solvent A = 0.1% Trifluoroacetic acid Solvent B = 10%A + 90% acetonitrile
Gradient = 10%B to 90%B in 30 minutes




For agarose gel electrophoresis, the marker used was EcoR  I/Hind III cut X DNA (NBL 
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Incubation time post-transfection (hours)
Incubation time for the expression of luciferase. B l6 murine melanoma cells were 
transfected with 2 jag of pCMV/wc complexed with DOTAP (A - 2.4) for four hours and 
cells harvested at various time points post transfection for analysis. Analysis was carried 
out as described in 2.6.2.1. Data points represent the mean triplicate samples + SI)
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